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Human immunodeficiency virus type 1 (HIV-1) persists as a lifelong infection, due to the 
establishment of a latent viral reservoir in rCD4+ T cells, representing a major barrier to 
eradication of HIV-1 infection. Therapeutic approaches to eliminate this latent reservoir have 
included the “kick and kill” strategy, which involves the administration of a latency reversing 
agent (LRA) to “kick” HIV-1 out of latency and “kill” the HIV-1-infected cells by cytolytic or 
viral cytopathic effects. rCD4+ T cells are heterogeneous, consisting of naïve (TN), stem cell-like 
memory (TSCM), central memory (TCM), transitional memory (TTM), effector memory (TEM), and 
terminally differentiated (TTD) cells. Preliminary studies demonstrated that the TCM and TTM cell 
subsets constitute the major proportion of the latent HIV-1 reservoir in infected individuals on 
ART, while HIV-1 DNA is consistently lower in TN cells. Consequently, there has been little 
emphasis on studying HIV-1 latency in TN cells. The primary goal of this thesis was to 
understand latent HIV-1 infection in TN cells in comparison to TCM cells, through the 
development of an appropriate in vitro primary cell model of HIV-1 latency in TN and TCM cells, 
as well as in ex vivo patient-derived cells. Employing the “kick and kill” approach to TN and TCM 
cells in our in vitro primary cell model revealed that although TN cells contained significantly 
less HIV-1 DNA than TCM cells, following reactivation, they produced as much, if not more, 
virus than TCM cells when normalized for infection frequency. This finding was also observed 
using ex vivo cells from 4 of 7 donors. Furthermore, we found that similar levels of replication-
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competent virus were recovered from TN and TCM cells when corrected for infection frequency. 
These findings suggest that quantifying HIV-1 DNA alone may not be predictive of the size of 
the inducible latent reservoir in different CD4+ T cell subsets. Furthermore, although TN cells 
constitute only a fraction of the HIV-1 DNA reservoir, they may contribute significantly to viral 
rebound following treatment interruption or failure. Thus, a greater attention should be given to 
the latent viral reservoir in TN cells in HIV-1-infected individuals on ART. 
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1.0  INTRODUCTION 
Human immunodeficiency virus type 1 (HIV-1) is the causative agent of acquired 
immunodeficiency syndrome (AIDS). HIV-1 infection has been one of the most devastating 
plagues of modern times and it is currently the second leading killer among infectious diseases 
worldwide, following tuberculosis13, 14. As of 2015, there were nearly 37 million people living 
with HIV-1, and of those 37 million, 17 million were receiving antiretroviral therapy to treat 
infection15. 
The HIV/AIDS epidemic was first brought to light in 1981 by a case report describing 
Pneumocystis carinii pneumonia (PCP) in five homosexual men with no known underlying 
illness or immunodeficiency16. This was of great concern because PCP in the United States had 
previously only been associated with severely immune-compromised individuals17. Shortly after 
this initial report, several other isolated case reports from around the United States described 
similar pathologies in previously healthy homosexual men, along with the addition of Kaposi’s 
sarcoma, mucosal candidiasis, and other opportunistic infections18-28.  
Many of the initial reports speculated that the causative agent for this unknown 
immunodeficiency was cytomegalovirus (CMV), which was found in nearly all of the affected 
individuals. It wasn’t until 1983 that Barre-Sinoussi et al. from the Pasteur Institute in France 
first demonstrated that a retrovirus closely related to the recently identified human T cell 
leukemia viruses (HTLV-I and HTLV-II) was associated with AIDS29. The direct proof that 
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HIV-1 (initially named lymphadenopathy virus [LAV] by the French or HTLV-III by the US) 
was the causative agent of AIDS came in four publications the following year from Dr. Robert 
Gallo’s lab at the National Cancer Institute (NCI)30-33. 
There are two different types of HIV, type 1 and type 2, transmitted to humans through 
several different zoonotic events34. HIV-1 was transmitted through chimpanzees35 and gorillas36,
37, and HIV-2 was transmitted through sooty mangabeys38-40. Each zoonotic event resulted in a 
new group. For HIV-1, there are four groups. Group M, which is the main group and pandemic 
form of HIV-1, can further be subdivided into at least nine different subtypes: A, B, C, D, F, G, 
H, J, K, as well as circulating recombinant forms. Additionally, there are groups N41, O42, 43, and 
P36. These last three groups are rare and are largely restricted to Western Africa44. HIV-2 is less 
pathogenic than HIV-1 and typically progresses much more slowly to AIDS45. HIV-2, largely 
confined to West Africa, is also less transmissible and is in decline44. The work presented in this 
thesis will focus solely on HIV-1, group M, subtype B. 
1.1 HUMAN IMMUNODEFICIENCY VIRUS TYPE-1 AND THE AIDS EPIDEMIC 
1.1.1 HIV-1 pathogenesis and disease 
In the two years between the first description of AIDS16 and the first isolation of the virus 
thought to cause the disease29, a remarkable wealth of information about risk factors associated 
with infection, modes of transmission, and clinical manifestations of disease was characterized. 
It was determined that HIV-1 was spread through intravenous drug use, sexual contact, blood 
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transfusions, organ transplantation, and from mother-to-child46-54. The biggest risk factor for 
contracting HIV-1 was to be a man who had unprotected sex with men.  
HIV-1 infection and the pathogenesis of AIDS can loosely be broken down into three 
stages: (i) primary or acute infection, (ii) clinical latency, (ii) and the development of AIDS. In 
the early 1980s, people went undiagnosed with HIV-1 until they presented with AIDS, largely 
because the etiological agent had not yet been identified and appropriate diagnostic tests had not 
yet been developed to detect the virus. During acute HIV-1 infection, there is a short eclipse 
phase that lasts from 1-2 weeks were the virus replicates uncontrollably and spreads from the 
initial site of infection to other tissues and organs. This is followed by what is called "acute 
retroviral syndrome" in which 50-70% of patients typically present with severe flu-like 
symptoms, including fever, lymphadenopathy, joint pain, rash, headaches, and a sore throat55, 56. 
Because of these non-specific symptoms, most cases at this stage went undiagnosed or were 
misdiagnosed as a non-specific viral infection55, 57. This phase typically lasts from two weeks to 
two months, and is characterized by a rapid decline in CD4+ T cells58, as well as having very 
high levels of HIV-1 in the blood, often reaching or exceeding 107 copies/mL56, 59-61. This spike 
in viremia, often referred to as ‘peak viremia’, is reached just before the host’s HIV-1-specific 
adaptive immune response appears and is able to recognize viral antigens and destroy free virus 
or HIV-1-infected cells62-64. 
The period of clinical latency is misleading because the virus is still replicating within the 
host and causes lymphoid tissue destruction. By definition, during clinical latency, an infected 
individual does not present with any signs or symptoms of disease, and may not even know that 
they are infected. During this period, which typically lasts from 1-10 years, HIV-1 replication is 
maintained at a viral set-point, in which plasma viremia remains stable, typically between 10,000 
4 
– 100,000 copies/mL of plasma, the peripheral CD4+ T cell count continuously declines and
immune function gradually deteriorates65. Throughout infection, there is also ongoing chronic 
immune activation, which among other things, results in irreversible collagen deposition and 
fibrosis of secondary lymphoid tissues66-70. This results in impaired thymopoiesis and 
lymphopoiesis, preventing the generation and maturation of new lymphocytes. 
At the point when CD4+ T cell counts decline to 200 cells/mm3 or less, a person is 
diagnosed with AIDS. With diminishing CD4+ T cell counts, accompanied with immune 
dysfunction and dysregulation, the immune system is no longer able to contain the infection and 
opportunistic infections appear. In the absence of therapeutic intervention, the mortality rate 
following AIDS diagnosis is >95% within 5 years with a median survival time of only 1 year71. 
1.1.2 HIV-1 replication 
The HIV-1 replication cycle can loosely be broken down into seven steps: (1) entry, (2) reverse 
transcription, (3) integration, (4) transcription/translation, (5) assembly, (6) budding, and (7) 
maturation. It was not long after the discovery of HIV-1 that it was determined that HIV-1 
primarily infects CD4+ T cells72 and that CD4 was the major receptor required for viral entry73,
74. It wasn’t until 1996, however, that the two main co-receptors, CCR575 and CXCR476, were
identified. Which co-receptor the virus uses for cellular entry determines the tropism of the virus 
and they are termed either R5- or X4-tropic77. Some viruses are able to use both CCR5 and 
CXCR4 as co-receptors and these viruses are termed dual-tropic77.  
HIV-1 entry is initiated when the HIV-1 gp120 subunit of the envelope (Env) protein 
binds to CD4 on the surface of a cell78, 79. This initial interaction causes a conformational change 
in Env that allows for subsequent co-receptor binding. Co-receptor binding initiates membrane 
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fusion in which the fusion peptide of the gp41 subunit of Env inserts into the cell membrane80. 
Membrane fusion is completed following six-helix bundle formation between the viral 
membrane and the cellular membrane81, 82. Following fusion of the HIV-1 virion to a target cell, 
a fusion pore is formed83 and the viral capsid core is released into the cytoplasm84. The entering 
capsid contains all of the viral components necessary for HIV-1 replication, including two copies 
of the positive sense single-stranded viral RNA genome, as well as the three HIV-1 enzymes: 
reverse transcriptase (RT), integrase (IN), and protease (PR). In addition to containing viral 
components necessary for HIV-1 replication, the incoming capsid also contains a few cellular 
factors, including tRNALys3 and cellular dNTPs, both of which are required for the initiation of 
reverse transcription (see below). 
Once in the cytoplasm, RT converts the single-stranded RNA genome into double 
stranded DNA in a process known as reverse transcription (reviewed in 85, 86). Although this 
process can initiate prior to cell entry, reverse transcription cannot complete without access to 
cellular dNTPs in the target cell87. Following reverse transcription, the viral genome is imported 
into the nucleus in association with both host and viral proteins, including IN88. Integration of the 
viral genome is mediated by HIV-1 IN in a non-random manner89. Once the HIV-1 genome is 
integrated into the host genome, it is termed a provirus90.  
Following integration, the resulting provirus is susceptible to transcription of its genome. 
HIV-1 transcription occurs in three stages. The HIV-1 genome contains both an identical 5’ and 
3’ long terminal repeat (LTR) sequence, both of which can act as the viral promoter, although the 
5’ LTR is highly favored over the 3’ LTR91 (Fig. 1). In early infection, only low levels of 
completely spliced HIV-1 mRNAs are produced that encode the three regulatory proteins, the 
trans-activator of transcription (Tat), Rev, and Nef (Fig. 1). With increases in Tat, HIV-1 
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transcription dramatically increases, resulting in incompletely spliced mRNAs that encode the 
viral envelope glycoprotein, Env, and the accessory proteins Vif, Vpr, and Vpu (Fig. 1). The last 
mRNA transcripts to be produced are the full-length unspliced transcripts that serve as both the 
virion genomic RNA and the mRNA for the Gag and Gag-Pol polyproteins92, 93 (Fig. 1). Tat 
increases HIV-1 transcription through interaction with the HIV-1 transactivation response (TAR) 
element, a highly conserved RNA structure that forms at the 5’ end of nascent viral transcripts, 
resulting in processive transcription elongation. While completely spliced HIV-1 mRNAs are 
exported to the nucleus through normal cellular pathways, incompletely and unspliced HIV-1 
mRNAs require Rev for export from the nucleus to the cytoplasm, through direct interactions 
with the Rev response element (RRE) RNA target sequence12 (Fig. 1). 
HIV-1 mRNAs are exported to the cytoplasm through the nuclear pore complex (NPC), 
where protein translation can occur through normal cellular pathways. Env and the accessory 
protein Vpu are translated on the rough endoplasmic reticulum (ER), whereas Gag, Gag-Pol, and 
other accessory proteins are translated on cytosolic polysomes94. Following translation, the Env 
glycoproteins are transported to the plasma membrane via the cellular secretory pathway95. The 
Gag and Gag-Pol polyproteins are translated in the cytoplasm as protein precursors (Fig. 1). Both 
the Gag and Gag-Pol polyproteins contain the structural proteins matrix (MA, p17), capsid (CA, 
p24), and nucleocapsid (NC, p7) (Fig. 1). The Gag-Pol polyprotein also contains the viral 
enzymes, RT, IN, and PR (Fig. 1). Both the Gag and Gag-Pol polyproteins are targeted to the 
plasma membrane by the MA domain, which subsequently promotes incorporation of Env 
glycoproteins to the forming virion95-97. The CA domain drives Gag multimerization at the 
plasma membrane while the NC domain recruits the viral genomic RNA into the forming 
virion95, 98.  
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Following virion assembly at the plasma membrane, budding is mediated by endosomal 
sorting complex required for transport (ESCRT) proteins, which catalyze membrane fission99. 
The resulting virion is in an immature form and is non-infectious without further processing. 
Virion maturation occurs following activation of PR, in which PR then cleaves the Gag and Gag-
Pol polyprotein precursors into their mature protein forms. These cleavage events result in 
morphological structural changes that lead to the formation of a mature, infectious virion. 
Figure 1: HIV-1 genome organization, transcription, and Rev-mediated mRNA export. A simplified 
overview of the HIV-1 genome organization, transcription of major mRNA species, and nuclear export of different 
mRNAs are shown. Upon transcriptional activation, different HIV-1 mRNAs are produced, including completely 
spliced, incompletely spliced, and unspliced species. Completely spliced mRNAs are able to export the nucleus 
and give rise to Tat, Rev, and Nef. In the absence of Rev, incompletely spliced and unspliced mRNAs are retained 
in the nucleus. In the presence of Rev, incompletely and unspliced mRNAs are able to export the nucleus to the 
cytoplasm, through direct interactions with Rev and the Rev response element (RRE) RNA target sequence. NPC 
= nuclear pore complex. (Figure adapted from Cullen, 2003 [doi:10.1016/S0968-0004(03)00142-7]12, with 
permission from Elsevier ©). 
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1.1.3 The development of antiretroviral therapy and combination antiretroviral therapy: 
turning a death sentence into a chronic illness 
With the identification of HIV-1 as a novel human retrovirus that causes severe and rapid 
disease, ultimately resulting in death, the race to develop or identify therapeutics to treat 
infection and prevent disease progression became a top priority in biomedical research. 
Antiretroviral drugs target five steps in the HIV-1 replication cycle: chemokine co-receptor 
binding, fusion, reverse transcription, integration, and maturation. Current Food and Drug 
Administration (FDA)-approved drugs fall into six classes based on the interaction or viral 
enzyme they inhibit: nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse 
transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), integrase strand-transfer inhibitors 
(InSTIs), fusion/entry inhibitors, and co-receptor antagonists.  
In the early 1980s, an AIDS diagnosis was essentially a death sentence. Following 
diagnosis, the median survival time was just over one year71. In 1987, the first antiretroviral drug 
to treat HIV-1 was FDA-approved. This drug was 3′-azido-3′-dideoxythymidine 
(azidothymidine, zidovudine, AZT), a chain-terminating thymidine nucleoside analog belonging 
to the class of NRTIs. NRTIs block HIV-1 replication by acting as chain terminators during 
reverse transcription. These drugs lack a 3’-hydroxyl group at the sugar moiety, which prevents 
the formation of a 3’-5’-phosphodiester bond between the NRTI and the incoming 5’-nucleoside 
triphosphate, resulting in the termination of viral DNA synthesis. Early clinical studies found 
that AZT treatment resulted in short-term increases in CD4+ T cell counts and improved 
immunological function, as well as decreases in opportunistic infections100-104. Follow-up studies 
on the long-term use of AZT, however, quickly revealed that AZT monotherapy provided limited 
benefit to HIV-1-infected individuals, delaying disease progression by only 1-3 years, with no 
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overall change in survival105-110. These results were likely due to the rapid appearance of drug-
resistant HIV-1 following initiation of therapy, in addition to AZT-related toxicities111-114.  
The development of NRTIs rapidly expanded, with several additional drugs reaching 
FDA-approval in the early 1990s115-118. Studies conducted using NRTIs as monotherapy or in 
combination as dualtherapy quickly shed light on the complex nature of HIV-1 infection119-122. 
Combinations of two NNRTIs showed slight delays in disease progression compared to 
monotherapy alone119-122. However, it quickly became clear that drug resistance to one NRTI 
could confer resistance to another NRTI123-125. These findings suggested that while scientists and 
physicians were on the correct path of using drug combinations to treat HIV-1, additional drug 
targets would need to be included in the treatment of HIV-1 to obtain long-term suppression and 
prevent outgrowth of drug-resistant variants. 
In an HIV-1-infected individual, there are typically between 104-105 virions/mL of 
plasma, with a turnover rate of approximately 1010 virions per day1, 2, 126. Combined with the low 
fidelity of HIV-1 RT, which makes about 1-10 mutations per cDNA synthesis127, 128, it was not 
surprising that monotherapy treatment led to the rapid expansion of drug resistant mutants109, 129,
130. Based on these characteristics, it was predicted that a viral quasispecies with reduced
susceptibility to one or two drug classes would likely exist in an individual before initiation of 
therapy131. Mathematical modeling predicted that any combination of antiretroviral drugs 
(ARVs) that required at least three mutations to generate resistance would provide durable 
suppression of viral replication131-134. These analyses explained the limited and fading effects of 
mono or dual therapy, ultimately providing the impetus for triple combination therapy.  
In the mid 1990s, several additional ARVs became FDA-approved and included two new 
drugs classes: the NNRTIs135, and the PIs136, 137. NNRTIs differ from NRTIs in that they are 
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allosteric inhibitors of RT. NNRTIs bind to a hydrophobic pocket proximal to the RT active 
site138, inducing a conformational change in the substrate-binding site that inhibits polymerase 
activity138, 139. PIs act as competitive inhibitors of HIV-1 PR by binding to the active site, thereby 
preventing cleavage of viral polyprotein precursors and inhibiting virion maturation140. With the 
increase in ARVs and drug classes, treatment of HIV-1-infected individuals with triple drug 
combinations was quickly underway. Triple drug combinations were able to improve both long-
term immunological and virologic outcomes while maintaining viral suppression135, 141, 142. The 
clinical benefits demonstrated in these studies ultimately led to the FDA approval of triple 
combination antiretroviral therapy (termed ART from here on) in 1996.  
With the ongoing need to develop less toxic and more efficacious ARVs, three additional 
drug classes and many additional ARVs were developed and FDA-approved in the 2000s. In 
2003, the first and only fusion inhibitor was approved, enfuvirtide, which acts as a peptide 
mimetic of a portion of gp41, preventing virion fusion to the target cell membrane143, 144. In 
2007, the first and only co-receptor antagonist, maraviroc (MVC), which is a CCR5 antagonist, 
was approved, along with the first InSTI, raltegravir (RAL). MVC is an allosteric inhibitor that 
alters the extracellular conformation of CCR5, preventing recognition by gp120145, 146. InSTIs 
target the active site of IN and block the reaction of HIV-1 DNA strand transfer into the cellular 
DNA genome, the process of integration147-150.  
To date, there have been over 30 FDA-approved antiretroviral drugs, including five 
single tablet combinations. The development of ART has revolutionized modern medicine. 
Through continued development of more potent ARVs and ARV combinations, individuals with 
HIV-1 who are on ART now have virtually the same life expectancy as those who are 
uninfected151. Although the number of people living with HIV-1 has been steadily increasing 
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over time, reaching approximately 37 million individuals in 2015, there has been a significant 
decline in HIV-1-related morbidity and mortality thanks to the tremendous advances in ART152. 
Not only have ART regimens improved over time, there has been an incredible global effort to 
increase access to ART, increasing coverage from 3% to 46% over the last 15 years world-
wide15. Ongoing efforts are being made to improve ART regimens through the development of 
novel ARVs, as well as efforts to increase HIV-1 diagnosis and treatment to decrease HIV-1 
transmission and increase clinical outcomes following diagnosis15. The fight against HIV/AIDS 
is far from over, but the expanding global efforts and increasing collaborations are putting the 
end of this epidemic within reach.  
1.2 VIRAL PERSISTENCE WHILE ON THERAPY REVEALS A LONG-LIVED 
LATENT RESERVOIR 
ART is now the standard care of treatment, and where available, administered immediately 
following diagnosis. ART blocks viral replication and reduces plasma viremia to below the limit 
of detection of clinical assays (50 copies/mL of plasma)153; however, it is not curative. In 1995, 
work by Chun et al. demonstrated for the first time that resting CD4+ T cells (rCD4) isolated 
from HIV-1-infected individuals contained integrated HIV-1 DNA and could thus function as a 
latent reservoir154. Furthermore, they demonstrated that these latently infected cells did not 
accumulate over time, suggesting that productively infected CD4+ T cells do not generally 
survive long enough in vivo to return to a resting memory state. In 1997, only a year after the 
introduction of ART, three independent groups identified the presence of an inducible latent viral 
reservoir in HIV-1-infected individuals on ART155-157. Importantly, the inducible virus recovered 
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from this reservoir was also found to contain replication-competent virus. It was also 
demonstrated that the latent viral reservoir resided in rCD4 T cells155. (Further discussion of the 
composition of the latent reservoir will be discussed in section 1.4.1.) Detailed quantitative 
analyses estimated that the frequency of rCD4 T cells harboring integrated HIV-1 DNA was on 
the order of 1-10 cells per million rCD4 T cells, with a total body load of 106–107 latently 
infected cells155, 158. Of these latently infected cells, approximately 1% were shown to contain 
inducible, replication-competent virus155, 159.  
Early observations of the decay kinetics of plasma HIV-1 RNA revealed that it declines 
in two distinct phases: an initial rapid phase with a half-life of 1-2 days, likely due to the rapid 
elimination of cell-free virions, followed by a shorter second phase, with a half-life of 1-4 weeks, 
likely due to the loss of productively infected cells3 (a summary of HIV-1 RNA and DNA decay 
following ART is shown in Fig. 2). Mathematical modeling based on these early decay 
characteristics estimated that ART could eliminate HIV-1-infected cells in an individual in 2-3 
years3. Based on the available information at the time, this provided hope for a cure in the near 
future. This prediction, however, was quickly proven to be incorrect. 
In 1999, a longitudinal quantitative evaluation of latently infected cells in HIV-1-infected 
individuals on ART estimated the half-life of latently infected rCD4 T cells to be 44 months, 
indicating that it would take >60 years of ART to eradicate infection, assuming a total body 
reservoir of only 105 cells159. This finding was confirmed in 2003 by a larger study of HIV-1-
infected individuals who had been on suppressive ART for up to 7 years4. More recent DNA 
analyses of HIV-1-infected individuals who have been on ART for 7-12 years, revealed that 
following ART, there is an initial rapid decline in HIV-1 DNA over the first year of 
approximately 85%, followed by a slower decay of approximately 23%/year between years 1-4, 
13 
while there is no measurable decay thereafter7. This indicates that long-term ART is unable to 
eliminate the pool of latently infected cell, even after up to 12 years of therapy.  
In 2003, a quantitative reverse transcriptase PCR (qRT-PCR) single copy assay was 
developed that could detect down to a single copy of HIV-1 RNA in 1mL of plasma160. This 
study demonstrated that despite maintaining suppressive ART, low-level viremia persisted in all 
subjects evaluated. A follow-up study in 2007 found that despite long-term suppression, 
ultrasensitive PCR methods were able to detect low-level residual viremia in approximately 80% 
of patients who were on ART for at least 7 years6. This study also showed that low-level plasma 
viremia persists at a median set point of approximately 3 copies/mL for at least 7 years, 
identifying a third phase of decay. It wasn’t until just this year that yet a fourth phase of HIV-1 
RNA decay was identified as having a half-life of approximately 11.5 years8. This analysis was 
only made possible through larger scale longitudinal analyses of individuals on ART for greater 
periods of time than were previous possible to evaluate.  
Although the source of residual viremia while on ART still remains somewhat 
controversial, three major hypotheses have been proposed to explain this phenomenon: (i) 
limited ongoing cycles of replication in the presence of ART, (ii) production of HIV-1 from 
sanctuary sites where antiretroviral drugs do not attain maximal penetration, and (iii) sporadic 
release of virus from latently infected cells4, 159, 161-165. Extensive research has shown a lack of 
viral sequence evolution while on ART166-177 and a lack of reduction in residual viremia or the 
size of the latent reservoir through the addition of a fourth or fifth ARV to treatment (treatment 
intensification)166, 178-189, which suggests that the major source of residual viremia while on ART 
comes from transcription of viral RNA from stable latent reservoirs. 
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Despite long-term suppression of HIV-1 replication by ART, treatment interruption 
studies have revealed that plasma HIV-1 RNA levels quickly rebound, typically within 1-8 
weeks, reaching near pre-therapy levels190-196. The persistence and stability of this latent 
reservoir requires remaining on ART for life, which comes with its own challenges. Therapeutic 
strategies to eliminate the latent reservoir are rigorously under investigation with the hopes of 
achieving a cure.  
Figure 2: Decay of HIV-1 RNA and DNA following initiation of ART. Observed decay of plasma HIV-1 RNA 
(blue) and PBMCs containing HIV-1 DNA (red) following initiation of ART. Upon initiation of ART, plasma 
viremia declines rapidly in a matter of days to weeks, likely due to the loss of free virus and activated CD4+ T cells 
(Phase 1) followed by the loss of monocytes/macrophages, and partially activated CD4+ T cells (Phase 2). The third 
and fourth phases of decay are likely due to the turnover of long-lived reservoirs, such as naïve CD4+ T cells and 
memory CD4+ T cells. HIV-1-infected cells decay much slower, with an initial phase between years 0-1 following 
treatment initiation with a slope of  -0.86. The second phase occurs between years 1-4 with a slope of -0.11. There is 
no significant decay of HIV-1-infected cells between years 4-12. d = days. wks = weeks. yrs = years. LOD = limit of 
detection. This figure is a generalized diagram generated using data combined from several studies1-9, and is an 
updated version of the graph previously published by Hilldorfer et al, 201210.  
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1.3 THE ONE AND ONLY CURE: LESSONS LEARNED FROM TIMOTHY RAY 
BROWN AND OTHER STEM CELL APPROACHES TO CURE HIV-1 INFECTION 
1.3.1 Early studies of transfusions, stem cell transplantations, and chemotherapy to treat 
HIV-1 infection 
The beginning of the AIDS epidemic presented largely with homosexual, previously healthy 
men, who were now suffering from severe immunodeficiency, opportunistic infections, and 
many presented with cancers such as Kaposi’s sarcoma or non-Hodgkin’s lymphoma20, 197, 198. 
Because of this common association of AIDS with cancer, the HIV/AIDS and oncology fields 
have been closely linked since the beginning. Prior to ART, cancer was a significant cause of 
mortality in HIV-1-infected individuals, largely due to uncontrolled co-infections with oncogenic 
viruses such as Epstein-Barr virus, Kaposi’s sarcoma-associated herpesvirus, and human 
papillomavirus199. Prior to ART, nearly 80% of malignancies in HIV-1-infected individuals were 
AIDS-related200. 
In the early 1980s, it had been shown that allogeneic stem cell transplantation (ASCT) 
was a successful clinical treatment option for children with severe combined immunodeficiency 
(SCID)201. Positive outcomes using ASCT to treat an immunodeficiency disorder laid the 
foundation for using ASCT in HIV-1-infected individuals to try to restore immune function and 
dampen disease progression202. Prior to ART, AIDS patients presented with such advanced 
disease that ASCT was limited due to the toxicity of the conditioning regimen required, 
including high-dose chemotherapy and radiation203. Therefore, early studies focused more on 
donor lymphocyte infusions, which do not require intensive conditioning regimens204, 205. These 
studies were unsuccessful, largely due to lack of engraftment and severity of disease prior to 
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infusion202. Additional studies conducted between 1983-1984, were performed using allogeneic 
stem cells from HLA-identical siblings or twins, which did not require a pre-transplantation 
conditioning regimen206-209. These studies also demonstrated little to no benefit in the treatment 
of AIDS, indicating that lymphocyte infusion or ASCT without conditioning is not beneficial to 
the clinical course of HIV-1 infection. 
With FDA-approval of AZT in 1987, ASCT was again revisited with the hope that if viral 
suppression could be maintained during transplantation, donor cells could be protected from 
infection202. Several studies were conducted to test the added protection of AZT as well as pre-
transplantation conditioning, including chemotherapy and total body irradiation (TBI), in HIV-1-
infected individuals with underlying lymphoma or leukemia210-212. Much like the earlier studies 
using identical twins or siblings, syngeneic transplantations performed in the presence of AZT 
were unsuccessful and had no effect on HIV-1 infection. Individuals who underwent ASCT in 
the presence of AZT showed more promising results. Despite all individuals ultimately 
succumbing to illness shortly after transplantation from recurrent lymphoma, graft-versus-host 
disease (GVHD), or acute respiratory distress syndrome, they showed no evidence of viremia 
prior to death. In two individuals, post-mortem autopsy and extensive tissue sampling revealed 
no detectable HIV-1 RNA and little to no detectable HIV-1 DNA by conventional PCR methods 
used at the time210, 212. This led the authors to conclude that the combination of myeloablative 
chemotherapy and ASCT could eradicate HIV-1 from an individual while AZT protected new 
cells from becoming infected. 
During this same time period, despite evidence of clinical benefit, several other groups 
performed syngeneic HSCT on a total of 20 HIV-1-infected individuals, comparing individuals 
who were treated with AZT compared to those who were untreated213-217. Although these studies 
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did show an increase in CD4+ T cell count following transplantation, there was persistence of 
HIV-1 in both groups, and there were no significant differences in disease progression or clinical 
outcome between the AZT-treated versus untreated arms. 
Despite two rare cases that achieved undetectable HIV-1 following ASCT, these studies 
collectively demonstrated that stem cell transplantation, even with the addition of AZT, was 
unsuccessful at controlling viral replication. Most individuals died within the first year following 
transplantation, due to recurrent malignancy, GVHD, or infection, making long-term analyses 
impossible. These studies were further complicated by the underlying bone marrow toxicity 
associated with AZT218 that may have contributed to poor engraftment and failure to achieve 
immune reconstitution following transplantation. 
With the introduction of ART in 1996, clinical prognoses of patients with HIV-1 
improved significantly219. ASCT could now be performed in the presence of ongoing ART. At 
this time, many of these studies were focused on clinical outcome and survival rather than 
eradication or reduction of HIV-1220-226. In addition to ASCT, studies were also being conducted 
using autologous HSCT in HIV-1-infected individuals on ART227-230. In general, these studies 
showed long-term survival and successful treatment of hematological malignancies. Many of 
these transplantations were also conducted using reduced-intensity conditioning (RIC), which 
limited toxicity and side effects from the procedure231. These studies demonstrated that HIV-1-
related malignancies could now be successfully treated with HSCT without significant increases 
in transplant-related mortality.  
Between 2007-2014, a handful of studies were also conducted to specifically look at the 
effect of autologous HSCT on viral persistence following transplantation232-235. Initial studies 
were met with conflicting results finding no changes in the level of HIV-1 DNA in peripheral 
blood mononuclear cells (PBMCs) in some individuals but a reduction in HIV-1 DNA in PBMCs 
in others232, 233. Two follow up studies were conducted here at the University of Pittsburgh to 
specifically evaluate the effect of autologous HSCT versus chemotherapy alone, respectively, on 
viral persistence. The results from these two studies revealed that autologous HSCT did not 
eliminate or significantly reduce the size of the HIV-1 reservoir235 and that moderate intensity 
chemotherapy given to HIV-1-infected individuals with HIV-1-associated malignancies had no 
long-term effect on plasma viremia or HIV-1 DNA in PBMCs234. 
Although it is clear that neither allogeneic nor autologous HSCT are a successful 
therapeutic option for eradicating or significantly reducing the HIV-1 reservoir, substantial 
advances have been made. Due to improved ART regimens and autologous HSCT procedures, 
there is currently no difference between HIV-1-infected and uninfected individuals in terms of 
clinical outcome and survival following autologous HSCT treatment for lymphoma236-238. In the 
presence of fully suppressive ART, both allogeneic and autologous HSCT are now a common 
practice to treat HIV-1-associated malignancies239. 
1.3.2 Timothy Ray Brown: the face of HIV-1 cure 
Timothy Ray Brown, also known as the "Berlin Patient," is an American homosexual man who 
contracted HIV-1 in 1995 while in Barcelona, Spain240. He was immediately put on AZT 
following diagnosis and was switched to ART once it became available in 1996. After living a 
relatively normal, healthy life for the next 11 years241, Mr. Brown was diagnosed with acute 
myeloid leukemia (AML) while studying in Berlin, Germany242. At the time of his AML 
diagnosis, Mr. Brown’s CD4+ T cell count was 415 cells per mm3, his viral load was 
undetectable, and he was otherwise healthy242. Mr. Brown underwent extensive chemotherapy to 
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treat his cancer242, and despite initial successes with chemotherapy, the AML quickly returned. 
This relapse indicated that he now needed to undergo TBI and receive an ASCT242. 
 In 1996, it had first been shown that individuals who were homozygous for the 
CCR5delta32 mutation were generally resistant to HIV-1 infection243, 244. Individuals who were 
heterozygous CCR5/CCR5delta32 were found to be less susceptible to HIV-1, and those who did 
become infected progressed more slowly to AIDS than wild type CCR5/CCR5 individuals244-248. 
The global frequency of individuals that are homozygous for CCR5delta32 is very low, being 
identified in only 10% of people of European descent and 2-5% of individuals throughout 
Europe, the Middle East and the Indian subcontinent249. The frequency of individuals who are 
heterozygous for CCR5delta32 is much higher, reaching close to 20% in some populations250. 
Given his knowledge on CCR5delta32 frequency and the resulting resistance to HIV-1 
infection, Mr. Brown's oncologist investigated whether a CCR5delta32 homozygous donor for 
stem cell transplantation could be identified242. Interestingly, Mr. Brown had a heterozygous 
genotype for CCR5delta32242. However, it is unclear if this had any impact on his disease 
progression or clinical outcome. One HLA-identical, homozygous CCR5delta32 match was 
identified242. Mr. Brown underwent conditioning chemotherapy, TBI, and received prophylaxis 
against GVHD containing rabbit antithymocyte globulin242, as well as cyclosporine and 
mycophenolate mofetil, both of which are immunosuppressive drugs that help prevent graft 
rejection following transplantation251, 252. He received ART until the day before transplantation, 
and engraftment was achieved 13 days after the procedure242. Complete chimerism was achieved 
61 days after transplantation and on day 159 following transplantation, a rectal biopsy was 
negative for HIV-1 DNA242.  
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Nearly eleven months after transplantation, Mr. Brown’s AML relapsed and his 
chimerism dropped to 15%242. He then underwent reinduction therapy and TBI before receiving 
a second ASCT from the same CCR5delta32 homozygous donor242. Again, he achieved 100% 
chimerism following transplantation242, and his AML went into remission242, 253. Following his 
first transplantation, Mr. Brown was never put on ART again and has not experienced viral 
rebound to this day254. Extensive sampling of blood, rectal tissue, gut tissue, cerebral spinal fluid 
(CSF), lymph node, and brain tissue was performed and analyzed by multiple labs for detection 
of HIV-1253, 255. These analyses revealed no replication-competent virus, no HIV-1 RNA, no 
HIV-1 DNA, no cells expressing CCR5, and a waning HIV-1-specific immune response255. 
These findings have collectively led to Timothy Ray Brown being labeled as the first and only 
person to be cured of HIV-1. 
The question still remains: how did this course of treatment and ASCT cure this one 
individual of HIV-1? Three main hypotheses have been proposed as to how Mr. Brown was 
cured of HIV-1 and has not experienced viral rebound following ASCT. His clinical success 
could be due to: (i) the successful ASCT from a CCR5delta32 homozygous donor, (ii) the 
intensive pre- and post-therapy conditioning, involving myeloablative TBI, multiple rounds of 
chemotherapy, and immunosuppression, or (iii) transplant-associated toxicities and 
complications, such as GVHD and leukoencephalopathy, which led to the further destruction of 
remaining recipient cells253, 256. Attempts have been made to recapitulate the successful 
elimination of HIV-1 from Mr. Brown. Some of those trials are explained in the next section. 
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1.3.3 The Boston Patients and other human and non-human primate stem cell transplant 
attempts to cure HIV-1
Stem cell transplantation is not an approved treatment for those living with HIV-1 in the era of 
ART due to the significantly high mortality rates associated with these procedures257, 258. 
However, in HIV-1-infected individuals with underlying malignancies, stem cell transplantations 
are sometimes required as a last resort to eliminate the cancer. In 2013, Henrich et al. reported on 
two HIV-1-infected individuals with underlying lymphomas who underwent ASCT to determine 
the impact this procedure had on HIV-1 reservoirs and persistence259. Because these studies were 
conducted in Boston, Massachusetts, these individuals became known as the "Boston Patients." 
Similar to Timothy Ray Brown, both of these individuals were homozygous for the CCR5delta32 
mutation and developed their cancer while on suppressive ART. 
The first patient relapsed after standard chemotherapy and again after salvage 
chemotherapy and autologous HSCT. This indicated the need for an ASCT. The patient 
underwent RIC and received a single human leukocyte antigen (HLA) mismatched HSCT from 
an unrelated donor. He also received post-transplantation anti-GVHD medication. The second 
patient underwent standard chemotherapy and then received a new diagnosis of stage IV mixed-
cellularity Hodgkin disease. He underwent unsuccessful chemotherapy, which then led to an 
autologous HSCT. Unfortunately, this patient suffered many complications, including persistent 
thrombocytopenia and anemia. Ultimately, he was diagnosed with myelodysplastic syndrome 
with multilineage dysplasia, which is a blood disorder in which bone marrow cells are unable to 
develop or develop properly260. This condition necessitated an ASCT, which he received from a 
matched sibling donor after RIC. This donor also received post-transplantation anti-GVHD 
medication. Both patients achieved full chimerism after seven months.  
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Following transplantation, both of the Boston Patients developed clinically significant 
GVHD requiring immunosuppressive treatments. Unlike Mr. Brown, both patients underwent 
RIC conditioning instead of myeloablative TBI. Furthermore, these individuals remained on 
ART after ASCT. Both patients had detectable HIV-1 DNA in PBMCs pre- and shortly post-
transplantation, as well as low level detectable HIV-1 RNA in plasma shortly after 
transplantation. However, both HIV-1 DNA and RNA levels became undetectable at later time 
points.  
To understand the full effect on HIV-1 persistence that ASCT had in these two patients, 
4.3 years (patient 1) and 2.6 years (patient 2) post-transplantation, extensive blood and tissue 
sampling was performed, followed by an analytic treatment interruption (ATI)261. Neither patient 
had detectable HIV-1 DNA or RNA. Both patients also had no significant HIV-1-specific 
cellular immune responses. Furthermore, microchimerism analyses revealed that less than 
0.0010% of PBMCs were of host origin. Both patients were closely monitored following the 
ATI. Patient 1 had detectable plasma HIV-1 RNA 84 days after ATI and patient 2 had high 
levels of plasma HIV-1 RNA after developing an illness. ART was immediately re-administered 
to both individuals, who quickly achieved full suppression again. 
These findings were quite devastating to the HIV field for many reasons. Most 
importantly, it revealed that despite having a ≥ 3-log10 reduction in the circulating proviral 
reservoir, as determined by the microchimerism data and undetectable HIV-1 DNA in tissue 
samples by ultrasensitive methods, viral rebound still occurred. While most individuals who 
undergo a treatment interruption without ASCT experience viral rebound within 1-8 weeks190-195, 
these two patients experienced a delayed rebound at 12 and 32 weeks261. Following these results, 
Hill et al. predicted with mathematical modeling and available clinical data that an 
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approximately 2000-fold reduction in the latent reservoir is required to achieve remission 
without ART for 1 year262. They also suggest that a greater than 10,000-fold reduction is likely 
required to prevent viral rebound altogether (i.e. to achieve a functional cure). Additional clinical 
studies with scheduled treatment interruptions will be needed, however, to determine if these 
predictions are correct263. 
Around the same time that the Boston Patient study was being conducted, Dr. Guido 
Silvestri’s group evaluated the affect of the conditioning regimen on clinical outcome and viral 
persistence following ASCT in a rhesus macaque model using a chimeric simian 
immunodeficiency virus (SIV) that contained HIV-1 RT (RT-SHIV)256. In this study, three RT-
SHIV-infected, ART-suppressed animals underwent autologous HSCT using cells that were 
collected prior to infection. These study animals underwent myeloablative TBI prior to 
transplantation, similarly to that given to Mr. Brown. These animals did not, however, receive 
antithymocyte globulin or chemotherapy242. These animals were compared to three control 
animals on the same ART regimen but that did not receive conditioning or autologous HSCT. 
Importantly, all six animals had equally suppressed viral loads to below the limit of detection. 
After successful engraftment had occurred (40-75 days post-transplantation), all six animals 
underwent an ATI. Along with the control animals, two of the three transplanted animals 
experienced rapid rebound of virus, as early as one week post-treatment interruption256. The third 
transplanted animal did not experience viral rebound within 14 days, when it had to be 
euthanized for clinical reasons. SIV DNA was detected in all three transplanted animals at 
similar levels to those seen in the control animals in several tissues following necropsy. This 
study revealed that conditioning alone is insufficient to prevent viral rebound following 
treatment interruption.  
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Given these findings, it seems clear that both the use of a CCR5delta32 homozygous 
donor, along with the associated toxicities and complications from the conditioning and ASCT, 
were significant contributors to the clearance of HIV-1 in Mr. Brown. Additional studies have 
been conducted to evaluate the role of using a CCR5delta32 homozygous donor to eliminate 
HIV-1 infection. At least six additional individuals have undergone ASCT from a CCR5delta32 
homozygous donor254, 264, 265. Unfortunately, all six patients died within 1 year of transplantation 
from recurrent malignancy, GVHD, or infection. One individual also experienced rebound of 
X4-tropic virus, providing a proof-of-concept that transplantation with CCR5-defective cells 
could result in a switch to or outgrowth of X4-tropic variants. These findings demonstrate the 
unrealistic feasibility of using CCR5delta32 homozygous donors and ASCT to eliminate HIV-1. 
Mr. Brown is a truly unique case of HIV-1 cure. 
Other approaches to transplant CCR5-deficient cells into HIV-1-infected individuals are 
currently being pursued. One approach is to use umbilical cord blood stem cells instead of 
peripheral blood or bone marrow stem cells266. While standard stem cell transplantations require 
closely matched HLA types to prevent graft rejection267, 268, complete HLA matching is not 
required when using umbilical cord blood stem cells266, 267. Given the rare frequency of 
individuals who are homozygous for the CCR5delta32 gene in addition to the need for HLA 
matching in stem cell transplantation, the odds of finding matched donors for HIV-1 individuals 
are very low. To overcome this limitation, a collaborative effort has been made to generate a 
cord blood inventory from CCR5delta32 homozygous donors to be used at later times for HSCT. 
Depending on the cell dose required for transplantation, the projected probability of finding a 
match from this inventory for a Caucasian patient ranges from 28% - 86%, which is significantly 
higher than through alternative approaches.  
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Another alternative approach is to genetically modify hematopoietic stem cells to render 
them resistant to HIV-1 infection. Several methods to genetically modify CCR5 or the 
expression of CCR5 have been assessed in pre-clinical studies using targeted ribozymes, RNA 
decoys, transdominant mutants, RNA interference (RNAi) through the use of small interfering 
RNAs (siRNAs), anti-sense RNAs, microRNAs, or short hairpin RNAs (shRNAs), zinc-finger 
nucleases (ZFNs), transcription activator-like effector nucleases (TALENS), and engineered 
clustered regularly interspersed palindromic repeats (CRISPR) coupled to a CRISPR-associated 
(Cas) nucleases269-300. Many of these studies were performed in humanized mouse models and 
demonstrated that moderate to high levels of resistance to HIV-1 infection with an R5-tropic 
virus could be achieved following infusion or transplantation of CCR5-deficient cells269-280, 296,
297, 299. Many of these approaches have also been evaluated in HIV-1-infected individuals300-305. 
In these studies, it was generally found that infusion or transplantation of CCR5-deficient cells 
containing an anti-HIV-1 vector was safe and well tolerated. There have been limitations to these 
studies, however, largely due to low transduction efficiency and insufficient sustainability of the 
modified cells. Improved techniques to overcome these challenges are under development. 
Clinical trials evaluating many of these approaches to eliminate HIV-1 are in progress282,
306. Despite some success, and little to no reporting of major adverse events related to treatment,
there is still significant concern that gene therapy approaches will lead to off-target effects and 
oncogenesis307. Furthermore, despite the decreased risk of using RIC regimens versus fully 
myeloablative therapy, there is still a risk treatment-related toxicities, which outweighs that of 
current ART regimens151, 231, 308. The future of these therapeutic strategies as an effective and 
acceptable approach to eradicate HIV-1 is still unknown. 
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1.4 HIV-1 LATENCY 
1.4.1 CD4+ T cell subsets and the composition of the HIV-1 latent reservoir 
The recovery of replication-competent HIV-1 from individuals on suppressive ART led to the 
discovery of HIV-1 persistence in a latent reservoir of rCD4 T cells155-157. Shortly thereafter, it 
became clear that the majority of HIV-1 DNA-containing cells were resting memory CD4+ T 
cells, while HIV-1 DNA was found at a much lower frequency in TN cells309-316. In 2009, a 
detailed analysis of HIV-1 DNA in different CD4+ memory T cell subsets, in addition to TN 
cells, was published, demonstrating that all rCD4 T cell subsets contribute to the pool of latently 
infected cells in patients on long-term ART, albeit to varying degrees317. At the time of this 
publication, there were 4 known distinct memory T cell subsets, termed central memory (TCM), 
transitional memory (TTM), effector memory (TEM), and terminally differentiated (TTD) cells. 
These memory cell subsets are distinct from each other, as well as from TN cells, based on 
phenotype, function, and location throughout the body. Ex vivo distinction between the TN and 
memory T cell subsets largely relies on characterization of several cell surface markers, 
including CD45RO, CD45RA, CCR7, CD62L, and CD27 (Fig. 3).  
CD45, also known as common leukocyte antigen318, is a tyrosine phosphatase319, 320 
important in T cell signaling and development321. Multiple CD45 isoforms exists as a result of 
alternative RNA splicing322. In humans, it has been shown that the antigen-inexperienced TN 
cells express the high molecular weight CD45RA isoform; however, upon T cell activation, 
expression of CD45RA is down-regulated and the low molecular weight CD45RO isoform 
becomes expressed321, 323-326. Expression of CD45RO is a marker of both memory and effector 
cells321. Because effector cells express T cell activation markers, such as CD25, CD69, or HLA-
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DR, they are easily distinguishable from the memory cell population. Therefore, TN and memory 
cell populations can be separated based on a lack of T cell activation and variable expression of 
CD45RA and CD45RO, respectively.  
CD62L (also known as L-selectin) and CCR7 are both essential for lymphocyte migration 
to secondary lymphoid organs327. CD62L is a selectin family adhesion molecule expressed on 
circulating lymphocytes328. CD62L is important for lymphocyte tethering to the vascular 
networks that surround secondary lymphoid organs, such as the lymph nodes328-330. Following 
lymphocyte tethering mediated between CD62L and its ligands, collectively known as 
peripheral-node addressin (PNAd) adhesion molecules329, the interaction between CCR7 with its 
ligands, either CCL19 or CCL21, leads to integrin activation, cell adhesion, and transmigration 
into the lymph node331, 332.  
Ag dose/duration 
Proliferative capacity 
Lifespan Effector function 
Naïve 
CD4+ T cell 
Effector 
CD4+ T cell 
TSCM TTM TEM TTD
Memory 
cell subsets 
-Ag -Ag-Ag-Ag
TCM
CD45RO	 -	 -	 +	 +	 +	 -	
CD45RA	 +	 +	 -	 -	 - +
CCR7	 +	 +	 +	 -	 -	 -	
CD27	 +	 +	 +	 +	 -	 -	
CD95	 -	 +	 +	 +	 +	 +	
CD62L	 +	 +	 +	 -	 -	 -	
Figure 3: CD4+ T cell maturation and generation of memory T cell subsets. Ag = antigen. 
–Ag = removal of antigen.
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In 1999, it was shown that either expression of or lack of expression of CCR7 could 
distinguish memory cells into two distinct groups333. CCR7+ cells express lymph node homing 
receptors and lack immediate effector functions, while the CCR7- cells express receptors for 
migration into tissues and are capable of immediate effector function. These two memory cell 
subsets became known as the TCM and the TEM cells, respectively. Further characterization of the 
expression of CCR7 in combination with CD62L in mice infected with lymphocytic 
choriomeningitis virus revealed an intermediate or TTM subset that lacked expression of CD62L 
but maintained expression of CCR7334.  
CD27 is a member of the tumor necrosis factor (TNF) receptor superfamily335, that was 
known to distinguish highly differentiated versus minimally differentiated memory T cells336. 
Interaction between CD27 and its ligand, CD70, plays an important role in T cell survival and 
proliferation337. Additional analysis of CD27, in conjunction CD62L and CCR7, led to further 
delineation of the memory T cell subsets, with the additional identification of TTD memory 
cells338.  
In 2011, a new memory T cell subset was identified in humans, termed the stem cell-like 
memory cells (TSCM)339. TSCM cells fall between TN and TCM cells, both phenotypically and 
functionally339. These cells maintain expression of CD45RA, CD62L, CCR7, and CD27, while 
lacking expression of CD45RO. These cells were also found to be antigen-experienced and 
expressed high levels of CD95, IL-2Rβ (CD122), CXCR3, and LFA-1, which are all 
characteristic of memory cells339. Under conventional subset isolation or flow gating strategies, 
TSCM cells falls within the TN cell population. Therefore, the additional characterization of CD95 
and/or CD122 is required to distinguish TSCM cells from TN cells. TSCM cells are an infrequent 
cell type, contributing to < 5% of the TN cell population in the peripheral blood340-345.  
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In addition to surface phenotype, the TN and memory T cell subsets are distinguished by 
many physiological features (Fig. 3). By definition, TN cells are antigen-inexperienced and 
require antigen, co-stimulation from an antigen presenting cell, and signals from the cellular 
microenvironment to become activated346, 347. These cells lack effector functions and circulate 
through secondary lymphoid tissues, via the blood, allowing for efficient immune surveillance of 
infection346. Among the rCD4 T cell subsets, TN cells are the least differentiated but have the 
highest proliferative capacity338, 348. These cells are also able to generate into effector cells as 
well as any of the memory T cell subsets, depending on the dose and duration of antigenic 
stimulation348, 349.  
The memory T cell subsets are distinguished by proliferative capacity, effector function, 
telomere length (as a marker for previous cell divisions), cytokine secretion, chemokine receptor 
expression, and many other physiological distinctions. The TSCM cells were found to have an 
enhanced capacity for self-renewal and the highest proliferative capacity among all of the 
memory T cell subsets339. These cells were also characterized as the least differentiated of the 
memory cells and, similar to TN cells, are able to maturate into the other memory cell types, as 
well as effector cells, upon stimulation339. The TCM cells are the second least differentiated 
memory T cell subset. They have a lower proliferative capacity than the TSCM cells but have 
enhanced immune recall upon secondary stimulation and a greater number of effector 
functions339. The TN, TSCM, and TCM cells express similar secondary lymphoid homing receptors 
that allow them to circulate through the blood and lymphoid tissues. The TTM cells are more 
differentiated than the TCM cells but less differentiated than the TEM cells. They do not express 
the lymph node homing receptor CD62L, but have increased expression of tissue homing 
receptors such as CCR6 and CXCR3348, 350. These cells have a reduced proliferative capacity in 
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comparison to TCM cells as well as contain shorter telomeres, but have a quicker immune 
response and greater effector functions338, 350. TEM cells lack expression of CD62L, CCR7, and 
CD27 and are largely located in peripheral tissues. These cells have a diminished ability to 
proliferate in comparison to the other memory cell subsets, but have the shortest secondary 
response time to antigen and have the highest functional capacity350. TTD cells are an end-stage 
phenotype with greatly reduced telomerase activity, almost entirely lacking the ability to 
proliferate338. These cells lack all lymphoid homing receptors and thus make up only a small 
fraction (1-3 %) of circulating CD4+ T lymphocytes317, 338, 351. The TTD cells will not be a focus 
of discussion in this thesis. 
All of these different rCD4 T cell subsets have been implicated in HIV-1 infection. While 
all of these cells express CD4, the HIV-1 co-receptors, CCR5 and CXCR4, are variably 
regulated on these different cell subsets, which likely contributes to their susceptibility to HIV-1 
infection. There is a maturational relationship between both CCR5 and CXCR4 expression 
among the different T cell subsets. CXCR4 is most highly expressed on TN cells, decreasing in 
expressing to the TEM cells (TN > TSCM > TCM > TTM > TEM), whereas expression of CCR5 is the 
opposite, being almost completely absent on TN cells to being expressed on the majority of TEM 
cells343, 344, 352. 
While essentially all studies to date that have evaluated the frequency of HIV-1 DNA in 
different CD4+ T cell subsets have found that TCM and/or TTM cells contain the highest levels of 
HIV-1 DNA, variations in the distribution of HIV-1 DNA among the different CD4+ T cell 
subsets have been associated with different rates of disease progression and clinical benefit. 
During HIV-1 infection, a fraction of individuals are able to naturally suppress viral replication 
or do not progress to AIDS in the absence of ART. These individuals are termed elite controllers 
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(EC), viremic non-progressors (VNP), and long-term non-progressors (LTNP) (broadly termed 
HIV-1 controllers here)353. While there are many different clinical features that distinguish ECs, 
VNPs, and LTNPs from each other and from normal or rapid progressors, including viral load, 
CD4+ T cell count, and duration of infection, how these three groups of HIV-1-infected 
individuals are able to control infection and prevent or delay disease progression is not well 
understood. Decreased infection in TCM cells has been observed in ECs354, as well as LTNPs who 
express the protective HLA-B27/B57 alleles355. Furthermore, limited infection in both TSCM and 
TCM cells has been found to correlate with a lack of disease progression in VNPs345. Although 
differences in HIV-1 infection of TN cells between HIV-1 controllers and progressors has not 
been directly observed, one major finding is that while lymphopoiesis and thymic output 
becomes severely impaired in progressive HIV-1 infection66, 356, 357, these functions are largely 
preserved in HIV-1 controllers353, 358, 359. This results in a stable level of TN cells and enhanced 
immune function353. 
Initiation of ART during acute HIV-1 infection has been shown to reduce the size of the 
latent reservoir360-372. Two studies have shown that some individuals who initiate ART during 
primary HIV-1 infection are able to control infection following treatment interruption for an 
extended period of time360, 362. In 2013, the ANRS VISCONTI Study Group reported that in 
some patients who received ART within 10 weeks of primary HIV-1 infection and remained on 
ART for a median of 3 years, viremia could be controlled for at least 24 months following 
treatment interruption360. These individuals were termed post-treatment controllers. Interestingly, 
HIV-1 DNA could only be detected in TN cells from 2 of 11 individuals, which suggests that the 
limited HIV-1 reservoir in TN cells may be important for long-term control of viral replication. 
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Furthermore, in these patients the short-lived TTM cells, and not the long-lived TCM cells, 
appeared to be the major contributor to the latent reservoir360.  
In 2015, the ANRS OPTIPRIM Study Group compared the effects of ART initiated 
during primary HIV-1 infection when continued for 2 or 6 years with the post-treatment 
controllers identified in the VISCONTI study362. This study found similarly low levels of HIV-1 
infection of TN cells (HIV-1 DNA was detected in 4 of 9 patients) as well as TCM cells, 
particularly in the 6-year treatment group. Two individuals who displayed similar characteristics 
as the post-treatment controllers underwent a treatment interruption. One individual controlled 
viral replication to < 20 copies/mL plasma HIV-1 RNA up to the 24 month follow-up, while the 
second individual was able to partially control HIV-1 replication to 530 copies/mL plasma HIV-
1 RNA up to 18 months following treatment interruption compared to > 100,000 copies/mL and 
> 1,500 copies/mL, respectively, prior to treatment initiation. These findings were in accordance
with the VISCONTI study, demonstrating that early initiation of ART could limit the size of the 
latent HIV-1 reservoir, particularly in TN and TCM cells, and lead to post-treatment control 
following prolonged ART prior to treatment interruption. These studies collectively highlight the 
importance of long-lived memory cells in the long-term control and maintenance of HIV-1 
infection.  
1.4.2 HIV-1 latency is maintained at the level of transcription 
Two general forms of HIV-1 latency have been described in HIV-1-infected individuals, based 
on whether or not the virus has integrated into the host genome. Pre-integration latency results 
from the inability of the viral genome to integrate into the host cell genome373. This can occur 
from incomplete reverse transcription, impaired nuclear import, or incomplete integration, 
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resulting in the formation of 1-LTR circles, 2-LTR circles, or linear unintegrated HIV-1 DNA374,
375. These unintegrated forms of HIV-1 DNA are labile and do not persist, indicating that pre-
integration latency does not contribute to the long-term latent reservoir in HIV-1-infected 
individuals on ART376. Post-integration latency results from viral DNA integration into the host 
cell genome whereby viral transcription is then blocked377. Unlike pre-integration latency, post-
integration latency is highly stable and can persist for the life of the infected cell. While 
incompletely understood, many host factors, pathways, and mechanisms that contribute to HIV-1 
latency have been resolved, largely through the use of cell line models or primary cell models of 
HIV-1 latency, which will be discussed more extensively below. 
The HIV-1 5’ LTR contains several DNA binding sites for cellular transcription factors 
such as Sp1, activator protein-1 (AP-1), NF-κB, and nuclear factor of activated T cells (NFAT). 
The chromatin organization around the HIV-1 promoter plays a key role in regulating viral gene 
transcription. Irrespective of where HIV-1 integrates into the host genome, nucleosomes, in 
particular nuc-0 and nuc-1, are bound to the HIV-1 5’LTR at fixed positions378. Nuc-1 prevents 
transcriptional elongation as it is positioned just downstream of the transcription start site379. In 
latently infected cells, the nucleosomes on the HIV-1 5’ LTR are typically found to contain 
deacetylated and both di- and trimethylated histones (H3K9 and H3K27), all of which are 
associated with repressive heterochromatic features380, 381. Both histone deacetylases and histone 
methyltransferases themselves have also been found to be associated with the proviral promoter 
in latently infected cells380-387. 
In addition to the positioning of nuc-1, transcriptional elongation is also inhibited by the 
presence of negative transcription elongation factor (NELF) and DRB-sensitivity inducing factor 
(DSIF), which induce RNA pol II pausing, resulting in abortive transcription388. In rCD4 T cells 
34 
or metabolically inactive cells in general, RNA pol II contains an unphosphorylated C-terminal 
domain (CTD), which allows RNA pol II to initiate transcription but lacks elongation abilities389. 
In order for processive transcription to occur, the CTD of RNA pol II becomes 
hyperphosphorylated, largely through the kinase subunit of the positive transcription elongation 
factor b (P-TEFb). P-TEFb is a heterodimeric protein composed of cyclin-dependent kinase 9 
(CDK9) and its regulatory partner cyclin T1. In rCD4 T cells, cyclin T1 is present at low levels 
and, while CDK9 is constitutively expressed, it is found in an inactive form390-393. Additionally, 
both P-TEFb subunits are sequestered in a 7SK small nuclear ribonucleoprotein complex (7SK 
snRNP), preventing activation of RNA pol II or other regulatory proteins. In addition to 
phosphorylating the CTD of RNA pol II, P-TEFb also phosphorylates NELF and DSIF, causing 
dissociation from the HIV-1 promoter and relieving transcriptional repression. 
Efficient HIV-1 transcription requires not only association of the HIV-1 Tat protein with 
the TAR element, but also association with P-TEFb394. P-TEFb can be released from the 7SK 
snRNP either through recruitment by Tat or by the chromatin-binding bromodomain protein 
BRD4395-397. Thus, BRD4 acts as a competitive inhibitor of Tat for binding to P-TEFb. 
Therefore, during latent HIV-1 infection, when P-TEFb levels are low and BRD4 levels are high, 
HIV-1 transcription is blocked. 
In contrast to activated CD4+ T cells, in which transcription factors are highly expressed 
in the nucleus, many transcription factors, including those important for HIV-1 transcription 
(NF-κB, NFAT, and AP-1) are sequestered in the cytoplasm in an inactive form in rCD4 T 
cells398, 399. NF-κB dimers are sequestered through interaction with inhibitory IκB proteins. 
NFAT is maintained in the cytoplasm in a phosphorylated, inactive state, unable to enter the 
nucleus. AP-1 is a heterodimeric protein composed of c-Fos, c-Jun, or ATF. The subunits that 
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make up AP-1 are functionally inactive in rCD4 T cells and cannot form active heterodimers. 
While there are likely many additional factors that contribute to the control of HIV-1 
latency that either have not been discussed above or have not yet been identified, the overall 
physiological environment of a rCD4 T cell provides a perfect setting for HIV-1 to maintain a 
lifelong persistent infection. 
1.4.3 Methods to study HIV-1 latency 
1.4.3.1 Cell line models 
Cell line models are an attractive and cost-effective way to study HIV-1 latency because they are 
generated from immortalized cell lines derived from the expansion of cells containing a single 
integration event, allowing for large scale, reproducible studies. Several different cell line 
models of HIV-1 latency have been developed to serve different experimental purposes. Some 
cell lines harbor full-length HIV-1 while others contain only minimal viral components. One of 
the greatest benefits to using a cell line model is that many of the integrated viral genomes also 
contain a reporter gene (such as luciferase or GFP) that is expressed only when viral 
transcription becomes activated, allowing for quick and easy analysis of latency reversal. As 
such, the use of cell line models has made large-scale screenings and mechanistic studies of 
latency reversing agents (LRAs) possible. 
The initial observation that HIV-1 could form a latent infection came in 1986 from in 
vitro infection experiments of the transformed T cell line, A3.01400. It was shown that upon 
infection of A3.01 cells with HIV-1LAV, over 95% of these cells became productively infected 
and the majority of them died400. However, a small fraction of the infected cells survived, and 
over long-term culture, these surviving cells were no longer producing virus or synthesizing viral 
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proteins400. Importantly, the authors demonstrated that these cells were still capable of producing 
virus following stimulation for up to 90 days, indicating that these cells contained an HIV-1 
provirus that was in an inactive, latent state.  
The first four cell lines of HIV-1 latency to be generated were U1 cells401, a 
promonocytic cell line; ACH-2 cells402, a T cell line; J1.1 cells403, also a T cell line; and OM-
10.1 cells404, a promyelocyte cell line. All four cell lines contained a full-length HIV-1 clone and 
were characterized by having little to no expression of HIV-1, but could be induced to produce 
virus when stimulated with TNF-α402-404 or mitogens such as phorbol-12-myristate 13-acetate 
(PMA)401. Early studies using these cell lines provided a great deal of insight into the control and 
regulation of HIV-1 latency.  
Although these cell lines have yielded tremendous advances in the field of HIV-1 latency 
research, they are not without their flaws. It was later identified that the latency phenotype in U1 
and ACH-2 cells resulted from mutations in Tat405 or in the TAR RNA stem loop406, 
respectively, which fail to recapitulate the complexity and natural state of HIV-1 latency in vivo. 
J1.1 cells express reduced surface levels of CD3 and contain defects in both IL-2 production and 
calcium mobilization following stimulation, rendering them defective in T cell receptor 
signaling403. Furthermore, it has recently been shown that these three cell types contain multiple 
viral integration sites, indicating that these cells are not clonal and have undergone some level of 
viral replication over time407.  
More recently, the J-Lat cell lines were developed, which are a series of T cell lines of 
HIV-1 latency408, 409. The original J-Lat cell lines were generated using a minimal, non-
replication competent HIV-1 vector that lacked several genes necessary for in vivo replication409. 
Additional J-Lat cell lines were created by infecting Jurkat cells with a full-length HIV-1 vector 
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containing a frameshift mutation in env and insertion of the enhanced green fluorescent protein 
(EGFP) gene in place of nef408. Through the generation of the J-Lat cell clones, several were 
identified that did not produce virus (measured by p24 enzyme-linked immunosorbent assay 
[ELISA]), did not produce viral proteins (measured by western blot analysis), and were GFP 
negative, indicating that these cells were transcriptionally silent and in a state of post-integration 
latency408. These features made these cell lines a more convenient way to study HIV-1 latency 
through the addition of the GFP reporter gene. 
Numerous other cell line models of HIV-1 latency have been developed, each containing 
unique integration sites, and were generated using different viral strains and viral constructs to 
serve different research purposes. Additional cell line models of HIV-1 latency will not be 
discussed further here. 
1.4.3.2 Animal models 
Animal models used to study HIV-1 latency and persistence offer unique and invaluable features 
that cannot be achieved by any other methods. The best and most widely used animal models to 
study HIV-1 latency are the non-human primate (NHP) models410. Many NHP models of HIV-1 
infection have been developed to serve different purposes, including the use of different NHPs, 
such as rhesus macaques, pigtailed macaques, cynomolgus macaques, African green monkeys, 
and sooty mangabeys410. Many species of African monkeys and apes are natural hosts for SIV 
and therefore do not develop an AIDS-like illness411. Asian macaques, however, are not natural 
hosts for SIV infection and tend to develop simian AIDS, displaying high plasma viremia, a loss 
of CD4+ T cells, and opportunistic infections before death412. The NHP models of HIV-1 
infection range from spontaneous control to rapid disease progression413-415. This wide spectrum 
of clinical manifestations is dependent on the NHP model, as well as the virus being used410. 
38 
These features allow for a vast diversity of studies that can be conducted to recapitulate human 
HIV-1 infection.  
SIV infection of Asian macaques shares many key features of HIV-1 infection in humans 
that make this model a great tool for latency research (reviewed in 410). Following administration 
of ART, plasma HIV-1 RNA can become suppressed to below the limit of detection. 
Furthermore, SIV DNA integration sites416-418 and cellular distribution between the blood, lymph 
nodes, and mucosal sites419-421 are similar to that seen with HIV-1 infection. These characteristics 
suggest that there are similar reservoir dynamics between HIV-1 infection in humans and SIV 
infection in macaques making this model particularly useful in latency research. 
The greatest benefits to using the NHP models to study HIV-1 latency and persistence are 
the controlled conditions in which the experiments are conducted. Drug regimens and dosing can 
be carefully administered and monitored to ensure adherence. With NHPs, it is not only possible 
to control the virus being used for infection, but different modes of transmission can also be 
evaluated. Given the relatively large size of NHPs, frequent tissue and blood samples can be 
collected to monitor disease and viral dissemination. To this end, macaque models of HIV-1 
latency have greatly advanced the field of HIV-1 latency research, providing a greater insight 
into viral dissemination following primary infection, establishment of the latent viral reservoir, 
and in vivo evaluation of novel LRAs. 
One major question that had remained unanswered was how quickly the latent viral 
reservoir is established following HIV-1 infection. Rhesus macaques were infected intrarectally 
with SIV and subsequently treated with daily ART 3, 7, 10, or 14 days following infection370. It 
was shown that although the animals treated 3 days post-infection never achieved measurable 
plasma HIV-1 RNA levels, virus in the animals rebounded following treatment interruption and 
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HIV-1 DNA had disseminated in lymph nodes and gut-associated lymphoid tissue (GALT) but 
not in PBMCs. This demonstrated that the HIV-1 latent reservoir is established within days of 
infection, much earlier than previously thought. These findings helped explain the ultimate 
results of the once-thought cured ‘Mississippi baby’422. The so-called ‘Mississippi baby’ was a 
perinatally infected child who received ART 30 hours after birth and remained on ART through 
18 months of age. ART was discontinued between 18 – 46 months of age but the child did not 
have detectable plasma HIV-1 RNA measured by ultrasensitive assays. It was unclear, however, 
if latent viral reservoirs had been established prior to initiation of ART just 30 hours after birth. 
At 46.4 months of age, plasma viremia rebounded, demonstrating that despite very early 
initiation of ART, a latent reservoir had been established, and although significantly delayed, 
ultimately replicating virus reemerged in the absence of therapy423. 
Another main question largely not addressed in humans is whether or not low-level viral 
replication occurs in tissues during successful ART and contributes to persistent plasma viremia 
that is seen in HIV-1-infected individuals. One study published in 2015, through the use an RT-
SHIV macaque model, clearly demonstrated that ongoing viral replication does not occur in 
tissues of ART-suppressed animals173. In this study, single-genome sequencing was performed 
on HIV-1 RNA and DNA from 11 anatomical sites obtained from 4 RT-SHIV-infected pigtail 
macaques. The authors found no differences in viral populations between the plasma and tissues 
as well as no sequence divergence in either the plasma or between the tissues of the two ART-
treated animals. This extensive sampling and sequencing analysis definitively demonstrated a 
lack of viral evolution while on ART, suggesting that viral replication was not taking place. 
Studies such as these provide a great deal of insight into the in vivo dynamics of HIV-1 
latency and the latent reservoir that cannot be obtained in humans. While studies in NHPs are 
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limited due to both cost and space required to maintain the animals, the continued use of NHPs 
in HIV-1 latency and reservoir research will surely provide invaluable information that cannot be 
obtained by other means. 
In addition to the NHP models, there are also several humanized mouse models of HIV-1 
that have been used for latency studies. Humanized mouse models represent an attractive 
alternative to NHP models due to the significantly reduced cost of purchasing, housing, and 
maintaining the animals. They are also much smaller and easier to work with than NHPs. In 
general, humanized mice are generated by reconstituting immunodeficient mice with human cells 
with or without human fetal tissues to allow them to develop a human immune system410, 424. It 
has been shown in several different humanized mouse models that HIV-1 latency can be 
established at a similar or greater frequency than that seen in humans425-429. In the context of 
HIV-1 latency and the latent viral reservoir, humanized mouse models have been widely used to 
study in vivo evaluation of LRAs430-436, and gene therapy approaches to reduce the latent 
reservoir or block HIV-1 infection using ZFNs273, 274, 279, 437, siRNAs269, 270, 296-299, shRNAs272, 276,
277, 280, 438, or ribozymes275. 
There are several limitations to using humanized mouse models, however that may limit 
their use for HIV-1 latency research. The HIV-1 latent reservoir is highly complex, involving 
many different CD4+ T cell subsets, which are distributed throughout the body of an HIV-1-
infected individual on ART. In humanized mouse models, the precise composition and 
distribution of human immune cells has not been fully evaluated. It has been shown, however, 
that there is incomplete colonization of mouse tissues with human cells, and that there are 
incomplete B and T cell responses, which may be important for the control of viral replication424,
439. Development of certain humanized mouse strains also require the use of human fetal tissue
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and requires surgical procedures to implant the fetal tissue410, 424. Given the current limitations to 
humanized mouse models for HIV-1 latency research, improved humanized mouse models with 
enhanced human immune cell distribution and function are currently being pursued. 
1.4.3.3 Primary cell models 
Tremendous advances have been made in the area of HIV-1 latency research through the use of 
primary cell models. The frequency of latently infected cells is very low, approximately 100 
copies of HIV-1 DNA per 106 rCD4 T cells measured in asymptomatic patients or patients on 
ART, which makes this population difficult to study158, 440, 441. To further complicate the study of 
these rare cells ex vivo, there are no known phenotypic markers that would allow for the 
enrichment of latently infected cells. To circumvent the rarity of latently infected cells in vivo, a 
large effort has been made to develop primary cell models of HIV-1 latency in which higher 
levels of infection can be achieved. Several models have been developed to date with the primary 
goal of studying LRAs and mechanisms of both the establishment and reversal of HIV-1 
latency442-451. Unlike cell line models or NHP models used to study latency and persistence, 
primary cell models allow for the investigation of HIV-1 latency in human, clinically relevant 
cell types. All of these models can loosely be divided into two groups: one group which relies on 
infection of activated CD4+ T cells prior to the establishment of HIV-1 latency, and one which 
relies on direct infection of rCD4 T cells. 
The first primary cell models of HIV-1 latency that were developed utilized methods of 
direct infection of rCD4 T cells in order to maintain phenotypic and biologic integrity. There are 
many limitations, however, to direct infection of rCD4 T cells, due to host restriction factors and 
blocks imposed by the cellular environment that make these cells non-permissive to infection 
(reviewed in 452, 453). The actin cytoskeleton is known to be a key regulator in many early HIV-1 
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processes including viral entry, reverse transcription, intracellular trafficking, and integration454-
456. In rCD4 T cells, cortical actin is static and is restrictive to HIV-1 infection due to actin and
its regulators being in an inactive state457. It has been shown that binding of HIV-1 gp120 to 
CXCR4 is able to enhance early stages of infection in rCD4 T cells by activating cofilin, which 
also results in actin polymerization and enhanced actin dynamics454, 455, 458. In rCD4 T cells, 
static cortical actin poses a post-entry restriction to HIV-1 infection, primarily in the case of R5-
tropic viruses. 
Another restriction is imposed by the sterile alpha motif and histidine/aspartic acid 
domain-containing protein 1 (SAMHD1), a deoxynucleoside triphosphate triphosphohydrolase 
(dNTPase), which is highly expressed in an activated form (unphosphorylated) in rCD4 T 
cells459. This protein was originally identified in myeloid cells as an HIV-1 restriction factor that 
blocked HIV-1 reverse transcription by depleting cellular dNTP pools460-463. More recently, it has 
been suggested that SAMHD1 inhibits HIV-1 infection by degrading the viral genomic RNA 
through the RNase activity of SAMHD1464, 465. However, this second mechanism has not been 
shown to contribute to the antiviral activity of SAMHD1 in cells466. Treatment of rCD4 T cells 
with the homeostatic cytokines IL-2 or IL-7 have been shown to inactivate SAMDH1 by 
inducing phosphorylation at threonine 592, making these cells more permissive to HIV-1 
infection467. It has also been shown that treatment of rCD4 T cells with either IL-2 or IL-7 
enhances HIV-1 infection468, possibly through alleviation of the SAMHD1 restriction. 
The first primary cell model of HIV-1 latency was published in 2005 by Una 
O’Doherty’s group449. In this study, the authors used spinoculation to infect primary rCD4 T 
cells. Spinoculation is centrifugal inoculation, in which cells and virus are centrifuged for 2 
hours in a small volume to ensure adequate virion-cell interaction. Using this method, they found 
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that a small fraction of cells became latently infected, as measured by integrated HIV-1 DNA, 
but they lacked intracellular Gag expression. They noted that both reverse transcription and 
integration were delayed when compared to infection of activated CD4+ T cells. When 
stimulated with either IL-7 or anti-CD3/CD28, a fraction of the latently infected cells produced 
intracellular Gag, suggesting a reversal of latent proviruses. This study demonstrated that HIV-1 
latency could be established in vitro by direct infection of rCD4 T cells without T cell activation. 
A subsequent paper was published demonstrating that spinoculation increases actin dynamics 
and cofilin activity, likely due to centrifugal stress469. This finding warrants caution when 
interpreting results using spinoculation techniques because of possible centrifugation-induced 
permissiveness. 
In 2007, a new primary cell model was published by Sharon Lewin’s group, in which 
they demonstrated that pre-treatment of rCD4 T cells with the chemokines CCL19 or CCL21 
(the two known ligands for CCR7) enhanced permissiveness of these cells to HIV-1 infection442. 
This group subsequently demonstrated that pre-treatment with the chemokines CXCL9, 
CXCL10, (ligands for CXCR3) and CCL20 (ligand for CCR6) also increased permissiveness of 
rCD4 T cells to HIV-1 infection456. Importantly, it was shown that pre-treatment with these 
chemokines did not induce T cell activation. Similar to the O’Doherty model, this chemokine-
induced model was also shown to involve changes in rapid dephosphorylation of cofilin and 
filamentous actin (F-actin), thereby overcoming restrictions to HIV-1 infection imposed by the 
actin cytoskeleton456. This method of infection resulted in a high percentage of rCD4 T cells 
becoming latently infected, although the number of cells containing integrated HIV-1 DNA was 
still lower than that seen in activated CD4+ T cells. It was also demonstrated that following PHA 
activation, these cells could produce virus. In 2011, this model was used to determine the 
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relevance of different LRAs in ex vivo latency reversal studies470. They found that, as with ex 
vivo studies, latency could be established without spontaneous production of virus. They also 
found that stimulation of latently infected rCD4 T cells with agents such as the protein kinase C 
(PKC) agonist, prostratin, or IL-7, closely mirrored what had been previously seen in ex vivo 
studies using rCD4 T cells isolated from patients on ART. These data demonstrated that this 
model was a useful tool for studying HIV-1 latency. 
A modified version of the O’Doherty model was developed by Warner Greene and 
colleagues to decrease culture times and increase ease of use with reporter viruses446. While this 
model still uses spinoculation to achieve latent infection of rCD4 T cells, infection is performed 
with a dual-labeled reporter virus to measure both the number of cells responding to an LRA and 
the magnitude of the response. This model was also used to evaluate the establishment and 
reversal of HIV-1 latency in different resting memory CD4+ T cell subsets to study the 
similarities and differences in purified cell types among this heterogeneous population. This 
model allows for efficient screening of LRAs in less than a week, which is desirable when 
screening large libraries of compounds.   
A fourth primary cell model of HIV-1 latency was developed by direct infection of rCD4 
T cells. This model is unique in that it establishes latent infection in rCD4 T cells following a 
brief co-culture with autologous, productively infected cells471. The rCD4 T cell population is 
subsequently isolated from co-culture, resulting in 1-12% of cells that contain integrated HIV-1 
DNA, with 0.5-5% of those cells capable of producing virus. This method establishes latent 
infection in all rCD4 T cell subsets, similar to that seen in vivo. 
To overcome the restrictions and limitations of using a primary cell model reliant on 
direct infection of rCD4 T cells, several additional models have been developed that take 
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advantage of infecting highly susceptible, activated CD4+ T cells, followed by a transition 
period into a resting, latent state. There are limitations to this strategy, however, primarily 
because most activated CD4+ T cells die shortly after activation and cannot survive long enough 
to transition into a quiescent state472. Because these models start with activated CD4+ T cells that 
are then allowed to transition into a resting state, long culture times are required (on the order of 
1-3 months). Increased survival times and transition from an effector to a memory state can be
achieved in culture following T cell activation with the addition of cytokines, such as IL-2 and 
IL-7472-475; however, both of these cytokines have also been found to reactivate latent HIV-1433,
476, 477. Therefore, alternative strategies were required to overcome these limitations. 
The first primary cell model of HIV-1 latency to infect activated CD4+ T cells prior to 
returning to a resting state, was published in 2006443. In this model, infected CD4+ T cells were 
co-cultured with the H80 feeder cell line, which was shown to promote cell survival over long-
term culture in the absence of additional cytokines. Although this model resulted in high levels 
of latently infected cells that could be reactivated to produce virus following stimulation with 
prostratin, PHA, or anti-CD3/CD28, a small fraction of the resting cell population expressed the 
early activation marker CD69, suggesting that these cells may not be in a resting or latent state. 
Additionally, there were low levels of both intracellular and extracellular p24 production, 
indicating that some cells had ongoing viral replication. In 2010, a second model was developed 
that also used the H80 feeder cell line to return activated, HIV-1-infected cells to a resting 
state447. In this model, activated CD4+ T cells were infected using a VSV-G pseudotyped 
construct that expressed either EGFP or mCherry in place of nef and also contained a mutation in 
tat that had previously been shown to enhance the establishment of latency in J-lat cells385. These 
reporter genes allowed sorting of productively infected cells by fluorescence-activated cell 
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sorting (FACS). This method was able to generate tens to hundreds of millions of latently 
infected CD4+ T cells. The majority of the resulting cells were found to have a TCM phenotype. 
Much like with the previous model using the H80 feeder cell line, this model also showed low-
levels of GFP expression and low-level virus production in the absence of stimulation. These 
cells also expressed a significant level of the activation marker CD25. Collectively, these data 
suggest that the H80 feeder cell line for establishing infection does not allow CD4+ T cells to 
return to a truly resting state. 
In 2008, a model by Marini et al. was published in which they infected activated CD4+ T 
cells co-cultured with antigen-loaded monocyte-derived dendritic cells (MDCCs)448. This proof 
of concept study demonstrated that HIV-1 latency could be established in vitro following 
antigen-driven proliferation. Following co-culture and activation of TN cells and subsequent 
HIV-1 infection, the cells were returned to a resting state. As with the previously described 
model, the resulting cells were found to be almost entirely TCM cells. While this model used 
more physiological parameters to infect cells and establish latency, there was a significant 
decrease in cell viability. And although these cells expressed little to no CD25 or HLA-DR 
compared to controls, they were found to be larger and more granular than freshly isolated CD4+ 
T cells, which suggested that these cells might not be truly resting. 
In 2009, the Bosque and Planelles model was published using a novel method to generate 
latently infected CD4+ T cells445. The authors used purified TN cells that were then stimulated 
with anti-CD3/CD28 in the presence of the cytokines tissue growth factor-beta (TGF-β), IL-4, 
and IL-2. This culturing method primed these cells into a non-polarized TCM phenotype, as had 
been previously described478. While the cells were activated, they were infected, via 
spinoculation, with a replication-defective HIV-1 clone permitting only a single round of 
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infection. This model was initially used to study different signaling pathways that could be 
targeted to reverse latency, specifically in latently infected memory CD4+ T cells. One major 
caveat to this model is that prior to reactivation of the latently infected cells, neither T cell 
activation nor viral integration were assessed, so it is unclear if the cells were truly in a resting 
state or if/how many cells harbored latent proviruses. A second paper published by this group 
extended this model to look at the effects of homeostatic proliferation, promoted by addition of 
the cytokines IL-2 and IL-7, on reversal of HIV-1 latency451. In this study, they measured both 
integrated HIV-1 DNA and the T cell activation marker CD25 before and after stimulation. They 
also assessed cellular DNA and RNA content under their culture conditions, which were found to 
be consistent with freshly purified rCD4 T cells. They did find, however, that a significant 
percentage of the TCM cells expressed CD25. Additionally, during culture with IL-2 and/or IL-7, 
there were increased levels of intracellular p24, indicating that HIV-1 was not latent. 
Another model from 2009 was published by the Siliciano group, in which they took 
advantage of the pro-survival protein, Bcl-2444. Bcl-2 is an anti-apoptotic protein downstream of 
the IL-7 signaling pathway that prevents cell death under conditions of cytokine withdrawal472,
479. It had previously been shown that overexpression of Bcl-2 was able to restore peripheral T
cell homeostasis in IL-7 receptor-deficient mice, demonstrating that the pro-survival benefits of 
IL-7 can be achieved through the use of Bcl-2, without inducing cellular proliferation or 
increased metabolic activity480, 481. Here, primary CD4+ T cells were transduced with a lentiviral 
vector expressing Bcl-2 and were subsequently expanded by activation using anti-CD3/CD28. 
Activated, transduced cells were infected with a pseudotyped, modified, reporter virus that 
expressed EGFP upon latency reversal. The expanded cells were allowed to return to a resting 
state over long-term culture, and the EGFP negative cells were sorted, providing a pure 
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population of rCD4 T cells, some of which were latently infected. This model provided a useful 
tool for long-term culture of primary cells and a reliable means to generate latently infected 
rCD4 T cells. The authors screened a total of 4400 compounds from two different libraries as 
LRAs, identifying a total of 17 compounds that were able to reactivate latent HIV-1. 
While there are clear benefits to the use of activation models, there are also drawbacks. 
Large numbers of latently infected cells can be generated, providing an efficient platform for 
large-scale evaluation of LRAs. However, the resulting rCD4 T cells after in vitro activation 
typically do not have the same phenotype as freshly isolated rCD4 T cells, lending the question 
of physiological relevance. Furthermore, these models largely result in cells of a TCM phenotype 
and do not allow for evaluation of TN cells, limiting their use for T cell subset analyses. 
While each primary cell model of HIV-1 latency has their strengths for studying certain 
aspects of latency or latency reversal, a recent report comparing LRAs in several of the models 
discussed above showed a high degree of variation and inconsistency between the models, none 
of which recapitulated the responses seen using ex vivo patient cells471. This report was not 
surprising given the vast differences between each model. Each model is unique in the type of 
cells isolated, treatment or modification of cells before infection, virus used for infection, and 
time of stimulation before readout measure (Table 1). Each model also uses a different readout 
method to quantify latency reversal, ranging from luciferase or GFP expression, quantification of 
HIV-1 mRNA, soluble RT activity in the supernatant, or infectious units per million CD4+ T 
cells (IUPM) (Table 1). Caution should be taken when comparing results between studies on 
HIV-1 latency because differences seen may be due to a lack of assay standardization and not on 
actual biological differences. 
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Table 1: Cell models to study HIV-1 latency 
Cell Model Type of input cells 
Cell cycle at 
time of 
infection 
Virus(s) used Duration of stimulationρ Assay readout 
Greene 
Total or 
memory CD4+ 
T cells 
Resting NL4-3-Δnef-luciferase/GFP/mCherry 1-3 d
Luciferase, 
GFP, mCherry 
Lewin Primary rCD4 T cells Resting NL4-3, AD8 7 d 
Soluble RT 
activity 
Spina Primary CD4+ T cells Resting NL4-3 7-14 d
Tat mRNA, 
ICε p24-gag 
O’Doherty Primary rCD4 T cells Resting IIIB 1-3 d IC
ε p24-gag 
Karn Primary CD4+ T cells Activated 
ΔgagΔnef-tat(H13L)-
IRES-EGFP 18 h 
EGFP, 
mCherry 
Planelles Naïve CD4+ T cells Activated Δenv or ΔenvΔnef-GFP 7 d 
ICε p24-gag or 
% GFP+ cells 
Cloyd Primary CD4+ T cells Activated JR-CSF 2 d IC
ε p24-gag 
Marini 
Activated TN 
and memory 
CD4+ T cells 
Activated IIIB 14 d 
ICε p24-gag 
and 
ECψ p24-gag 
Siliciano Primary CD4+ T cells Activated NL4-3-Δ6-drEGFP 2-3 d % GFP+ cells 
Patient cells Primary rCD4 T cells NA Endogenous 14–21 d 
Infectious units 
(IUPMϒ) 
ρ Indicates time between stimulation and assay readout. 
ϒ Infectious units per million cells. 
ε Intracellular. 
ψ Extracellular. 
1.4.3.4 Ex vivo patient-derived cell models 
The low frequency of latently infected cells in HIV-1-infected individuals on ART makes ex 
vivo studies using patient-derived cells a particular challenge. Latency reversal studies using ex 
vivo patient-derived cells usually requires either large volume blood draws or leukophereses to 
obtain enough cells, adding another level of complexity to these already difficult studies. 
Because of these limitations, ex vivo patient-derived cell models to evaluate putative LRAs have 
been limited.  
One method using ex vivo patient-derived cells to evaluate LRAs is to treat rCD4 T cells 
isolated from HIV-1-infected individuals with putative LRAs prior to plating the cells for the 
50 
viral outgrowth assay, which measures the frequency of replication-competent HIV-1471. 
Comparing LRA-treated to untreated cells will determine whether or not the LRA had a specific 
effect on latency reversal and virus production. A modified version of this approach has been 
described to evaluate putative LRAs482. Instead of treating the patient-derived cells with the 
LRAs prior to co-culture with PHA-stimulated, allogeneic PBMCs for the viral outgrowth assay, 
treated cells are instead co-cultured with the permissive MOLT-4/CCR5 cell line that supports 
robust HIV-1 replication. Following co-culture, viral outgrowth was measured by extracellular 
p24 ELISA, and cell-associated HIV-1 RNA and DNA were measured by qPCR. This model is 
particularly useful because it measures virus production and replication-competent HIV-1 in 
addition to measuring both cell-associated HIV-1 RNA and DNA to assess the effect of each 
LRA has on the size of the latent reservoir. 
1.4.4 Latency reversal as a strategy to reduce or eliminate the latent reservoir in vitro and 
ex vivo 
Dating back to as early as 1998, it was hypothesized that if viral transcription and subsequent 
virus production could be induced from latently infected cells in HIV-1-infected individuals on 
ART, then these latently infected cells could possibly be eliminated either through cytopathic 
effects or through host immune effector mechanisms483-487. This proposed mechanism to 
eliminate the latent reservoir later became known as the “kick and kill” strategy (Fig. 4)488, 489. 
With elucidation of mechanisms that maintain proviral latency, attempts have been made to 
target or block those host factors that maintain proviral latency in the hopes of turning on viral 
transcription, resulting in the ultimate clearing of the now productively infected cells, and will be 
discussed in greater detail below. 
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To date, the most widely studied LRAs have been histone deacetylase inhibitors 
(HDACi) that target histone deacetylases. As chromatin remodeling and histone deacetylation 
are important for the silencing of HIV-1 transcription in rCD4 T cells490, 491 and treatment of 
latently infected rCD4 T cells with HDACi were found to reverse HIV-1 latency491, 492, at least 
15 different HDACi have been evaluated for their effectiveness as LRAs to date, many of which 
are FDA-approved or under clinical evaluation for treatment of various cancers493, 494. These 
include: valproic acid492, 495, 496, trichostatin A (TSA)491, 497, 498, oxamflatin499, 500, scriptaid500, 501, 
apicidin500, 502, sodium butyrate495, 503, M344500, 504, CG05/CG06505, MC1293506, givinostat500, 507,
508, entinostat497, 509, belinostat496, 508, vorinostat (suberoylanilide hydroxamic acid, SAHA)510-512, 
panobinostat (PNB)496, 508, and romidepsin (RMD)496, 513. HDACi are particularly attractive 
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compounds to assess for latency reversal potential because, in general, they have a low toxicity 
profile and do not induce global T cell activation514. While there have been too many studies to 
discuss individually at length, many of these HDACi proved to be ineffective at reversing latent 
HIV-1 or were too toxic at concentrations required to reverse latent HIV-1 and are thus no longer 
under investigation for clinical use. A few of the HDACi that were able to reverse HIV-1 
latency, either measured by increased viral transcription or virus production, have now been 
evaluated clinically and will be discussed in greater detail in section 1.5.2. 
Both in vitro and ex vivo evaluation of several histone methyltransferase inhibitors 
(HMTi) as potential LRAs have been conducted. Chaetachin515, 516, an inhibitor of SUV39H1 
(which mediates trimethylation of H3K9), BIX-01294383, 516, an inhibitor of G9a (which mediates 
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Figure 4: “Kick and kill” strategy of latency reversal and elimination of the latent reservoir. Latently infected 
rCD4 T cells are treated with an agent, such as a T cell activator or PKC agonist, to ‘kick’ HIV-1 out of latency and 
produce new virions. This is performed in the presence of ART to prevent new rounds of infection. Newly produced 
virions will be eliminated by the host’s immune system. The producer cells will also be eliminated by the host’s 
immune system or will be killed by viral cytopathic effects. HDACi: histone deacetylase inhibitor. Figure adapted 
from Garrido and Margolis, 201511. 
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dimethylation of H3K9), 3-deazaneplanocin A (DZNep)380, a pan histone methylation inhibitor 
and non-specific inhibitor of EZH2, and GSK343, a selective inhibitor of EZH2, have all been 
evaluated as potential LRAs. Ex vivo evaluation of both chaetachin and BIX-01294 found that 
both of these agents potently induced virus production from rCD4 T cells isolated from HIV-1-
infected individuals on ART517. Importantly, non-specific T cell activation was not assessed and 
both agents had a dose-effect on cell viability. In vitro analysis of DZNep revealed only modest 
effects in viral transcription when administered alone, however, there was an additive effect 
when combined with an HDACi, suggesting that DZNep may prime latently infected cells to be 
more responsive to HDACi380. Importantly, DZNep was cytotoxic at concentrations required to 
achieve latency reversal as a single agent. Ex vivo evaluation of GSK343 found similar results to 
those found with DZNep, such that treatment with GSK343 alone had minimal effects on 
reversal of proviral latency518. However, when cells were treated with GSK343 followed by 
treatment with SAHA, there were significant increases in viral transcription and virus production 
over treatment with SAHA alone. While there are currently no FDA-approved methyltransferase 
inhibitors, making their clinical evaluation in the setting of HIV-1 limited, many are currently 
under clinical evaluation for different cancer treatments519. 
In addition to the evaluation of HMTi, one DNA methyltransferase inhibitor (DNMTi) 
has also been evaluated as a potential LRA. 5-aza-2’-deoxycytidine (5-AzadC, 5-AZA-CdR, 
decitabine) is an FDA-approved DNMTi used to treat myelodysplastic syndromes520. At least 
three independent in vitro and ex vivo studies have evaluated the effectiveness of 5-AzadC as a 
potential LRA496, 521, 522. All three studies found that 5-AzadC was unable to substantially 
reactivate latent HIV-1 when used as a single agent. However, 5-AzadC did show substantial 
increases in virus production when combined with either an NF-κB activator521 or an HDACi496. 
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These studies suggest that while DNMTi may have limited effects on reversal of latent HIV-1, 
they may have synergistic effects when combined with other agents, such as NF-κB activators or 
an HDACi and could be further evaluated under combinatorial conditions. 
Activation of the PKC pathway was one of the first suggested targets to reverse latent 
HIV-1. PKC is a family of serine/threonine kinases composed of several different isoforms. 
Activation of PKC induces activation of the ERK1/2 mitogen-activation protein kinase pathway. 
This pathway stimulates IKK-dependent phosphorylation of NF-κB inhibitors, the IκB proteins, 
via activation of IκB kinase, leading to their subsequent degradation, ultimately leading to 
activation and nuclear translocation of NF-κB. Once in the nucleus, NF-κB is able to mediate 
transcription of target genes523, 524. Because the HIV-1 promoter contains NF-κB binding sites, it 
was believed that upregulation of transcription factors such as NF-κB could activate transcription 
from a latent provirus.  
To this effect, synthetic phorbol esters, such as PMA, natural non-tumor promoting 
phorbol esters, such as prostratin, non-tumor promoting lactones, such as bryostatin-1, and 
ingenols and ingenol derivatives, that all activate the PKC pathway have been evaluated as 
potential LRAs524-534. In general, PKC agonists have been shown to be potent activators of latent 
HIV-1. They consistently and reproducibly reactivate latent HIV-1 across T cell line models and 
primary cell models, often being used as an activation control. In addition to PKC activation, 
ingenol derivatives have also been shown to increase HIV-1 transcription through upregulation 
and activation of P-TEFb535. 
While PKC agonists are clearly potent LRAs, there are many concerns with using PKC 
modulation as a means to eradicate the HIV-1 latent reservoir in HIV-1-infected individuals on 
ART. The result of PKC activation on transcription is non-specific to HIV-1. Phorbol esters have 
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been shown to activate PKC-dependent transcription in multiple different cell types, raising 
concerns about systematic, non-specific effects, which would likely result in a detrimental 
outcome. In cell culture models, PKC modulation induces non-specific T cell activation and 
proliferation, resulting in a dose-dependent increase in cytotoxicity. Although there are no 
published studies reporting these results, PKC activators, mainly prostratin, have been reported 
to be highly toxic in NHPs at doses required to achieve a therapeutic effect on the HIV-1 latent 
reservoir410. 
One notable exception among the PKC agonists is bryostatin-1. Unlike the other PKC 
agonists, bryostatin-1 demonstrated robust in vitro latency reversal at low nanomolar 
concentrations without inducing T cell activation or effecting cell viability525. Additionally, ex 
vivo evaluation of putative LRAs to induce viral outgrowth from cells isolated from HIV-1-
infected individuals on ART revealed that bryostatin-1 was able to significantly increase both 
cell-associated HIV-1 RNA and viral outgrowth while other single agents failed to do so482, 536.  
Bryostatin-1 has been evaluated clinically for non-HIV-1 related illnesses, including various 
malignancies and Alzheimer’s disease, and has largely been found to be safe and well 
tolerated537. Given these findings, bryostatin-1 has now been evaluated clinically for the 
treatment of HIV-1 and will be discussed further in section 1.5.4. 
Sequestration of P-TEFb prevents transcriptional elongation in rCD4 T cells. Two 
approaches have been made to free up P-TEFb in rCD4 T cells to reactivate latent HIV-1. 
Hexamethylbisacetamide (HMBA), a hybrid bipolar compound, was identified as an inducer of 
HIV-1 transcription in the early 1990s538. HMBA was later evaluated as a LRA and was found to 
induce viral transcription by recruiting CDK9 to the HIV-1 promoter and inducing chromatin 
remodeling around nuc-1539, 540. Importantly, this effect was found to be independent of cellular 
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activation or proliferation539. While HMBA was originally developed as an anti-cancer drug, its 
limited effects at clinically tolerable doses have prevented further clinical development541. Thus, 
clinical evaluation of HMBA as an anti-HIV-1 agent may be difficult. 
Another agent shown to release P-TEFb from the 7SK snRNP is the BRD4 inhibitor, 
JQ1542-544. P-TEFb can be released from the 7SK snRNP either by BRD4 or by HIV-1 tat, 
thereby presenting BRD4 as a competitive inhibitor of P-TEFb in relation to tat397. JQ1 was 
found to be a weak activator of latent HIV-1, however, it remains of interest because it does not 
induce T cell activation or cellular proliferation. There are currently several bromodomain 
inhibitors under pre-clinical or clinical evaluation, including JQ1545, suggesting that this drug 
will continue to undergo evaluation as an anti-HIV-1 agent. 
Disulfiram, a compound originally identified (in the context of HIV-1) in a high-
throughput screen to identify compounds that could induce HIV-1 transcription without 
increasing T cell activation in a primary T cell model of HIV-1 latency546. Disulfiram was found 
to significantly increase viral transcription through an unknown mechanism. It was later 
identified by our lab that disulfiram reactivates latent HIV-1 through depletion of the 
phosphatase and tensin homolog (PTEN), resulting in activation of the protein kinase B (Akt) 
pathway, subsequently leading to activation of NF-κB547. Disulfiram is an FDA-approved drug 
used to treat alcoholism that has been in clinical use for decades, with a well-characterized safety 
and tolerability profile548-550. Because of these findings, disulfiram has been clinically evaluated 
as an anti-HIV-1 agent and will be discussed in section 1.5.3. 
It is important to note that there has been a great deal of variation in responses to these 
LRAs between studies and between models. In 2013, a detailed comparative study was published 
comparing the effects of 13 different LRAs or LRA combinations on latency reversal in five 
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different primary cell models, four T cell line models, and ex vivo patient-derived cells471. 
Strikingly, this study showed that there was an impressive inability of different LRAs to elicit an 
effect on latency reversal across models, and none of the cell models were able to recapitulate 
what was seen with ex vivo patient-derived cells. Additionally, a study from the Siliciano lab 
published in 2014 was designed to us an ex vivo patient-derived cell model to distinguish 
effective versus ineffective single agents for latency reversal482. This study found that no single 
agent that was evaluated was able to significantly or reproducibly induce viral transcription or 
production from rCD4 T cells isolated from HIV-1-infeted individuals on ART. The one 
exception was bryostatin-1, which was able to significantly increase viral transcription but not 
virus production. As described in section 1.4.2, control of post-integration latency in rCD4 T 
cells is highly dynamic and tightly regulated at many levels. All of these findings suggest that 
reversal of HIV-1 latency may require multiple LRAs that work synergistically to activate 
proviral transcription. 
Several studies have now been published describing the enhanced effects of LRA 
combinations on latency reversal versus using single agents alone. A second study by the 
Siliciano lab published in 2015 found that combining PKC agonists with either HDACi or JQ1 
led to a synergistic increase in latency reversal536. Additional studies found synergistic effects 
between ingenol derivatives and either JQ1551, 552 or PNB534, between bryostatin-1 and JQ1551, 
between prostratin and JQ1543, and between HMBA and prostratin553. These studies highlight the 
critical need of additional evaluations of not just single LRAs but LRA combinations that will 
likely be required to achieve a clinically significant reduction in the HIV-1 latent reservoir.  
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1.5 CLINICAL EVALUATION OF HIV-1 LATENCY REVERSAL AS A CURATIVE 
STRATEGY 
1.5.1 Cytokines 
The first study to describe latency reversal as a possible mechanism to reduce the latent reservoir 
dates back to 1998, in a publication by Chun et al477. Using their knowledge of HIV-1 
pathogenesis and the direct role of particular cytokines, especially pro-inflammatory cytokines, 
in modulating HIV-1 replication, the authors tested ex vivo single or combinations of cytokines 
on virus production using cells from both ART-naïve and ART-treated HIV-1-infected 
individuals. They found that the combination of IL-6 + TNF-α + IL-2 induced virus production 
to similar levels as that seen from treatment with anti-CD3/CD28 in the ART-treated individuals. 
These findings demonstrated that modulation of the cytokine microenvironment in vivo could 
theoretically be used to induce latent proviruses and reduce the size of the latent reservoir. 
During HIV-1 infection, it had been well documented that peripheral lymphocytes had 
both decreased production of and responsiveness to IL-2554. Therefore, both pre-clinical and 
clinical in vivo IL-2 administration was evaluated in HIV-1-infected individuals, largely as a 
means to try and increase CD4+ T cell counts and improve immune function554-570. While the 
collective findings from these early studies were largely inconclusive, showing increased CD4+ 
T cell counts in some with no clinical benefit in others. It quickly became clear that high-dose or 
continuous administration of IL-2 was associated with significant toxicity, while low-dose, 
intermittent administration was more tolerable. In 2000, a large retrospective study of 157 
patients who participated in randomized clinical trials of IL-2 therapy to treat HIV-1 infection 
prior to the introduction of ART (1995) was published571. This study found that IL-2 treatment 
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led to a significant increase in CD4+ T cell counts and lower plasma HIV-1 RNA levels; 
however, there were no significant improvements on clinical outcome. When clinical 
recommendations to initiate ART were based on CD4+ T cell counts and not on diagnosis, a 
clinical trial was conducted to assess the effect of IL-2 on time to initiate ART based on current 
CD4+ T cell counts572. This study found that while the time to initiate ART was deferred by up 
to 92 weeks following IL-2 therapy, there were no significant differences in adverse or AIDS-
defining events.  
Based on their ex vivo preliminary findings, as well as their knowledge from previously 
published data on IL-2 administration for the treatment of HIV-1, Chun et al. hypothesized that 
intermittent low-dose administration of IL-2 to HIV-1-infected individuals on ART could induce 
both transient induction of HIV-1 RNA and elimination of latently infected cells through viral 
cytopathic effects and/or immune effector mechanisms483-487. This mechanism to eradicate latent 
HIV-1 reservoirs later became known as the “kick and kill” approach. In this study, they found 
that administration if IL-2 led to significant reductions in the recovery of replication-competent 
virus from peripheral blood CD4+ T cells. In a subset of IL-2-treated individuals, virus could not 
be isolated from large bulk cultures of peripheral blood CD4+ T cells or from lymph node 
biopsies. This led the authors to conclude that intermittent administration of low-dose IL-2 with 
continuous administration of ART could significantly reduce the size of the latent reservoir.  
A second similar study was attempted in 3 HIV-1-infected individuals who had 
suppressed plasma viremia to below 5 copies/mL for at least 26 weeks573. In addition to 
administration of IL-2 while on continuous ART, they also included administration of the 
antibody OKT3, which is an anti-CD3-specific antibody. The idea behind this study was that IL-
2 and OKT3 may work synergistically to promote T cell proliferation and increase immune 
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function to aid in elimination of the latent reservoir. Administration of IL-2 + OKT3 led to a 
significant decrease in CD4+ T cells while showing transient effects on plasma viremia and no 
overall effect on the size of the latent reservoir. They also found significant increases in non-
specific T cell activation, cellular proliferation, and antibody-mediated immune responses 
against OKT3. There were also severe adverse events due to treatment, including seizures and 
renal failure. This finding suggested that the addition of OKT3 to IL-2 therapy was too toxic and 
should not be considered. 
The only way to determine if the latent reservoir has been eliminated following some sort 
of therapeutic intervention is through treatment interruption and subsequent evaluation of viral 
rebound. In order to determine if intermittent low-dose IL-2 administration during continuous 
ART was able to eliminate latently infected cells, two individuals from the Chun et al. study, 
with undetectable replication-competent virus from both blood and lymph node biopsies, were 
enrolled in a second study to undergo a treatment interruption574. Following treatment 
interruption, both patients experienced viral rebound within 3 weeks, indicating that the latent 
reservoir had not been eliminated. 
In 2009, a large-scale prospective study evaluating the effect of IL-2 therapy with ART 
on CD4+ T cell counts and clinical benefit was published575. This study, enrolling nearly 6,000 
people between the treatment and control groups, found no clinical benefit to IL-2 treatment with 
ART versus ART treatment alone. They did find, however, that the addition of IL-2 treatment led 
to a higher frequency of grade 4 adverse events. Collectively, all of these studies have 
demonstrated no clinical benefit to the use of IL-2 in reducing the HIV-1 latent reservoir or long-
term outcomes of disease. 
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Similarly to what had previously been demonstrated with the use of cytokine 
combinations in ex vivo cultures, IL-7 was also shown to potently induce latent HIV-1 in ex vivo 
cultures of purified rCD4 T cells isolated from suppressed individuals on ART476. 
Administration of IL-7 to HIV-1-infected individuals had previously shown clinical benefit 
through restoration of T cell homeostasis and increased thymic output576-578. In light of these 
findings, in vivo IL-7 administration was evaluated to assess its impact on latency reversal and 
the size of the latent reservoir579. While this study demonstrated that IL-7 had a minimal effect 
on virus production from latently infected cells, IL-7 significantly increased the size of the latent 
reservoir in ART-suppressed individual by increasing the total number of cells containing 
integrated HIV-1 DNA. This study demonstrated that the use of the homeostatic cytokine, IL-7, 
was not a useful therapeutic intervention for latency reversal but instead actually expanded the 
size of the latent reservoir in vivo. 
1.5.2 Histone deacetylase inhibitors (HDACi) 
While it became increasingly clear that the use of cytokines or non-specific T cell activation 
were either ineffective at reducing the latent reservoir or were found to be highly toxic, scientists 
searched for novel strategies that may provide better clinical benefit. In 2005, a small study 
evaluating the use of valproic acid plus intensified ART in 4 HIV-1-infected individuals on ART 
was published580. Valproic acid is an FDA-approved anti-convulsant and mood stabilizing drug 
that functions as an HDACi581. It had previously been shown that treatment of rCD4 T cells in 
vitro at clinically achievable concentrations of valproic acid did not induce T cell activation492. 
Therefore, it was speculated that the use of HDACi, such as valproic acid, could be a safe and 
effective way to eliminate the latent reservoir. In this study, 4 HIV-1-infected individuals 
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underwent ART intensification through addition of enfuvirtide plus administration of oral 
valproic acid. This study found a significant reduction in the size of the latent reservoir in 3 out 
of 4 individuals. They also found that the addition of valproic acid to ART was well tolerated. 
This preliminary study led to the further investigation of valproic acid as a possible treatment 
option to reduce or eliminate the latent reservoir. 
Despite these promising initial findings, several additional small-scale studies found that 
administration of valproic acid to HIV-1-infected individuals on ART had limited to no effect on 
the size of the latent reservoir179, 582-585. In light of these conflicting results, a randomized 
multicenter, cross-over study was conducted in 56 virologically suppressed individuals who 
would be under study observation for up to 1 year586. This study conclusively found no clinical 
benefit to the addition of valproic acid to ART and showed no decrease in the size of the HIV-1 
latent reservoir. This suggested that more potent HDACi may be needed in order to effectively 
reverse HIV-1 latency in vivo and reduce the size of the latent reservoir. 
In 2009, it was shown that selective class 1 HDACi could potently induce virus 
production from both latently infected cell lines and rCD4 T cells isolated from ART-treated 
individuals587. The recently licensed class 1 HDACi, SAHA, was evaluated as an inducer of 
latent HIV-1 expression510, 511. SAHA, also known as vorinostat, is FDA-approved for treatment 
of cutaneous T cell lymphoma and had previously been evaluated for safety and tolerability588,
589. This study found that SAHA was a more potent and selective inducer of latent HIV-1 versus
valproic acid, and thus provided a rationale for clinical evaluation of SAHA administration to 
HIV-1-infected individuals on ART. 
The first clinical evaluation of SAHA administration on the HIV-1 latent reservoir was 
published by Archin et al. in 2012590. This study evaluated the effect of oral single-dose SAHA 
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administration on the HIV-1 latent reservoir of 8 patients who had plasma viral loads below the 
clinical limit of detection. While this study found an increase in cell-associated HIV-1 RNA in 
all 8 individuals treated with SAHA, they did not observe a reduction in the level of replication-
competent virus that could be recovered from peripheral rCD4 T cells. Furthermore, changes in 
HIV-1 DNA were not measured so it could not be determined if SAHA treatment had any effect 
on the size HIV-1 DNA reservoir. One major caveat to this study was that 6 of 8 patients had low 
basal levels of viral transcription prior to treatment, suggesting that these cells were not truly 
latent. This raised the question of whether SAHA reactivated de novo viral transcription or 
simply increased basal levels of transcription that were already occurring. Despite the limitations 
of this study, it demonstrated the use of a specific therapeutic agent targeted at the HIV-1 latent 
reservoir that was safe and increased viral transcription from rCD4 T cells. 
While this initial evaluation of SAHA used single dose administration, two additional 
studies evaluated the use of multi-dose591 or daily administration592 of SAHA on latency reversal 
and the size of the latent reservoir. The first study, also by Archin et al., recruited 5 study 
participants from the single-dose study who agreed to receive oral administration of SAHA for 
three consecutive days a week for 8 weeks591. The authors found that cell-associated HIV-1 RNA 
only increased in 3 of 5 patients following multi-dose administration of SAHA. Importantly, they 
found no significant changes in plasma HIV-1 RNA or HIV-1 DNA, indicating that multi-dose 
administration of SAHA did not reduce the size of the latent reservoir.  
The second study enrolled 20 HIV-1-infected individuals on ART with undetectable 
plasma HIV-1 RNA who would receive daily single-dose SAHA for 14 consecutive days592. In 
contradiction to the previous study, this study showed statistically significant increases in cell-
associated HIV-1 RNA (7.4 median fold increase) following the 14-day administration of 
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SAHA, however, there was a large degree of variation between donors. Aside from increases in 
cell-associated HIV-1 RNA, they found no significant changes in plasma HIV-1 RNA, HIV-1 
DNA (total or integrated), level of inducible virus, or markers of T cell activation. These studies 
collectively suggest that administration of SAHA alone, either as a single dose or in multiple 
doses, is insufficient at reversing latent HIV-1 or reducing the latent reservoir. 
In addition to SAHA, two other HDACi have been evaluated for their clinical potency as 
LRAs. PNB, a HDACi that is newly FDA-approved for the treatment of multiple myeloma593, 
was evaluated in a phase I/II clinical study. In 2013, a comparison of multiple HDACi in phase 
II/III clinical evaluation for non-HIV diseases identified PNB as a potent HIV-1 LRA in a 
primary cell model508. PNB was found to significantly increase virus production from latently 
infected cells in comparison to SAHA, without affecting cell viability and only minimally 
increasing T cell activation. Therefore, clinical evaluation of PNB seemed credible.  
Fifteen HIV-1-infected individuals on ART were enrolled to receive PNB for three 
consecutive days a week for 8 weeks in a similar design as one of the previous SAHA trials591. 
This study found a significant increase in cell-associated HIV-1 RNA (3.5 median fold increase) 
as well as a significant increase in plasma viral load. However, there were no significant 
decreases in HIV-1 DNA (total or integrated), or recovery of replication-competent virus. Nine 
of the 15 study participants underwent an ATI to evaluate the effect of PNB treatment on time to 
rebound. The median time to rebound was 17 days and was not significantly delayed from 
previous findings. These findings suggested that while PNB was able to effectively disrupt HIV-
1 latency in vivo, it did not lead to a reduction in the HIV-1 latent reservoir or prevent or delay 
viral rebound following treatment interruption. 
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In an additional analysis of HDACi in clinical use or development revealed that the 
HDACi, RMD, was an even more potent LRA than PNB513. RMD is an FDA-approved drug 
used to treat T cell lymphomas594. A proof-of-concept phase 1b/IIa trial of 6 aviremic 
individuals, intravenous administration of RMD once a week for three weeks, found an increase 
in cell-associated HIV-1 RNA and plasma HIV-1 RNA595. Consistent with the previous findings 
from the use of other HDACi, they found that RMD did not significantly change the size of the 
latent reservoir or the level of replication-competent virus. Moderate increases in T cell 
activation were noted. 
1.5.3 Disulfiram 
In addition to the clinical evaluation of cytokines and HDACi to reduce the HIV-1 latent 
reservoir, the drug disulfiram has also been evaluated. This compound was originally identified 
(in the context of HIV-1) in a high-throughput screen to find LRAs that didn’t increase T cell 
activation in a primary T cell model of HIV-1 latency546. Disulfiram is an FDA-approved drug 
used to treat alcoholism that has been in clinical use for decades, with a well-characterized safety 
and tolerability profile548-550. Following the identification of disulfiram as a potential LRA in an 
in vitro primary cell model, in was evaluated at FDA-approved clinical doses in HIV-1-infected 
individuals on ART for its ability to increase plasma viremia and/or decrease the size of the 
latent reservoir in a small phase I, single arm study. This drug was found to be safe and well 
tolerated. While there were no overall significant increases in plasma viremia or changes in the 
size of the latent reservoir, there were rapid but transient increases in plasma viremia noted in a 
subset of individuals that was significantly increased from baseline. This study warranted further 
66 
evaluation, possibly using higher doses or multiple doses of disulfiram to achieve clinical 
significance. 
Following this study, a phase II dose escalation study was conducted in 30 HIV-1-
infected individuals on ART596. This study demonstrated that doses up to 2000mg of disulfiram 
(4 times the FDA-approved dose) were safe and well tolerated. This study specifically assessed 
the impact of different doses of disulfiram on HIV-1 transcription. They found increases in cell-
associated HIV-1 RNA following administration of disulfiram with all doses. No significant dose 
effects were seen. While this study warrants further investigation of disulfiram administration as 
a LRA, possibly in combination with other therapeutic interventions, the overall impact on 
latency reversal was limited. 
1.5.4 PKC agonists 
In pre-clinical evaluations, bryostatin-1 proved to be unique among other known PKC agonists. 
It induced robust in vitro and ex vivo latency reversal at low nanomolar concentrations without 
inducing T cell activation or effecting cell viability482, 525, 536. These collective findings led to the 
clinical evaluation of bryostatin-1 as a LRA in a phase I pilot study597. 
Much like many of the other LRAs under clinical evaluation for the treatment of HIV-1, 
bryostatin-1 has been evaluated in several phase I and II clinical trials as an antineoplastic agent 
to treat various cancers598. In this pilot study, 12 participants were enrolled and divided into two 
arms receiving different doses (10 vs 20 µg/m2) of bryostatin-1. They measured both cell-
associated and plasma HIV-1 RNA as well as PKC activity and biomarkers of inflammation. 
Much like previous trials, this study found that bryostatin-1 was safe and well tolerated at both 
concentrations tested, however, there was no increase in cell-associated or plasma HIV-1 RNA. 
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There were also no detectable increases in PKC activity or in biomarkers of activation. These 
findings suggest that the concentrations of bryostatin-1 used in this study to reverse latent HIV-1 
were likely not high enough to achieve a clinical effect. Further studies are required to determine 
if higher doses of bryostatin-1 are safe and if they are able to reverse HIV-1 latency and reduce 
the size of the latent reservoir. 
The collective findings thus far from clinical evaluations of LRAs have demonstrated that 
while some agents are able to provide a "kick," in terms of either increased viral transcription or 
virus production from latently infected cells, they are not effective at inducing a "kill," as 
measured by no change in the size of the HIV-1 DNA reservoir or recovery of replication-
competent virus. Because of their known clinical recommendations, the LRAs that have been 
tested clinically to target the HIV-1 latent reservoir have been found to be safe and well 
tolerated, with minimal increases in adverse events over ART treatment alone. These findings 
provide hope that putative LRAs, such as the HDACi, may be used clinically in combination 
with other agents that are able to efficiently aid in the kill of latently infected cells to reduce or 
eliminate the HIV-1 latent reservoir in infected individuals on ART. A further evaluation of the 
HIV-1 latent reservoir, including a better understanding of HIV-1 latency in the individual 
subsets of CD4+ T cells that constitute the latent reservoir, will help provide useful insight into 
the mechanisms or pathways that may need to be exploited to significantly reduce the size of the 
latent reservoir. 
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2.0  SPECIFIC AIMS 
The presence of an HIV-1 latent viral reservoir in rCD4 T cells155-157, established shortly after 
infection370, presents a stable mechanism for life-long persistent infection4, 159. rCD4 T cells are a 
heterogeneous population consisting of TN, TSCM, TCM, TTM, TEM, and TTD cells, all of which 
have been implicated as reservoirs of latent HIV-1599. A preliminary evaluation of the 
contribution of each CD4+ T cell subset to the HIV-1 latent reservoir in HIV-1-infected 
individuals on ART revealed that the TCM cells, followed by the TTM cells, were the major 
contributing cell subsets to the latent reservoir, based on both the frequency of each subset in the 
peripheral blood and the frequency of HIV-1 DNA317. This study also found that TN cells were 
only a minor contributor to the latent viral reservoir and were regarded as insignificant. As such, 
the vast majority of studies evaluating HIV-1 latency and latency reversal have focused on 
resting memory cells as a whole or in purified TCM cells, largely omitting TN cells from further 
evaluation. Therefore, we propose to investigate the establishment and reversal of HIV-1 
latency in purified TN and TCM cells using both an in vitro primary cell model as well as in 
ex vivo patient-derived cells. 
Based on this previously published data, we hypothesize that both the establishment and 
reversal of latent HIV-1 would differ between the different subsets of rCD4 T cells that 
constitute the latent reservoir. As such, we would expect the efficiency of the “kick and kill” 
approach to be different in the different CD4+ T cell subsets. This would suggest that more than 
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one approach may be needed to efficiently eliminate all infected cells within the latent reservoir 
in HIV-1-infected individuals on ART. 
AIM 1: Develop a primary cell model of HIV-1 latency in purified CD4+ TN and TCM cells. 
a. Determine the efficiency of virus production from TN and TCM cells following latency
reversal with a variety of LRAs that target different signaling pathways or repressive
transcription mechanisms.
b. Determine how CCL19 makes rCD4 T cells permissive to HIV-1 infection.
The limited evaluation of TN cells has largely demonstrated that virus production following 
latency reversal is limited when assessed on a population level317, 360. However, one study 
revealed similar levels of virus production between TN cells and TCM, TTM, or TEM cells 
following latency reversal when normalized for differences in infection frequency600. We 
hypothesize that TN cells will produce similar levels of virus compared to TCM cells following 
latency reversal when using rigorous, ultrasensitive quantitative evaluations to measure low-level 
virus production and normalize for differences in infection frequency. 
AIM 2: Determine if the data obtained using our primary cell model of HIV-1 latency in 
AIM 1 are reproducible in purified TN and TCM cells from HIV-1-infected individuals on 
long-term ART. 
a. Determine if TN cells produce similar levels of virus compared to TCM cells when
normalized for differences in infection using a variety of LRAs.
b. Determine the frequency of replication-competent virus recovered from TN and TCM cells.
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Using the same quantitative analyses as used in AIM 1, we hypothesize that we would also see 
similar levels of virus production from TN and TCM cells following latency reversal using cells 
isolated from HIV-1-infected individuals on ART. While there are currently conflicting views in 
the field on using PCR-based quantitative measures as a surrogate marker for cell culture-based 
quantitative measures of latency reversal441, 601, we would expect to see similar levels of 
replication-competent virus recovered from TN and TCM cells using the quantitative viral 
outgrowth assay, if total virus production (measured by extracellular HIV-1 RNA) is a surrogate 
measure for replication-competent virus.  
AIM 3: Determine if specific ARVs or ARV drug classes affect virus production in latency 
reversal strategies using a primary cell model of HIV-1 latency. 
Previous publications have demonstrated that NNRTIs are able to prevent virus production in 
HIV-1-transfected transformed cell lines through increased intracellular processing of Gag and 
Gag-Pol and premature activation of HIV-1 protease602, 603. Based on these findings, we 
hypothesize that NNRTIs will decrease virus production compared to other ARV drug classes 
when employing the “kick and kill” strategy of latency reversal.  
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3.0  MATERIALS AND METHODS 
Purification of CD4+ T cell subsets from HIV negative donors 
Blood was either obtained as a 180mL whole blood large volume blood draw or a buffy coat 
obtained from the Central Blood Bank, which were approved by the University of Pittsburgh 
Institutional Review Board. Written informed consent was provided for all donors. PBMCs were 
isolated by Ficoll-PaqueTM PLUS (GE Healthcare) density gradient centrifugation. rCD4 T cells 
were purified by first isolating total CD4+ T cells by magnetic bead negative selection using a 
CD4+ T cell purification kit, followed by magnetic bead negative selection using anti-CD25, 
anti-CD69, and anti-HLA-DR antibodies. TN cells were isolated from the rCD4 T cells by 
magnetic bead depletion of CD45RO+ cells. TCM cells were isolated from the rCD4 T cells by 
magnetic bead depletion of CD45RA+ cells, followed by positive selection of CCR7 expressing 
cells. Increased labeling times were used to increase cell purity. All magnetic bead purification 
kits and antibodies were obtained from Miltenyi Biotec. The purity of the TN and TCM cells was 
assessed by flow cytometry (LSR II, BD Biosciences) using the following antibodies: CD3-
V450, CD4-PerCP-Cy5.5, CD45RA-FITC, CCR7-PE, CD27-APC-H7, and CD62L-APC (BD 
Biosciences). Data were analyzed using FlowJo vX.0.7.  The TN and TCM cell surface phenotypes 
were as follows: TN cells (CD45RA+, CCR7+, CD27+, CD62L+) and TCM cells (CD45RA-, 
CCR7+, CD27+, CD62L+). CD4+ TN and TCM cell purity was routinely found to be ≥ 98 % and 
≥ 96 %, respectively (see Fig. 6A).  
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Purification of CD4+ T cell subsets from HIV-1+ leukophereses 
Leukophereses were obtained from long-term suppressed HIV-1+ individuals following written 
informed consent and approval by the University of Pittsburgh Institutional Review Board. 
Purification of rCD4 T cells was performed the same as described above; however, we also 
saved cell pellets of total CD4+ T cells and the CD25+CD69+HLA-DR+ activated T cells for 
DNA quantification. CD4+ TN cells were purified from the rCD4 T cells first by removing cells 
that expressed CD45RO, yielding the total naïve cell fraction, followed by removal of cells 
expressing CD95, splitting this fraction into ‘true’ TN cells and TSEM cells. The TCM cells were 
purified from the rCD4 T cells first by removing cells that expressed CD45RA followed by 
positive selection for cells expressing CD62L. The CD62L- fraction was also saved as the 
TTM+TEM cell population for DNA quantification and additional experiments. A detailed 
schematic outlining the purification process and all CD4+ T cell subsets isolated is shown in Fig. 
5.
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Figure 5: Schematic representation of strategy utilized to purify CD4+ T cell subsets from Leukaphereses. 
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Infection of primary CD4+ T cell subsets 
Purified resting TN or TCM cells were cultured at a density of 1-2 x 106 cells/mL in RPMI-1640 
supplemented with 10% fetal bovine serum (FBS), 100 units/mL penicillin, 100 µg/mL 
streptomycin and 0.29 mg/mL glutamine (all from Life Technologies). CCL19 (100 nM final 
concentration) was added to the cells 2 days prior to infection with HIV-1, as described 
previously604. Cells were infected with either the CXCR4-tropic strain HIV-1LAI605 or the CCR5-
tropic strain HIV-1BaL at a multiplicity of infection (MOI) of 1 (as titered on GHOST cells606) for 
2 to 3 h at 37°C. HIV-1BaL was obtained through the NIH AIDS Reagent Program, Division of 
AIDS, NIAID, NIH: HIV-1BaL from Drs. Gartner, Popovic and Gallo607. Cells were then washed 
twice with fresh media to remove free virus. Every 2 days following infection 10 units/mL 
recombinant IL-2 (Roche) was added to the media, in addition to 300 nM efavirenz (EFV, NIH 
AIDS Reagent Program) to inhibit multiple rounds of HIV-1 infection. For some experiments 
where noted, 300 nm RAL (NIH AIDS Reagent Program), was also included to block multiple 
rounds of HIV-1 infection. 
Flow Cytometry 
T cell activation was assessed by flow cytometry using the following antibodies from BD 
Biosciences: CD3-V450, CD4-PerCP-Cy5.5, CD25-PE-Cy7, CD69-PE, and HLA-DR-FITC. To 
measure the expression of the HIV-1 co-receptors CCR5 and CXCR4, TN and TCM cells were 
stained with CD3-V450, CD4-PerCP-Cy5.5 and either CCR5-PE or CXCR4-PE (BD 
Biosciences). Typically 50,000-100,000 cells were collected per sample in the CD3+CD4+ gate 
to adequately measure CCR5 or CXCR4 expression. Dead cells were excluded based on SSC-A 
and FSC-A plots.  For some experiments where noted in the text, cell viability was determined 
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using a LIVE/DEAD fixable cell viability dye for flow cytometry (Invitrogen). The intracellular 
proliferation marker, Ki-67, was stained following the manufacturer’s protocol (BD 
Biosciences); however, instead of using the cell viability solution (7AAD) to discriminate live 
cells from dead cells, the cells were first stained with LIVE/DEAD-APC (Invitrogen) prior to 
fixation and permeabilization for Ki-67 staining. All samples were run on an LSRII and the data 
were analyzed using FlowJo vX.0.7. 
Reactivation of latent HIV-1 from TN and TCM CD4+ T cells following in vitro infection 
Seven days post-infection, the TN and TCM cells were washed with media and plated in a 96-well 
plate at a density of 100,000 cells/well. Anti-CD3/CD28 antibodies (3 beads per cell; Life 
Technologies), 10 nM PMA (Sigma Aldrich) + 10 µg/mL PHA (Remel), 5 µM prostratin, or 500 
nM SAHA (Cayman Chemicals) was then added to duplicate wells. Unstimulated cells were 
used as a control. Three and 7 days post-stimulation, IL-2 (10U/mL) and EFV (300nM) were 
added to each well. 
Reactivation of latent HIV-1 from TN and TCM cells isolated from HIV-1-infected donors 
Following purification, TN and TCM cells were plated in separate 24-well plates at a density of 
106 cells/well. Cells were cultured in the presence of 300 nM EFV + 300 nM RAL to prevent 
viral spread, in addition to 10 U/mL IL-2 to maintain cell viability. Cells were stimulated in 
duplicate wells with anti-CD3/CD28 antibodies (3 beads per cell; Life Technologies), 10 µg/mL 
PHA (Remel) + 100 U/mL IL-2 (Roche), 5 nM PMA + 500 µg/mL ionomycin (Sigma), 5 µM 
prostratin, 17 nM PNB (pulsed for 30 minutes, Selleckchem), or 50 nM RMD (pulsed for 4 
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hours, Selleckchem). Unstimulated cells were used as a control. Two and four days post-
stimulation, IL-2 (10U/mL), EFV (300nM), and RAL (300nM) were added to each well. 
Extraction and quantification of HIV-1 DNA 
Total cellular DNA was extracted from pooled duplicate culture wells, and was assayed for total 
HIV-1 DNA and 2-LTR circle DNA levels by qPCR, as described previously183, 235. Each sample 
was run in triplicate using the LightCycler® 480 System (Roche). DNA standards were included 
as described previously183, 235. HIV-1 DNA and 2-LTR circles were normalized to the total 
number of cells assayed by qPCR amplification of the CCR5 gene608. 
Extraction and quantification of extracellular virion-associated HIV-1 RNA 
Culture supernatant was centrifuged at 16,100 x g for 70 min to pellet HIV-1 virions. Viral RNA 
was then extracted using the RNeasy PLUS Mini Kit (Qiagen), and quantified using a real-time 
reverse transcriptase (RT)-initiated PCR assay with single-copy sensitivity, as described 
previously160 using AffinityScript Multiple Temperature RT (Agilent technologies) in place of 
Superscript II RT. The primers and probe used to quantify HIV-1 RNA were the same as those 
used to quantify total HIV-1 DNA. No RT control wells were run for each sample to ensure 
amplification was from RNA only and not DNA. 
Calculating decay of HIV-1-infected cells following latency reversal 
HIV-1 DNA was quantified by qPCR and normalized to cell number as described above at each 
respective time point following latency reversal with anti-CD3/CD28, PMA + PHA, prostratin, 
and SAHA. The level of HIV-1 DNA/cell in unstimulated control cells was normalized to 100 
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for each donor. The level of HIV-1 DNA/cell following treatment with each LRA was then 
normalized to the level of HIV-1 DNA/cell from the unstimulated control cells. The log10 of each 
value was then plotted on a linear scale to generate linear regression curves and decay rates. 
Integration site sequencing 
Genomic DNA (20 µg) was isolated using the DNeasy Blood and Tissue Kit (Qiagen) from 
resting TN, TCM, and PHA-activated CD4+ T cells infected with HIV-1LAI. DNA was digested 
overnight with 100 U each of MseI and BglII and purified using the QIAquick PCR Purification 
Kit (Qiagen). Double-stranded asymmetric linkers were prepared by heating 10 µM of each 
oligonucleotide to 90°C in 10 mM Tris–HCl, pH 8.0 and 0.1 mM EDTA and slowly cooled to 
room temperature. Linker DNA (1.5 µM) was ligated with digested cellular DNA (1 µg) 
overnight at 12°C with 800 U T4 DNA ligase in four parallel reactions, and the DNAs were 
pooled and re-purified using the QIAquick PCR Purification Kit. Semi-nested PCR was used to 
selectively amplify integration sites, with reactions multiplexed into eight separate samples per 
PCR stage. The first and second rounds of PCR utilized nested HIV-1 U5 primers, whereas the 
same linker-specific primer was used for both rounds. The linker primer and second round U5 
primer each encoded adapter sequences necessary for Illumina sequencing, as well as sequencing 
primer binding sites. To afford the identification of unique library samples from multiplexed 
sequencing runs, unique bar-coded linker DNAs and linker-specific primers were employed for 
each sample, and the nested U5 primer additionally encoded a unique 6 bp index sequence. The 
sequences of utilized oligonucleotides are shown in Table 2. Each PCR contained 100 ng 
template DNA, 1.9 µM U5 primer and 0.375 µM linker primer. Each reaction was carried out 
using the Advantage 2 Polymerase Mix (Clontech) according to the manufacturer’s instructions, 
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and incubated at 94°C for 2 min, followed by 30 cycles at 94°C for 15s, 55°C for 30s, and 68°C 
for 45s, which was followed by a final extension for 10 min at 68°C. Pooled PCRs were purified 
using the QIAquick PCR Purification Kit, and second round reactions were submitted for 
sequencing on the Illumina MiSeq platform at the Dana-Farber Cancer Institute Molecular 
Biology Core Facilities. Resulting sequences were mapped to the hg19 version of the human 
genome using BLAT, allowing for a minimum of 97 % unique sequence identity match. 
Correlations of integration site distributions relative to various genomic features were conducted 
using BEDTools609. Statistical analysis of resulting integration frequencies was determined using 
R610, 611, with statistical significance being calculated by Fisher’s exact test and Wilcoxon rank 
sum test. 
Table 2: Oligonucleotide sequences used for integration site mapping. 
Oligonucleotide Use Oligonucleotide Sequence (5'-3') 
First Round HIV-1 
LTR Primer TGTGACTCTGGTAACTAGAGATCCCTC 
Linker Top Strand 
(Activated CD4+) PO4-GTCCCTTAAGCGGAG-NH2 
Linker Bottom Strand 
(Activated CD4+) GTAATACGACTCACTATAGGGCCTCCGCTTAAGGGACT 
Linker Primer 
(Activated CD4+) 
CAAGCAGAAGACGGCATACGAGATCGGTCTCGGCATTCCTGCTGAACCGCTCT
TCCGATCTGTAATACGACTCACTATAGGGC 
HIV-1 LTR Primer 
(Activated CD4+) 
AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCG
ATCTCGATGTGAGATCCCTCAGACCCTTTTAGTCAG 
Linker Top Strand 
(CD4+ TN) 
PO4-CGAGGCGTCTAATGC-NH2 
Linker Bottom Strand 
(CD4+ TN) 
GCTATAGCAGCACATCAGTTAGGCATTAGACGCCTCGT 
Linker Primer 
(CD4+ TN) 
CAAGCAGAAGACGGCATACGAGATCGGTCTCGGCATTCCTGCTGAACCGCTCT
TCCGATCTGCTATAGCAGCACATCAGTTAG 
HIV-1 LTR Primer 
(CD4+ TN) 
AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCG
ATCTTGACCAGAGATCCCTCAGACCCTTTTAGTCAG 
Linker Top Strand 
(CD4+ TCM) 
PO4-CTATGACGGTGACGC-NH2 
Linker Bottom Strand 
(CD4+ TCM) 
GAGAATCCATGAGTATGCTCACGCGTCACCGTCATAGT 
Linker Primer 
(CD4+ TCM) 
CAAGCAGAAGACGGCATACGAGATCGGTCTCGGCATTCCTGCTGAACCGCTCT
TCCGATCTGAGAATCCATGAGTATGCTCAC 
HIV-1 LTR Primer 
(CD4+ TCM) 
AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCG
ATCTACAGTGGAGATCCCTCAGACCCTTTTAGTCAG 
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Quantification of F-actin density 
F-actin density was quantified both by flow cytometry and confocal microscopy. For flow
cytometry, cells were first surface stained for CD3-V450 and CD4-PerCP-Cy5.5 (BD 
Biosciences), then fixed in 1% paraformaldehyde (PFA), permeabilized with 0.1% Triton-X 
(Sigma Aldrich) supplemented with 5% FBS, and then stained with 100 nM phalloidin-FITC 
(Sigma Aldrich) in phosphate-buffered saline (PBS) supplemented with 5% FBS. Following 
staining, cells were washed with PBS supplemented with 5% FBS to remove any unbound 
phalloidin. All samples were run within 24 h on an LSRII and the data were analyzed using 
FlowJo vX.0.7. 10,000 events were collected per sample in the CD3+CD4+ gate. Dead cells 
were excluded based on SSC-A and FSC-A plots. Where specified, latrunculin A (Thermo 
Fisher) was added to cells 6 h prior to the addition of CCL19. Forty-eight hours post-CCL19 
treatment, cells were analyzed for F-actin density and cell viability by flow cytometry as 
described above. For imaging, cells were fixed in 1% PFA, permeabilized with 0.1% Triton-X 
supplemented with 5% FBS, washed with PBS supplemented with 5% FBS, and then stained 
with 1U/mL phalloidin-AF488 (Life Technologies) in PBS supplemented with 5% FBS. The 
cells were washed, stained with 1µg/mL 4',6-diamidino-2-phenylindole (DAPI) (Life 
Technologies ), and washed again. After the second wash, the cell pellets were resuspended in 
gelvatol mounting media and mounted onto microscope slides for imaging. Images were 
collected using a Nikon A1 R spectral confocal microscope with a 100x 1.4NA oil immersion 
objective. Following collection using NIS-Elements images were parsed to Imaris (Bitplane) and 
rendered in three-dimensions. The total actin volume in each cell was calculated following 
surface extraction and volume rendering in Imaris. 
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Quantification of cellular dNTP concentrations  
Cellular dNTPs were extracted from 5-8 million cells and quantified as described previously612. 
Quantification of replication-competent virus 
Replication-competent virus was measured using the quantitative viral outgrowth assay as 
previously described613. Duplicate wells were cultured in five-fold dilutions starting with one 
million cells per well down to 320 cells per well. Before PHA-activated lymphoblasts were 
added to each well, they were CD8-depleted by positive selection using CD8 microbeads 
(Miltenyi Biotec). The infectious units per million cells were calculated as described 
previously613, 614. The frequency of cultures harboring replication-competent virus was calculated 
by dividing the total number of wells that were p24 positive by the total number of wells that 
were cultured. 
Cell lines 
J89GFP cells615 and jurkat cells (clone E6-1, ATCC® TIB-152™) were cultured at a density of 1-
2 x 106 cells/mL in RPMI-1640 supplemented with 10% FBS, 100 units/mL penicillin, 100 
µg/mL streptomycin, and 0.29 mg/mL glutamine (all from Life Technologies). Prior to treatment 
with ARVs (EFV, 1-10µM; RPV, 1-10µM; 3TC, 50µM, 250µM; TNV, 100µM, 500µM; all from 
the AIDS Reagent Repository), cells were plated in 96 well plates at a density of 200,000 
cells/well. ARVs were added to triplicate wells prior to stimulation with 30nM PMA (Sigma 
Aldrich). Both stimulated and unstimulated jurkat cells were used as negative controls. 
Unstimulated J89GFP cells were used as a background control. To assess viral transcription, the 
cells were harvested 48 h post-stimulation and first stained for cell viability by LIVE/DEAD-
81 
APC staining (Invitrogen), and then run on an LSRII to measure both cell viability and GFP 
expression. The culture supernatant was used to measure virus production by p24 ELISA 
according to the manufacturer’s instructions (ZeptoMetrix Corporation). 
Statistical analyses 
Statistical analysis of integration sites was determined by Fisher’s exact test or Wilcoxon rank 
sum test (Supplemental Table 1). Statistical comparison between paired samples was analyzed 
using a Wilcoxin matched-pairs signed rank test for nonparametric analyses or a student t test for 
parametric analyses. For all unpaired samples in which the distribution was either unknown or 
was not normally distributed, p values were determined using a Mann-Whitney test. Spearman 
correlation analyses were used to determine significant correlations between virion production 
and the frequency of HIV-1 infection post-treatment with LRAs. For all statistical analyses, a p 
value < 0.05 was considered significant.  
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4.0  ESTABLISHMENT AND REVERSAL OF HIV-1 LATENCY IN PRIMARY CD4+ 
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4.1 INTRODUCTION 
The rCD4 T cell population is heterogeneous and includes TN, TCM, TTM, TEM, and TTD cells. In 
HIV-1-infected individuals, viral DNA has been detected in all of these CD4+ T cell subsets, 
although the levels of total HIV-1 DNA are typically highest in the TCM and TTM compartments, 
suggesting that they may be the major reservoirs of latent viral infection317, 360, 362, 600. The 
quantitative viral outgrowth assay (QVOA), which measures the frequency of replication-
competent HIV-1, has long been considered a gold standard measure of the size of the inducible 
latent reservoir in individuals on suppressive ART613. The frequency of replication-competent 
HIV-1 has shown a great deal of variation between studies and is dependent on how long the 
patient population has been on therapy and if they were treated during chronic or acute 
infection371, 441, 616. Replication-competent virus in cells from infected individuals on suppressive 
ART has also been recovered in all of the different T cell subsets317, 340, albeit to varying degrees 
due to donor variation. One study revealed that while replication-competent HIV-1 was 
consistently detected within TCM cells, it was not frequently detected in the TTM cell 
compartment616. They further showed that more infectious virus could be recovered from TN 
cells than TTM cells when individuals were treated during chronic versus acute HIV-1 
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infection616. These findings highlight that quantification of viral DNA alone is not necessarily 
predictive of the size of the inducible latent reservoir, and suggests caution in labeling a cellular 
reservoir of latent HIV-1 as “major” based solely on the frequency of infection.  
In addition to the memory CD4+ T cell subsets, HIV-1 DNA is almost always detected in 
TN cells in both viremic and suppressed individuals, although with a much lower frequency 
compared to the TCM and TTM compartments309-317, 340, 600, 617-619. Interestingly, in 2013 Saez-
Cirion et al. reported that in some HIV-1-infected individuals who received ART within 10 
weeks of primary infection, viremia could be controlled for at least 24 months post-treatment 
interruption360. In this patient population, HIV-1 DNA was only detected in CD4+ TN cells in 2 
of 11 individuals, whereas all the resting memory CD4+ T cell subsets (TCM, TTM and TEM) 
harbored comparable levels of HIV-1 DNA360. This finding suggests that the latent HIV-1 
reservoir in CD4+ TN cells may be more important than previously considered.  
The naïve and different resting memory CD4+ T cell subsets differ in lifespan, 
proliferative capacity, antigen response time, residence throughout the body, and in their HIV-1 
co-receptor, CCR5 and CXCR4, expression levels355, 620, 621. In light of this, we hypothesized that 
the establishment and reversal of HIV-1 latency would differ between naïve and memory CD4+ 
T cells, and that understanding these phenotypes in different CD4+ T cell subsets could facilitate 
the development of effective cure strategies to purge the latent reservoir. Given the low 
frequency of latently infected cells in ART-suppressed individuals, approximately 100 copies of 
HIV-1 DNA or one infectious unit per 106 rCD4 T cells158, 440, 441, we sought to compare and 
contrast latent HIV-1 infection using a primary cell model in highly purified TN and TCM CD4+ 
T cells. 
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4.2 RESULTS 
4.2.1 Direct Infection of rCD4 Naïve and Central Memory T Cells With HIV-1 
Given the low infection frequency of HIV-1 in individuals on ART, it is difficult to use donor-
derived cells to perform detailed in vitro analyses. Therefore, we established an appropriate in 
vitro primary cell model of HIV-1 latency in rCD4 TN and TCM cells. We chose to expand the 
assay system developed by Saleh et al., which uses the chemokine CCL19 to enhance the 
permissiveness of rCD4 T cells to HIV-1 infection, thereby maintaining the integrity and 
authenticity of the TN and TCM cell populations without inducing T cell activation or 
differentiation442. Because prior published studies using this model had only characterized the 
establishment and reversal of HIV-1 latency in total rCD4 T cells442, 456, 470, we first quantified 
the ability of X4- (HIV-1LAI) and R5-tropic (HIV-1BaL) strains of HIV-1 to infect highly purified 
CD4+ TN and TCM cells (Fig. 6A) in the absence and presence of CCL19 (Fig. 6C, 6D). Both cell 
types were equally resistant to HIV-1LAI and HIV-1BaL infection in the absence of CCL19 (Fig. 
6C, 6D). We found that CCL19 significantly enhanced HIV-1LAI infection of both TN (Fig. 6C) 
and TCM (Fig. 6D) cells as assessed by quantification of total HIV-1 DNA. However, TCM cells 
were more efficiently infected (mean fold increase = 15.5) than were the TN cells (mean fold 
increase = 3.65). CCL19 was also found to increase the ability of HIV-1BaL to infect TCM, but not 
TN, cells (Fig. 6C, 6D). The latter could be due to the extremely low surface expression of CCR5 
on TN cells, which was not affected by exposure to CCL19 (Fig. 7). Treatment with CCL19 also 
had no affect on the surface expression of CCR5 on TCM cells or CXCR4 expression on either 
cell type (Fig. 7). A small percentage of HIV-1 reverse transcripts that fail to integrate are 
converted to two long terminal repeat (2-LTR)-containing circles622. 
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Figure 6: Infection of TN and TCM cells by CXCR4-tropic (HIV-1LAI) and CCR5-tropic (HIV-1BaL) HIV-1 in 
the absence and presence of CCL19. (A) TN and TCM cells were purified from rCD4 T cells based on the variable 
cell surface expression of CD45RA, CCR7, CD27 and CD62L. TN cells were defined as 
CD45RA+/CCR7+/CD27+/CD62L+. TCM cells were defined as CD45RA-/CCR7+/CD27+/CD62L+. The purity of each 
subset was determined by surface expression of each marker as measured by flow cytometry. Representative 
histograms from one donor are shown. (B) Schematic representation of the experimental approach. (C) 
Quantification of total HIV-1 DNA in TN cells 7 days post-infection. (D) Quantification of total HIV-1 DNA in TCM 
cells 7 days post-infection. (E) Quantification of HIV-1 2-LTR circles in TN cells 7 days post-infection. (F) 
Quantification of HIV-1 2-LTR circles in TCM cells 7 days post-infection. For graphs in (C-F), each dot represents a 
unique donor and data are normalized to cell number by qPCR quantification of the CCR5 gene. ND = not detected. 
P values between No CCL19 (LAI) and CCL19 (LAI) were calculated using a Wilcoxin matched-pairs signed rank 
test. P values between LAI and BaL were calculated using a Mann-Whitney test. 
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Accordingly, we quantified HIV-1 2-LTR circle levels as a surrogate for unintegrated HIV-1 
DNA (Fig. 6E, 6F). As expected, this analysis revealed that 2-LTR circles constituted only a 
minor proportion of the total intracellular HIV-1 DNA of both subsets. Moreover, the relative 
levels of 2-LTR circle DNA mimicked total HIV-1 levels across the different conditions of virus 
infection (Fig. 6).  
Next, we determined whether CCL19 or direct HIV-1 infection induced T cell activation 
or cellular proliferation of the purified TN or TCM cells (Fig. 8). We found that CCL19 treatment 
did not up-regulate surface expression of the T cell activation markers CD25, CD69, or HLA-DR 
(Fig. 8A). However, a slight increase in CD25 expression was observed in all cells after 7 days 
of culture, which could not be attributed to HIV-1 infection (Fig. 8A). Purified rCD4 TN and TCM 
cells have been shown to express only very low levels of the intracellular proliferation marker, 
Ki-67, when they are freshly isolated from the blood317. Here, we measured cellular proliferation, 
Figure 7: CCL19 treatment does not alter the expression of HIV-1 co-receptor expression on primary CD4+ 
TN or TCM cells. (A) Percent expression of CCR5 or CXCR4 on TN or TCM cells 2 days following treatment with 
CCL19 or anti-CD3/CD28 antibodies by antibody staining and flow cytometry. Untreated cells were used as a 
control. (B) CCR5 and CXCR4 surface density as assessed by mean fluorescence intensity under the same 
conditions as described above. No significant differences in the number of cells expressing CCR5 or CXCR4 or 
density of expression were noted between control cells or cells treated with CCL19 (statistics not shown; N=5). 
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both by quantification of total cell number in culture (Fig. 8B) and by intracellular staining for 
Ki-67 (Fig. 8C). Importantly, we show that both CCL19 treatment and HIV-1 infection do not 
increase cellular proliferation throughout our experiments (Fig. 8B, 8C). It is also important to 
note that CCL19 treatment and HIV-1 infection did not induce cell death of either cell type (Fig. 
8D). 
Figure 8: T cell activation, proliferation, and cell viability of purified CD4+ TN and TCM cells. (A) T cell 
activation markers CD25, CD69, and HLA-DR were assessed by antibody staining and flow cytometry on TN and 
TCM cells following purification (day -2), CCL19-treatment (day 0), HIV-1LAI infection (day 7, left), and no 
infection (day 7, right). Data are presented as the mean ± SEM (N=7). (B) Cellular proliferation of unstimulated 
cells was measured by qPCR of the CCR5 gene throughout the time course of the experiment. Data are presented as 
the mean ± SEM (N=6). (C) Cellular proliferation was also measured by intracellular staining and flow cytometry 
for the proliferation marker, Ki-67. Data are presented as the mean ± SEM (N=2 performed in duplicate). (D) Cell 
viability of freshly isolated TN and TCM cells, after CCL19 treatment for 2 days, no CCL19 treatment for 2 days, 
HIV-1 infection after 7 days, and no infection after 7 days was measured by LIVE/DEAD staining and flow 
cytometry. Data are presented as the mean ± SEM (N=3 performed in duplicate). 
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4.2.2 Genomic distribution of HIV-1 integration sites in CD4+ TN and TCM cells
We next compared the genomic distribution of HIV-1 integration sites in infected TN and TCM 
cells, and, as a control, compared these values to those obtained using total CD4+ T cells that 
were broadly stimulated by treatment with PHA. A total of 729, 2,260 and 133,697 unique 
integration sites were mapped in the TN, TCM, and PHA-activated cells, respectively, with regard 
to several genomic annotations including RefSeq genes, transcriptional start sites (TSSs), CpG 
islands, and gene density (Table 3). The statistical relevance of the observed frequencies versus a 
matched random control (MRC) dataset was determined by Fisher’s exact test for RefSeq genes, 
TSSs, and CpG islands, and by a Wilcoxon rank-sum test for gene density (p values provided in 
Supplementary Table. 1). Distributions relative to CpG islands and TSSs were calculated by 
counting sites that fell within a 5 kb window (+/− 2.5 kb) of these features, while gene density 
was calculated by counting the number of RefSeq genes falling within a 1 Mb window (+/− 500 
kb) of each integration site, and then averaging this value for the entire dataset. Our MRC dataset 
revealed that 44.7% of human DNA comprised RefSeq genes.  
Table 3: HIV-1 integration site preference in PHA-activated, TN and TCM CD4+ T cells. 
Sample 
Unique 
integration 
sites 
Within Refseq 
genes (%) 
Within 5kb (± 
2.5kb) of a 
transcriptional 
start site (%) 
Within 5kb (± 
2.5kb) of a 
CpG island (%) 
Average gene 
density within 
1Mb (±0.5Mb) of 
integration sitesa 
Activated CD4+ 
T cells 133,697 114,110 (85.3)
c 6,242 (4.7)c 7,052 (5.3)c 20.3c 
CD4+ TN cells 729 613 (84.1)
c 30 (4.1%)c 33 (4.5)c 18.4c 
CD4+ TCM cells 2,620 2,291 (87.4)
c 109 (4.2%)c 112 (4.3)c 19.0c 
MRCb 50,000 22,328 (44.7) 2,010 (4.0) 2,100 (4.2) 8.7 
 aBased on complete gene 
bMatched random control of 50,000 computer-generated integration sites in proximity to Mse1/BglII restriction sites 
in hg19 
cP values are provided in Supplementary Table. 1 
As expected623, HIV-1 targeted RefSeq genes significantly more frequently than random 
sequences (TN, 84.1%; TCM, 87.4%; PHA-stimulated, 85.3%; p values ranging from 3.5 x 10-106 
to <2.2 x 10-308). By contrast, the frequency of gene targeting across the different infection 
conditions was largely similar, with only minor differences noted for the TCM versus PHA-
stimulated and TN versus TCM comparisons (Supplementary Table 1 in Appendix A). Integration 
into gene dense regions of chromosomes was similarly highly significant as compared to 
random, whereas the differences between infected cell datasets were largely similar (p values 
from 0.0002 to 0.05). As expected624, HIV-1 integration sites nearby CpG islands or TSSs in 
CD4+ TN and TCM cells were similar to the MRC value, although small but significant 
differences were noted between the MRC and PHA-activated cells (Table 4; Supplementary 
Table 1). 
4.2.3 CCL19-mediated HIV-1 infection of CD4+ TN and TCM cells is not due to an 
increase in filamentous actin (F-actin) density  
The actin cytoskeleton is known to be a key regulator in many early HIV-1 processes including 
viral entry, reverse transcription, intracellular trafficking, and integration, as described in section 
1.4.3.3. It has been shown that differences in actin dynamics and actin density play a major role 
in the differential susceptibility of TN and memory cells to HIV-1625, 626. Memory CD4+ T cells 
express a higher density of cortical actin than do TN cells and also have increased actin 
dynamics625, 626. Infection of rCD4 T cells via spinoculation or CCL19 pre-treatment have both 
been shown to enhance HIV-1 infection by triggering cofilin dephosphorylation, actin 
polymerization, and enhance actin dynamics456, 469. Binding of HIV-1 gp120 to CXCR4 has also 
been shown to enhance early stages of infection in rCD4 T cells by activating cofilin, which also 
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results in actin polymerization and enhanced actin dynamics454, 455, 458. This mechanism helps 
explain why TN cells are more susceptible to X4-tropic strains of HIV-1 but are still less 
susceptible than memory cells despite having higher levels of CXCR4. Our data are consistent 
with this finding in which we show greater than three-fold more HIV-1 DNA in TN cells infected 
with HIV-1LAI versus HIV-1BaL (Figure 6B), and a 15.5 decrease in HIV-1 DNA in TN cells 
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Figure 9: Inhibition of F-actin polymerization blocks HIV-1 infection of total rCD4 T cells in a dose-
dependent manner. (A) Schematic representation of the experimental approach. (B) Cells were treated with 
different concentrations of lat-A for 6 h, followed by treatment with CCL19 for an additional 2 days. F-actin was 
stained with phalloidin and measured by flow cytometry. Cells stimulated with PMA + IL-2 were used as a positive 
control. Unstained cells were used as a negative control. (C) Following the same experimental conditions as in (B), 
cell viability was assessed by flow cytometry using LIVE/DEAD staining. Untreated cells were used as a negative 
control and cells heated at 56°C for 1 h prior to staining were used as a dead cell control. (D) F-actin density and 
HIV-1 infection of rCD4 T cells are plotted. Following the experimental approach shown in (A), HIV-1 infection 
was measured 7 days post-infection by quantification of total intracellular HIV-1 DNA, normalized to cell number. 
HIV-1 DNA and F-actin density were normalized to treatment with CCL19 only. Data shown for (B-D) are 
representative of 2 independent experiments and error bars represent standard deviations. 
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versus TCM cells infected with HIV-1LAI (Figure 6B, 6C). 
To validate the role of F-actin density in HIV-1 infection, we first isolated total rCD4 T 
cells and exposed them to different concentrations of latrunculin A (lat-A), a natural product that 
prevents F-actin assembly, for 6 h prior to the addition of CCL19 (Fig. 9A). Forty-eight hours 
later, cell viability (Fig. 9B) and F-actin density (Fig. 9C) were measured by live/dead and 
phalloidin staining, respectively, and flow cytometry. After the 48 h treatment, cells were 
infected with HIV-1LAI and cultured for seven days (Fig. 9A). HIV-1LAI infection was then 
assessed by quantification of total HIV-1 DNA (Fig. 9D). Lat-A decreased F-actin density in a 
dose-dependent manner as determined by phalloidin staining intensity (Fig. 9B), but did not 
impact cell viability (Fig. 9C). Importantly, the decrease in F-actin density correlated with a 
decrease in the ability of HIV-1LAI to infect the rCD4 T cells (Fig. 9D). 
In light of these findings, we next used confocal microscopy (Fig. 10A, 10B) and flow 
cytometry (Fig. 10C) to evaluate whether exposure of TN and TCM cells to CCL19 increased F-
actin density. As described by Permanyer et al., we observed a higher baseline of F-actin density 
in TCM cells compared to TN cells (Fig. 10B, 10C)625. However, we found no evidence that 
CCL19 increased F-actin density in either T cell subset after incubation with the chemokine for 2 
days (Fig. 10B, 10C). It should be noted that Cameron et al. only observed a rapid increase in F-
actin density within a few minutes of exposure to CCL19, but after 30 min no significant 
differences were noted456. Collectively, these data suggest that the very transient CCL19-
mediated increase in F-actin density, reported previously, cannot explain the increased 
permissiveness of rCD4 T cells to HIV-1 infection 48 h post-chemokine exposure.  
Merge 
F-actin
(AF488)
DAPI 
 No CCL19  CCL19  PMA + IL-2  No CCL19  CCL19  PMA + IL-2 
TN cells TCM cells A 
B 
TN cells TCM cells 
C 
Unstained 
control 
No CCL19 
CCL19 
PMA + IL-2 
MFI = 53.3 
MFI = 580 
MFI = 483 
MFI = 1138 
MFI = 57.1 
MFI = 1706 
MFI = 1574 
MFI = 2904 
TN cells TCM cells 
Phalloidin (FITC) Phalloidin (FITC) 
Figure 10: CCL19 does not have an effect on F-actin density in TN or TCM cells. (A) Representative confocal 
microscopy images of TN and TCM cells in the absence or presence of CCL19 or PMA+IL-2 for two days. 
Phalloidin and DAPI were used to stain F-actin and nuclei, respectively. (B) Total F-actin volume was measured in 
the TN and TCM cells imaged by confocal microscopy in the absence or presence of CCL19 or PMA+IL-2. 
Quantification was performed using Imaris software. (C) Flow cytometric analysis of F-actin density, 
measured by phalloidin staining, in TN or TCM cells under the same conditions as described above. 
Representative data from 3 independent experiments. MFI = mean fluorescence intensity.
4.2.4 CCL19 does not alter intracellular dNTP levels in CD4+ TN or TCM cells 
The cellular restriction factor SAMHD1 has been shown to inhibit HIV-1 infection in rCD4 T 
cells, as described in section 1.4.3.3. SAMHD1 is highly expressed in resting TN and memory 
cell subsets. Blockade or degradation of SAMHD1 has been shown to greatly enhance the 
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susceptibility of rCD4 T cells to HIV-1 infection, especially in TN cells, without inducing T cell 
activation344, 461. These findings are consistent with earlier studies showing that addition of 
dNTPs to TN or memory cells significantly enhanced reverse transcription and integration627, 628. 
Differences in cellular restriction factors, such as SAMHD1, could also help explain the 
differential susceptibility of TN and TCM cells to HIV-1 infection.  
Table 4: dNTP concentrations in purified TN and TCM cells following treatment with either 
CCL19 or anti-CD3/CD28. 
Cell type and 
treatment 
Nucleotide Concentration (fMol/106 cells)ρ 
dATP dGTP dCTP dTTP 
TN cells 8.70 (<4 – 10.7) 32.0 (14.6 - 44.5) 27.7 (<4 – 43.1) 5.90 (<4 – 7.60) 
TN cells + CCL19 4.70 (<4 – 6.10) 28.2 (17.5 – 29.4) 14.7 (<4 – 30.6) 4.70 (<4 – 7.30) 
TN cells + 
anti-CD3/CD28 379 (112 - 513) 484 (404 - 622) 88.6 (62.7 - 111) 649 (244 - 735) 
TCM cells 3.70 (<4 – 5.8) 30.0 (19.5 – 77.1) 11.5 (5.75 – 21.0) 4.40 (<4 – 6.90) 
TCM cells + CCL19 4.10 (<4 – 4.90) 24.6 (11.6 – 61.6) 10.0 (4.80 – 17.3) 4.90 (<4 – 12.3) 
TCM cells + 
anti-CD3/CD28 285 (57.2 - 294) 232 (217 - 345) 41.0 (31.9 – 61.8) 164 (106 - 188) 
 ρ Nucleotide concentrations were measured following a two-day treatment with either CCL19 or anti-CD3/CD28 
and were compared to untreated control cells. Data are presented as the median (range) of three independent 
experiments. < 4 indicates below the limit of detection based on the number of cells used for quantification. 
Given these findings, we asked whether CCL19 enhanced HIV-1 permissivity of TN and 
TCM cells by increasing intracellular dNTP levels, which in turn would facilitate HIV-1 reverse 
transcription and viral infection. Nucleotide levels in the TN and TCM cells were much lower than 
in anti-CD3/CD28-activated cells (Table 4). However, treatment of TN or TCM cells with CCL19 
did not increase the intracellular dNTP levels compared to the untreated controls (Table 4), 
which suggests that CCL19 does not enhance HIV-1 infection of TN and TCM cells by increasing 
the nucleotide pool concentration.  
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4.2.5 Latency reversal from CD4+ TN and TCM Cells infected with HIV-1LAI 
We next quantified total virus production (i.e. extracellular virion-associated RNA (vRNA) in 
the culture supernatant) from latently-infected TN and TCM cells using an ultrasensitive assay 
capable of single copy detection of HIV-1 RNA160, 629 before and after exposure to the LRAs: (i) 
anti-CD3/CD28 antibodies; (ii) PMA + PHA; (iii) prostratin; or (iv) SAHA (Fig. 11A). As 
expected, given that the TCM cells contained significantly higher levels of HIV-1 DNA than did 
the TN cells, we saw more total virus production from TCM cells than from the TN cells (Fig. 
11B). To account for differences in HIV-1 infection frequency between the TN and TCM cell 
subsets, as well as between different donors, we normalized extracellular vRNA production to 
the total HIV-1 DNA copy number per cell at each respective time point (Fig. 11C). 
Surprisingly, our data revealed that TN cells exposed to anti-CD3/CD28 antibodies, PMA+PHA, 
or prostratin yielded as much, or more, vRNA than did the TCM cells (Fig. 11C). For example, at 
day 10 the median production of extracellular HIV-1LAI vRNA after exposure to anti-CD3/CD28 
antibodies, PMA+PHA, or prostratin was 69.7, 71.5, and 29.6 from TN cells, compared to 18.8, 
57.2, and 21.2 from TCM cells, respectively. There was, however, significant variation between 
donors (Fig. 11D) For example in donors 2, 4, 5, and 6 more HIV-1LAI vRNA was produced 
from the TN cells; whereas more HIV-1LAI vRNA was produced from the TCM cells of donors 1 
and 3 (Fig. 11D). As such, the differences between the two cell types were not statistically 
significant.  
Collectively, these data suggest that donor genetic differences, in addition to the rCD4 T 
cell compartment, impact the establishment and reversal of HIV-1 latency. In contrast to the 
other LRAs, SAHA did not significantly increase vRNA production in either TN or TCM cells 
(Fig. 11B, 11C). This finding is consistent with recent studies that demonstrated the inability of 
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SAHA to increase extracellular HIV-1 production from rCD4 T cells isolated from infected 
individuals on suppressive ART482, 512, 630.  
Viral integration into the host cell genome is an essential step in HIV-1 replication, yet 
many reverse transcripts fail to integrate, resulting in the accumulation of viral DNA that has the 
potential to persist in rCD4 T cells. The stability of unintegrated forms of HIV-1 DNA in rCD4 T 
cells has been somewhat controversial. While some studies have shown that unintegrated forms 
of HIV-1 DNA are short-lived and degraded rapidly631-634, other studies have reported that 
unintegrated forms of HIV-1 DNA can persist for several days or weeks in rCD4 T cells374, 635-
637. Regardless of the longevity of unintegrated forms of HIV-1 DNA, it has been shown that
upon CD4+ T cell activation, some forms of unintegrated HIV-1 DNA can become integrated, 
and can result in productive infection634, 637-639. Because anti-CD3/CD28 antibodies induce T cell 
activation, we next assessed the contribution of unintegrated HIV-1LAI DNA to extracellular 
vRNA production from both TN and TCM cells by including the integrase inhibitor, RAL, at the 
same time as anti-CD3/CD28 (Fig. 11E, 11F). This analysis suggested that unintegrated viral 
DNA did not significantly contribute to the extracellular vRNA quantified in the supernatant 
following reversal of latency in our model system. 
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Figure 11: Reversal of HIV-1 latency in CD4+ TN and TCM cells infected with HIV-1LAI following treatment 
with LRAs. (A) Schematic representation of the experimental approach. (B) Total copies of extracellular virion-
associated HIV-1LAI RNA produced from TN or TCM cell after exposure to anti-CD3/CD28 antibodies, PMA+PHA, 
prostratin, or SAHA. Background HIV-1 RNA from unstimulated controls at each time point are shown. Data are 
shown as the mean ± the SEM from 6 donors. (C) Copies of extracellular virion-associated HIV-1LAI RNA produced 
per infected TN or TCM cell after exposure to anti-CD3/CD28 antibodies, PMA+PHA, prostratin, or SAHA, 
normalized to the level of infection at each respective time point. Background HIV-1 RNA from unstimulated 
controls at each time point are shown. Data are shown as the mean ± the SEM from 6 donors. (D) Copies of 
extracellular virion-associated HIV-1LAI RNA produced per infected TN or TCM cell after exposure to anti-
CD3/CD28 antibodies from 6 donors. Contribution of unintegrated HIV-1LAI DNA to the level of extracellular HIV-
1 RNA copy number produced after exposure of infected (E) TN cells or (F) TCM cells to anti-CD3/CD28 antibodies 
was determined with or without EFV only or EFV + RAL treatment throughout the experiment. Unstimulated cells 
treated with EFV only were used as a control. Cells stimulated in the absence of any antiretroviral drugs were used 
as a positive control. Data are representative of 2 independent experiments. 
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4.2.6 Correlation between level of infection and virion production from latently infected 
TN and TCM cells 
Given the differences in infection frequency (Fig. 6B, 6C) and virion production post-stimulation 
(Fig. 11B, 11C), we wanted to determine if there was a correlation between virion production 
post-stimulation and the frequency of infection between TN and TCM cells. Following stimulation 
of TN cells with anti-CD3/CD28, PMA+PHA, and prostratin, there was no correlation between 
virion production and level of infection at 3 (Supplementary Fig. 1A), 7 (Fig. 12A), and 10 days 
post-stimulation (Supplementary Fig. 1B). However, there was a strong correlation between 
virion production and level of infection from TCM cells with all three treatments at 3 
(Supplementary Fig. 1C), 7 (Fig. 12B), and 10 days post-stimulation (Supplementary Fig. 1D). 
There was no correlation from either cell type between copies of HIV-1 RNA produced per 
infected cell versus frequency of infection (data not shown). These data suggest that there are 
different mechanisms or different mechanistic regulations promoting or suppressing virion 
production following latency reversal. 
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4.2.7 Latency reversal from CD4+ TN and TCM cells infected with HIV-1BaL 
We also evaluated extracellular HIV-1BaL RNA production from infected TN and TCM cells 
exposed to the same LRAs, however, we excluded SAHA given that we did not see an effect in 
our previous experiments (Fig. 11B). HIV-1BaL vRNA was produced from TCM cells, with no 
differences noted compared to HIV-1LAI (Fig. 13). In contrast, almost no detectable HIV-1BaL 
vRNA was produced from the TN cells (data not shown). However as noted in Figure 6C, these 
cells were largely refractory to infection by HIV-1BaL. 
A 
B 
TN cells 
TCM cells 
Figure 12: Correlation analyses between level of infection and virus production seven days post-stimulation 
from TN and TCM cells latently infected with HIV-1LAI. Correlation analysis of TN cells (A) and TCM cells (B) 
seven days post-stimulation with anti-CD3/CD28 microbeads, PMA+PHA, and prostratin. P value determined by 
Spearman correlation analysis. Spearman correlation coefficients (r) are shown. Each dot represents a different 
donor. Dotted lines represent linear regression curve. 
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4.2.8 Decay of HIV-1LAI-infected CD4+ TN and TCM cells after exposure to LRAs  
Lastly, we measured the decay kinetics of HIV-1LAI-infected cells in both T cell populations after 
exposure to the different LRAs (Fig. 14A, 14B). The rates of decay (t1/2) of the HIV-1LAI-
infected TN cells treated with anti-CD3/CD28, PMA+PHA, or prostratin were 4.2, 3.5, and 4.8 
days, respectively (Fig. 14A), which were similar to the values calculated for the TCM cells (2.6, 
2.5, and 5.2 days for cells treated with anti-CD3/CD28, PMA+PHA, or prostratin, respectively) 
(Fig. 14B). No appreciable decay was observed in either TN or TCM cells treated with SAHA. Of 
note, the anti-CD3/CD28 antibodies, PMA+PHA, and prostratin all induced cellular proliferation 
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Figure 13: Reversal of HIV-1 latency in CD4+ TCM cells infected with HIV-1BaL following treatment 
with LRAs. The experimental approach was the same here as shown in Figure 11A. Copies of extracellular 
virion-associated HIV-1BaL RNA produced per infected TCM cell after exposure to anti-CD3/CD28 antibodies, 
PMA+PHA, or prostratin, normalized to the level of infection at each respective time point. Background HIV-
1 RNA from unstimulated controls at each time point are shown. Data are presented as the mean ± SEM from 
3 donors. For comparative purposes, data for HIV-1LAI RNA from infected TCM cells (Fig. 11C) are included.  
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(Fig. 14C) and T cell activation in both T cell subsets, as evidenced by increased expression of 
CD69, CD25, and HLA-DR (Figure 14C). The level of cellular activation was also similar 
between TN and TCM cells and likely does not contribute to the differences observed in virus 
production between these cell types.  
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Figure 14: Decay of HIV-1LAI-infected cells and T cell activation post-treatment of latently infected CD4+ TN 
and TCM cells. Decay of HIV-1LAI-infected (A) TN or (B) TCM cells was measured over 10 days of treatment with 
anti-CD3/CD28 antibodies, PMA+PHA, prostratin, or SAHA. Total intracellular HIV-1 DNA was quantified as 
described in Figure 5. Data are presented as the mean ± SEM from 6 donors (except for the SAHA data, where 
N=4). (C) Cellular proliferation of TN and TCM cells was measured by qPCR of the CCR5 gene following 
stimulation with anti-CD3/CD28 antibodies, PMA+PHA,  prostratin, or SAHA. Background samples represent 
unstimulated CD4+ TN and TCM cells. Data are presented as the mean ± SEM (N = 6, except for SAHA data where 
N = 4). (D) T cell activation was measured by antibody staining and flow cytometry for surface expression of CD25, 
CD69 and HLA-DR on TN or TCM cells 3, 7, and 10 days after treatment with anti-CD3/CD28 antibodies, 
PMA+PHA, prostratin, or SAHA. Untreated cells were used as a negative control. Data are representative of 2 
independent experiments.  
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4.3 DISCUSSION 
Latently infected rCD4 T cells constitute the major reservoir of persistent HIV-1 infection, and 
significant reduction or elimination of this reservoir could lead to either a functional or sterilizing 
cure, respectively. It has been hypothesized that therapeutic approaches that reactivate latent 
HIV-1 infection will promote death of the infected cell by viral cytopathic effects and/or by host 
cell effector mechanisms640. This strategy is typically referred to as the “kick and kill” 
approach488. The rCD4 T cell population, however, is heterogeneous and consists of different T 
cell subsets, including naïve and memory cells. It is not known whether the “kick and kill” 
approach will be equally effective in the different T cell subsets, which differ in lifespan, 
proliferative capacity, antigen response time, residence throughout the body, and in their HIV-1 
co-receptor, CCR5 and CXCR4, expression levels355, 620, 621. Therefore, mechanistic insights into 
the establishment and reversal of latent HIV-1 infection in different rCD4 T cell subsets could 
provide important clues to eradicating this persistent reservoir. 
In this study, we compared the establishment and reversal of HIV-1 latency in rCD4 TN 
and TCM cells using a primary cell model of latency that utilizes direct infection of highly 
purified cells. Prior studies demonstrated that HIV-1 latency could be established in vitro in 
rCD4 T cells pre-treated with chemokines that bind to the CCR6, CCR7 or CXCR3 receptors456. 
From an important biological perspective, the concentration of CCL19 (the chemokine ligand for 
CCR7 that was used in this study) significantly increases during acute HIV-1 infection, in which 
the latent reservoir is established, and correlates with disease progression641-644. Furthermore, 
pre-treatment of TN or TCM cells with CCL19 does not induce T cell activation or proliferation 
(Fig. 8). As such, the integrity of the purified T cell subsets is largely preserved in the 
experiment, which was an important prerequisite for the objectives of this study.  
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We show that CCL19 pre-treatment of TN and TCM cells significantly increased the 
capacity for X4-tropic HIV-1 to infect these cells (Fig. 6). However, as reported in other in vitro 
systems340, 344, 627, the levels of HIV-1 infection in the TCM cells, as assessed by quantitation of 
total viral DNA, were higher compared to the TN cells.  In contrast, CCL19 only increased R5-
tropic virus infection of TCM cells but not TN cells, a finding which may be attributable to the 
extremely low levels of CCR5 expression on TN cells isolated from healthy donors (Fig. 7). 
However, several studies have demonstrated that R5-tropic virus can be isolated from CD4+ TN 
cells from HIV-infected individuals309, 311, 645, 646. There are two possible explanations that could 
account for the discrepancies between in vitro studies and the in vivo observations: (i) HIV-1 
infection systematically upregulates CCR5 expression on TN cells, thus making them more 
susceptible to infection; and/or (ii) R5-tropic virus may be more efficiently transferred to TN 
cells by plasmacytoid dendritic cells. Previous studies have shown that CCR5 expression is 
systemically upregulated following HIV-1 infection on CD4+ T cells as well as on purified TN 
cells isolated from HIV-1-infected individuals647-651. It has also been shown that monocyte-
derived dendritic cells (MDDCs) and primary isolated plasmacytoid dendritic cells (pDCs) are 
capable of transferring R5-tropic HIV-1 to lymphocytes652-654. Both explanations are possible, 
however, further studies are needed to elucidate the mechanism(s) by which TN cells become 
infected in vivo.  
We also attempted to address the mechanism by which CCL19 increases the ability of 
HIV-1 to infect TN and TCM cells. In this regard, Cameron et al.456 reported that ligation of the 
CCR6, CCR7, and CXCR3 receptors led to changes in cortical actin, allowing for rapid 
migration of the pre-integration complex to the nucleus and efficient nuclear localization and 
integration. While our data show a critical role for F-actin density in the ability of HIV-1 to 
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infect rCD4 T cells (Fig. 9D), and suggest that TN cells may be less susceptible to HIV-
1infection than TCM cells due to a lower F-actin density as reported previously625, 626, our 
comprehensive imaging and flow cytometry data do not support a role for CCL19 in increasing 
F-actin density in either cell type (Fig. 10).
SAMHD1 has also been identified as an effective restriction factor to HIV-1 infection in 
rCD4 T cells by enzymatically decreasing cellular dNTP pools and impeding HIV-1 reverse 
transcription355, 460, 462, 463. Blockade or degradation of SAMHD1 has been shown to greatly 
enhance the susceptibility of rCD4 T cells to HIV-1 infection, especially in TN cells344, 461. These 
findings are consistent with earlier studies showing that addition of dNTPs to TN or memory 
cells significantly enhanced reverse transcription and integration627, 628. In this study, we found 
that CCL19 does not alter intracellular dNTP concentrations (Table 3), and that HIV-1 can infect 
both TN and TCM cells despite having low nucleotide concentrations (Fig. 6). Collectively, these 
data suggest that CCL19 pre-treatment could potentially impact an as yet undocumented 
restriction factor in rCD4 T cells. 
An unexpected finding from this study was that TN cells exposed to LRAs produced more 
extracellular virion-associated RNA per infected cell compared to the TCM population (Fig. 6). 
This observation was found to be independent of the LRA used. These data suggest one of two 
things: (i) either more latently infected TN cells produce virus than TCM cells, or (ii) more virus is 
produced per infected TN cell versus TCM cell. We observed no major differences in the genomic 
distribution of HIV-1 integration sites between the two T cell subsets (Table 4). Given these 
differences in virus production between TN and TCM cells, we also evaluated whether HIV-1 
reactivation resulted in death of the infected cell. We found that the rates of decay of the HIV-1-
infected cells in the TN and TCM populations treated with anti-CD3/CD28 antibodies, 
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PMA+PHA, or prostratin were largely equivalent (Fig. 14A, 14B). Using a different in vitro 
primary cell model of latency, Shan et al. reported that if the LRA induced T cell activation, 
reactivation of latent HIV-1 resulted in death of the infected cell655. Our data support this 
finding. However, the authors also reported that following administration of SAHA, which does 
not induce T cell activation, the HIV-infected rCD4 T cell population survived, even in the 
presence of autologous cytolytic T lymphocytes655. In other words, SAHA facilitated the “kick” 
but not the “kill”. In contrast, we observed that SAHA promoted neither reactivation of latent 
HIV-1 nor death of the infected cell.  
In conclusion, this study highlights the differences of the establishment and reversal of 
HIV-1 latency in TN and TCM cells. Importantly, the data reveal that despite low infection 
frequency, TN cells produce more extracellular virion-associated RNA per infected cell than TCM 
cells. This suggests that TN cells may be an important reservoir of latent HIV-1 infection, and 
should not be ignored simply because the frequency of infection of these cells is lower than in 
the memory T cell subsets in infected individuals on ART. Importantly, we have presented a 
novel approach to study HIV-1 latency in a primary cell model, focusing specifically on CD4+ 
TN and TCM cell subsets that can further be used to understand the establishment, maintenance, 
and reversal of latency in both subsets. 
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5.1 INTRODUCTION 
It has long been known that HIV-1 latency is primarily established in rCD4 T cells155-157. A more 
detailed analysis of the composition of this reservoir of latently infected cells in individuals on 
suppressive ART, based on quantification of HIV-1 DNA and the frequency of each cell type in 
the peripheral blood, revealed that TCM cells were the major contributing cell type to the latent 
reservoir, followed by TTM cells and TEM cells, while TN cells contributed only minorly317. Many 
studies since then have further characterized the CD4+ T cell subset distribution of the HIV-1 
DNA reservoir, consistently finding that either TCM and/or TTM cells were the major contributing 
cell types to the latent reservoir, while TN and TEM cells showed slightly more variation316, 340, 360,
600. In light of these findings, the vast majority of in vitro and ex vivo latency reversal studies
have focused on resting memory CD4+ T cells or memory T cell subsets, and have largely 
overlooked the TN cell subset. 
In this study, we wanted to extend our findings from chapter 4.0, using an in vitro 
primary cell model of HIV-1 latency, to ex vivo cells from HIV-1-infected individuals. Using 
our in vitro primary cell model, we found that TN cells contributed significantly to virus 
production following latency reversal, despite having lower levels of HIV-1 DNA. While 
previous studies measuring the contribution of different T cell subsets to the HIV-1 latent 
reservoir have largely neglected TN cells altogether342, or analyzed their significance on a 
population level317, 360, 600, here, using ultrasensitive quantitative analyses, we were able to 
determine the significance of the TN cell population, in comparison to the TCM cell population, on 
a per cell basis. 
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5.2 RESULTS 
5.2.1 Study participant characteristics and baseline measurements 
This study enrolled 7 long-term suppressed HIV-1-infected individuals from the Pitt AIDS 
Center for Treatment in an IRB-approved study. All study participants gave informed, written 
consent at the time of enrollment. The participant characteristics are shown in Table 5. Plasma 
HIV-1 RNA was suppressed by ART for an average of 9.5 years in the study participants. The 
mean age of the participants was 52 years (range 36-62 years); of which 57% were female, and 
71% were African American, with the remaining 29% being Caucasian. 
Table 5: Baseline characteristics of study participants. 
τ Current CD4+ T cell count given as cells/µL 
ρ Years of suppression without ART failure 
Sex Age (years) Race 
Current 
CD4τ 
Pre-ART 
viral load 
Years of 
suppressionρ 
Current ART 
regiment 
Donor 1 Female 36 African American 809 802,000 10.2 FTC/RPV/TDF 
Donor 2 Female 57 African American 380 143,000 5.2 FTC/TDF/r/ATZ 
Donor 3 Male 57 Caucasian 656 520,000 12 EFV/FTC/TDF 
Donor 4 Male 51 Caucasian 603 Unknown 7.3 EVG/c/FTC/TAF 
Donor 5 Male 46 African American 714 41,952 6.0 3TC/ABC/EFV 
Donor 6 Female 58 African American 1426 366,200 15 FTC/RPV/TDF 
Donor 7 Female 62 African American 1033 Unknown 10.7 DTG/FTC/TDF 
Mean - 52 - 803 - 9.5 -
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HIV-1 DNA was quantified in total CD4+ T cells (tCD4s) as well as activated (aCD4s) 
and rCD4s, TN, TCM and TTM+TEM cells (Fig. 15A). The TTM+TEM cell population was not further 
subdivided for DNA analysis. There were slightly higher levels of HIV-1 DNA in the rCD4 T 
cell compartment versus the activated compartment; however, this difference was not significant. 
Consistent with previous studies313, 340, 360, 600, we found significantly higher levels of HIV-1 
DNA in TCM cells versus TN cells in all 7 donors (p = 0.0175) with a 4.2 median fold increase, 
ranging from 1.2 - 14.7. Interestingly, we also found higher levels of HIV-1 DNA in the 
TTM+TEM cells compared to the TCM cells in all 7 donors, with a 1.5 median fold increase, 
ranging from 1.1 – 3.0. This increase in HIV-1 DNA was not significantly higher than that seen 
in TCM cells, however, it was significantly higher than that in TN cells (p = 0.0006). 
During HIV-1 infection, the composition and the distribution of T cell subsets change 
compared to that seen in uninfected individuals, somewhat complicating the analysis of 
significance for each T cell subset. In healthy, HIV-1-uninfected individuals, the primary rCD4 T 
cell type in the peripheral blood is TN cells, accounting for nearly 40-50% of the total population, 
closely followed by TCM cells, accounting for approximately 30% of the total population (Fig. 
15B)351. In HIV-1-infected individuals, however, the frequency of these two cell types in the 
peripheral blood becomes reversed, while the frequency of TTM, TEM, and TTD cells remains 
largely the same (Fig. 15B)317, 351. When we measured the contribution of HIV-1 DNA in the 
reservoir of rCD4 T cells, taking into consideration the frequency of HIV-1 DNA in each subset 
compared to the total amount of HIV-1 DNA in the reservoir, we found that TTM+TEM cells 
contributed significantly higher to the DNA reservoir than TCM cells, which in turn was 
significantly higher than in TN cells (Fig. 15C). However, when we also took into consideration 
the frequency of each cell subset in the peripheral blood to calculate the percent contribution to 
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the HIV-1 reservoir in rCD4 T cells, we found that TCM cells were the major contributing cell 
type (Fig. 15D).  
More recent studies have identified an additional CD4+ T cell subset that contributes to 
the HIV-1 latent reservoir, and under conventional subset isolation or flow gating strategies, this 
cell subset falls within the TN cell population. TSCM cells have been shown to contain higher 
levels of HIV-1 DNA compared to TN cells340, 342, 344, 371. However, the level of HIV-1 DNA in 
the TSCM cell population seems to be dependent on whether the individual initiated ART during 
Figure 15: Quantification of HIV-1 DNA in freshly isolated CD4+ T cell subsets from long-term suppressed 
HIV-1-infected individuals. (A) HIV-1 DNA was quantified in various CD4+ T cell subsets following purification. 
Total HIV-1 DNA was normalized to cell number assayed by quantification of the CCR5 gene. (B) The frequency 
of rCD4 T cell subsets were measured in the peripheral blood of 7 HIV-1-infected and 7 HIV uninfected donors. (C) 
The percent contribution of HIV-1 DNA in TN, TCM, and TTM+TEM cells to the total HIV-1 DNA pool among these 
three cell populations was calculated. (D) The percent contribution of TN, TCM, and TTM+TEM cells to the total HIV-1 
latent reservoir in rCD4 T cells was calculated. For C and D, each symbol represents a unique donor. All p values 
were determined using a Mann-Whitney test. 
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acute versus chronic infection371. These cells are distinct from both the TN and TCM cell subsets, 
as described in section 1.3.1, and can be differentiated from TN cells based on cell surface 
expression of CD95 and/or CD122339. TSCM cells constitute < 5% of the TN cell population in the 
peripheral blood340-345, thus making this cell type difficult to study, particularly in HIV-1-
infected individuals where the frequency of TN cells is significantly reduced. Much like the TTM, 
TEM, and TTD cells, the frequency of TSCM cells in the peripheral blood of HIV-1-infected 
individuals on suppressive ART remains relatively stable340, 342. In order to determine the 
contribution of the TSCM cells to the TN cell population, we depleted cells expressing CD95 from 
a fraction of the total CD45RA population, keeping both the CD45RA+CD95+ and the 
CD45RA+CD95- populations (see Fig. 5) for DNA quantification (Fig. 16). There were slightly 
higher levels of HIV-1 DNA in the CD45RA+CD95+ subset compared to the CD45RA+CD95- 
subset and the total TN compartment; however, this increase was not significant. In this study, 
TSCM cells do not seem to contribute significantly to the HIV-1 DNA reservoir within the total TN 
cell population. 
Figure 16: Quantification of HIV-1 DNA in TN cell subsets. CD4+ TN cell subsets were purified as described in 
figure 4. Total HIV-1 DNA was quantified in 1-2 million cells from donors 3-7 and normalized to total cell number 
assayed. Copies of HIV-1 DNA per 106 cells are shown. No significant differences were found between any of the 
three cell subsets as determined by Mann-Whitney tests. 
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5.2.2 Latency reversal from TN and TCM cells following treatment with LRAs 
In order to assess the ability of infected TN and TCM cells to produce virus, TN and TCM cells were 
stimulated with a panel of LRAs (Table 6) that have previously been shown or suggested to 
reactivate latent HIV-1 in rCD4 T cells. Our primary goal was to determine if virus could be 
produced from both cell types. As such, we largely chose LRAs that induce potent T cell 
activation in order to achieve a response. Additionally, we chose two HDACi that are in clinical 
evaluation as LRAs in hopes to reduce the HIV-1 latent reservoir595, 656, 657. The concentrations 
used and duration of RMD513 and PNB658 exposure were chosen based on predictions from 
previously determined clinical recommendations. Our secondary goal was to determine if virus 
production was equal between the two cell types when corrected for differences in the frequency 
of HIV-1 DNA. 
Drug Action Concentration 
No drug Media control - 
anti-CD3/CD28 T cell activation (positive control) 3 beads/cell 
PHA + IL-2 Mitogen, cytokine 10µg/mL, 100U/mL 
PMA + Ionomycin 
PKC agonist, Ca2+ ionophore
(DAG and IP3 analogs, 
respectively) 
5nM + 500µg/mL 
Prostratin PKC agonist 5µM 
Panobinostat HDACi 17.5nM, 30 min pulse 
Romidepsin HDACi 50nM, 4 hr pulse 
Table 6: LRAs, proposed mechanism of latency reversal, and treatment conditions used in this 
study. 
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  In order to assess virus production, purified TN and TCM cells were stimulated with each 
of the LRAs in duplicate wells containing 1 million cells. Cells were cultured in the presence of 
EFV and RAL to prevent viral spread throughout the culture, as well as IL-2 to maintain cell 
viability. Seven days post-treatment, virion-associated HIV-1 RNA was quantified in the culture 
supernatant (Fig. 17A, see Materials and Methods for more details). Following treatment with 
LRAs, we found that TN and TCM cells produced similar levels of HIV-1 RNA averaged across 
all 7 donors (Fig. 17B). It has previously been demonstrated that HIV-1-infected cells from the 
peripheral blood of individuals on ART contain only a single integrated provirus617, 659. 
Therefore, we used copies of HIV-1 DNA as a surrogate marker for the number of HIV-1-
infected cells. Interestingly, and in accordance with our previous findings using an in vitro 
primary cell model of HIV-1 latency (see chapter 4.0), when HIV-1 RNA levels were normalized 
Figure 17: Virus production following treatment with LRAs. (A) Schematic representation of experimental 
approach. (B) Total virus production, measured as copies of HIV-1 RNA in the culture supernatant, following 
treatment with LRAs was quantified. The limit of quantification (LOQ) for this assay was 1 copy per reaction. (C) 
Copies of HIV-1 RNA in the culture supernatant were normalized to the number of infected cells in each cell subset. 
The calculated lower LOQ for HIV-1 RNA produced per infected cell was found to be 0.001. Each dot represents a 
unique donor. Horizontal bars represent the mean. 
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to the number of infected cells, there was more HIV-1 RNA produced per infected TN cell when 
treated with anti-CD3/CD28, PHA+IL-2, and prostratin, compared to infected TCM cell (Fig. 
17C). Both RMD and PNB failed to increase virus production in both cell types in the majority 
of donors (Fig. 17C). This finding is consistent with previous studies demonstrating that HDACi, 
including RMD and PNB, are able to increase viral transcription but do not consistently increase 
virus production482, 512, 534, 536. 
These findings were remarkable because unlike in our primary cell model of HIV-1 
latency, where significantly higher levels of infection can be achieved and virus production is 
observed in all donors, we only observed significant virus production from TN cells in 4 of 7 
donors (Fig. 18). For example, two donors had no measurable virus production from TN cells 
following treatment with anti-CD3/CD28, while 1 donor had only very low levels of virus 
production (Table 7). In contrast, all 7 donors had high responses from their TCM cells (Table 7). 
Despite a lack of response in TN cells from 3 of 7 donors, total virus production was similar 
between TN and TCM cells (18,290 versus 15,135 copies/106 cells for TN and TCM cells, 
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Figure 18: Virus production from individual donors following treatment with LRAs. Copies of HIV-1 RNA 
produced per infected TN and TCM cell are shown for each of the 7 donors. 
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respectively, Table 8). When corrected for differences in the number of infected cells between 
the two cell types, we found that TN cells produced 7.7 times more virus per infected cell than 
per infected TCM cell (Table 8). Although striking, due to variation between donors (Fig. 18), this 
difference is not significant. 
Table 8: Average (mean) copies of HIV-1 RNA produced, and average (mean) copies of HIV-1 
RNA produced normalized to HIV-1 DNA following treatment with anti-CD3/CD28. 
Mean copies of HIV-1 RNA produced 
per 106 cells 
Mean copies of HIV-1 RNA produced 
per HIV-1 DNA-containing cell 
TN cells 18,290 45.5 
TCM cells 15,135 5.91 
 
In order to determine if the differences in virus production observed between TN and TCM 
cells were due to T cell activation or cell viability following treatment with LRAs, we measured 
the surface expression of the activation markers CD25, CD69, and HLA-DR on both cell types 
from donors 4-7 (Fig. 19). Additionally, we assessed cell viability by LIVE/DEAD staining in 
cells from donors 4-7 (Fig. 20). As expected, treatment with anti-CD3/CD28, PHA+IL-2, 
PMA+ionomycin, and prostratin induced T cell activation in both cell subsets. Only minor 
differences were noted in T cell activation following treatment with anti-CD3/CD28. No other 
significant differences were observed in the level of T cell activation measured on day 7 
following treatment with LRAs between TN and TCM cells.  
Donor 1 Donor 2 Donor 3 Donor 4 Donor 5 Donor 6 Donor 7 
TN cells 57,663 <1 43,600 397 12,670 <1 13,700 
TCM cells 13,400 71,350 3,890 5,245 2,260 7,210 2,590 
 
Table 7: Copies of extracellular virion-associated HIV-1 RNA in the culture supernatant from 
each donor following treatment with anti-CD3/CD28. 
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In addition to comparing virus production between TN and TCM cells, we also compared 
virus production from TN cells that either contained (RA+) or had been depleted of (-CD95) 
TSCM cells. TN cells from donors 5-7 were further purified, as described above (Fig. 16) to either 
contain only CD95+ cells or no CD95+ cells. Because the frequency of CD95+ cells within the 
TN cell population is so low, we were only able to conduct experiments using the 
CD45RA+CD95- subset in comparison to the total TN population. We found that similar levels 
of virus were produced from TN (RA+) cells, TN (-CD95) cells, and TCM cells, despite the fact 
that donor 6 had no measurable virus production from either TN (RA+) cells or TN (-CD95) cells 
(Fig. 21). Importantly, we found no significant difference in virus production between these two 
subsets when corrected for HIV-1 DNA, and TN (-CD95) cells from these three donors still 
produced as much, if not more virus per infected cell compared to the TCM cells in the absence of 
TSCM cells. This finding highlights that "true" TN cells that have been depleted of TSCM cells 
contribute significantly to virus production following latency reversal. 
Figure 21: Virus production from TN cells with and without CD95-expressing cells compared to TCM cells 
from donors 5-7 following treatment with LRAs. (A) Total virus production was measured from TN cells either 
containing (RA+) or excluding (-CD95) CD95-expressing cells (see Materials and Methods for more details) from 
donors 5-7 and were compared to virus production from TCM cells from the same donors. (B) Copies of HIV-1 RNA 
in the culture supernatant from panel A were normalized to the number of infected cells in each cell subset. Data are 
presented as the mean ± SEM. 
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5.2.3 Measure of replication-competent HIV-1 in TN and TCM cells 
In addition to quantifying HIV-1 RNA in the culture supernatant, we also measured replication-
competent HIV-1 using the viral outgrowth assay from donors 4-7613. When comparing the 
frequency of cultured wells positive for replication-competent HIV-1, there was 4 times more 
replication-competent virus found in TCM cells compared to TN cells (Table 9). When we 
accounted for differences in HIV-1 DNA between TN and TCM cells, there is only 1.4 times more 
replication-competent virus found in TCM cells compared to TN cells (Table 9). This 
demonstrates that TN cells are not only able to produce virus following latency reversal, but a 
portion of the virus produced from these cells is replication-competent. 
Table 9: Frequency of TN and TCM cell cultures yielding replication-competent HIV-1 from 
donors 4-7. 
In addition to measuring replication-competent virus from TN and TCM cells, we were 
also able to measure replication competent virus from TN cells with and without CD95-
expressing cells as done previously for total virus production using cells from donors 5-7 (see 
Fig. 21). Replication-competent virus was recovered from all three donors in both TN cell 
populations (Table 10). The frequency of replication-competent HIV-1 recovered from the two 
cell types was similar (4.44% vs. 5.56%), and when corrected for minor differences in HIV-1 
TN cells 
Wells positive (%) Fold difference 
(TCM/TN) 
Fold difference corrected 
for HIV-1 DNA 
(TCM/TN) 10/216 (4.63) 
TCM cells 
Wells positive (%) 
4 1.4 
40/216 (18.5) 
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DNA, there was slightly more replication-competent HIV-1 recovered from the TN (RA+) cell 
population than the TN (-CD95) cell subset (1.4 fold increase). In agreement with our latency 
reversal data (Fig. 21), "true" TN cells that have been depleted of TSCM cells contribute 
significantly to the production of replication-competent HIV-1 in comparison to the total TN 
population containing TSCM cells. 
Table 10: Frequency of TN (RA+) and TN (-CD95) cell cultures yielding replication-competent 
HIV-1 from donors 5-7. 
5.3 DISCUSSION 
In this study, we evaluated the contribution on TN cells to the HIV-1 latent reservoir in HIV-1-
infected long-term suppressed individuals. Evaluation of the efficacy of LRAs to reactivate latent 
HIV-1, either in terms of viral transcription or virus production, have largely been inconsistent 
between studies471. While certain LRAs prove effective in some models, they show no effect in 
others. This is likely, at least in part, due to the different cell types assayed between studies. 
Most in vitro primary cell models of HIV-latency focus on TCM cells or resting memory cells as a 
whole (discussed in section 1.4.3.3). In order to better understand the efficacy of LRAs across 
TN (RA+) cells 
Wells positive (%) Fold difference 
[TN (RA+) cells / 
TN (-CD95) cells] 
Fold difference corrected 
for HIV-1 DNA 
[TN (RA+) cells /  
TN (-CD95) cells] 
8/180 (4.44) 
TN (-CD95) 
cells 
Wells positive (%) 
1.25 1.4 
10/180 (5.56) 
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studies, it is important to evaluate LRAs on an individual T cell subset basis. In one study, it was 
shown that treatment with anti-CD3/CD28 resulted in higher levels of virus production from all 
memory cell subsets compared to TN cells; however, when cells were stimulated with anti-
CD3/CD28 + IL-7, the TN cells produced higher levels of HIV-1 RNA compared to the memory 
T cell subsets600. This finding emphasizes important differences between T cell subsets following 
latency reversal with different LRAs. 
In this study, we found that following treatment with LRAs that induce T cell activation 
(Fig. 19), similar levels of virus were produced from TN and TCM cells averaged across 7 donors 
(Fig. 17B), despite there being little to no virus production from TN cells in 3 of 7 donors (Fig. 
18). When we compared virus production between TN and TCM cells normalizing for HIV-1 
infection, we found that as much, if not more, virus was produced per infected TN cell compared 
to infected TCM cell (Fig. 17C). These findings are consistent with our in vitro primary cell 
model data discussed in chapter 4.0. 
One caveat to this is study is that among the 4 donors who showed more virus production 
from TN cells compared to TCM cells, we were unable to evaluate if this is due to (i) more latently 
infected TN cells producing virus than latently infected TCM cells, or (ii) more virus being 
produced per infected TN cell versus infected TCM cell. Given the extensive cell numbers 
required to perform such a detailed analysis660, this evaluation was beyond the scope of this 
current study. However, the latency reversal data combined with the viral outgrowth data 
suggests that there is more virus being produced per infected TN cell. 
Consistent with previous studies (as discussed in section 1.4.2), we found that TN cells 
contained significantly lower levels of HV-1 DNA than did TCM cells (Fig. 15). Despite 
containing significantly less HIV-1 DNA than TCM cells, TN cells produced more virus in 4 of 7 
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donors compared to TCM cells. This suggests that quantification of HIV-1 DNA alone may not 
predict the size of the inducible latent reservoir in different CD4+ T cell subsets. Furthermore, 
we demonstrated that even though TN cells produced more virus than TCM cells, there was more 
replication-competent virus recovered from TCM cells, even when taking into account the 
differences in HIV-1 DNA (Table 9). This suggests that the size of the inducible latent reservoir 
may not predict the size of the replication-competent reservoir in different CD4+ T cell subsets. 
The data presented in this study highlight the significance of TN cells to the HIV-1 latent 
reservoir in patients on long-term ART and suggest that these cells may contribute significantly 
to viral rebound following treatment interruption or failure. As such, a greater attention should be 
given to this T cell subset when studying latency reversal strategies and they should not be 
excluded from such analyses. 
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6.1 INTRODUCTION 
Latency reversal strategies have become a major area of research to reduce the size of the latent 
reservoir. It has been widely speculated that reduction or elimination of the latent reservoir in 
rCD4 T cells may lead to a functional or sterilizing cure661, 662. The “kick and kill” strategy488, 489 
has been the most widely utilized method to try and purge the latent reservoir, using a wide 
variety of LRAs. During latent HIV-1 infection, the integrated HIV-1 provirus remains 
transcriptionally silent in the absence of stimulation or cellular activation. However, upon 
cellular activation HIV-1 RNA is transcribed (latency is reversed) and virus is produced. 
Because this strategy induces virus production, experiments are always carried out in the 
presence of ART to prevent virus spread to new cells. In in vitro cell line and primary cell 
models, as few as one ARV can be used to prevent viral spread. This approach has been 
evaluated in several clinical studies657, in which the ART regimen is dependent on each donor.  
It is currently unknown if ARVs impact the efficacy of the “kick and kill” strategy. In 
this study, we determined whether different ARVs or ARV drug classes had an effect on the 
“kick and kill” approach using a primary cell model of HIV-1 latency described in chapter 3.0.  
6.2 RESULTS 
To address whether ARVs impacted the “kick” phenotype, we used a primary cell model that 
utilizes direct HIV-1 infection of highly purified rCD4 T cells to generate latently infected cells 
(Fig. 22A), as described previously604. The rCD4 T cells were infected with either X4-tropic 
HIV-1LAI605 or R5-tropic HIV-1BaL607. Following the establishment of latency, the cells were 
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treated with one of several different ARVs from five distinct drug classes, including attachment 
inhibitors [MVC (CCR5 antagonist) or AMD3100 (CXCR4 antagonist)], NRTIs [lamivudine 
(3TC) or tenofovir (TFV)], NNRTIs [rilpivirine (RPV) or efavirenz (EFV)], an InSTI (RAL), 
and PIs [darunavir (DRV) or atazanavir (ATV)]. Following the addition of one of these ARVs, 
the latently HIV-1-infected rCD4 T cells were stimulated with anti-CD3/CD28 antibodies to 
reactivate latent HIV-1. Virus production was quantified by measuring extracellular virion-
associated HIV-1 RNA in the culture supernatant, as described previously160. We found that 
equivalent amounts of R5-tropic (Fig. 22B) and X4-tropic (Fig. 22C) HIV-1 were generated 
from cells treated with attachment inhibitors, NRTIs, an INSTI, or PIs. In contrast, we observed 
a 10-fold or greater decrease in virus production from cells that had been treated with the 
NNRTIs, EFV or RPV (Fig. 22B, 22C). This decrease in HIV-1 production was not due to 
toxicity (Fig. 23A), or the NNRTI impacting global T cell activation (as assessed by CD25, 
CD69 or HLA-DR expression) in the absence (Fig. 23B) or presence (Fig. 23C) of anti-
CD3/CD28 antibodies. Of note, more HIV-1 particle production was observed in the no ARV 
controls due to spread of the reactivated HIV-1 (Fig. 22B, 22C). The reduction in virus 
production following treatment of the latently HIV-1-infected rCD4 T cells with either EFV or 
RPV was dose-dependent for both the X4- (Fig. 22D) and R5-tropic (Fig. 22E) strains, with 50% 
inhibitory concentration (i.e., EC50) in the low nanomolar range, which is equivalent to their 
EC50 values for inhibition of reverse transcription663. 
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Next, we asked whether NNRTIs decreased HIV-1 virus production by down-regulating 
HIV-1 gene transcription or protein translation. To address this question, we performed similar 
experiments in J89GFP cells, which are a Jurkat T-cell line that contains a stably integrated, full-
length dual-tropic HIV-189.6 provirus with the EGFP reporter gene incorporated into the viral 
Figure 22: NNRTIs reduce virus production following HIV-1 latency reversal in rCD4 T cells in vitro. (A) 
Schematic of experimental approach. Copies of HIV-1 RNA in the culture supernatant are shown following 
treatment with anti-CD3/CD28 antibodies from cells infected with HIV-1LAI (B) and HIV-1BaL (C). Dose-dependent 
responses in virus production following treatment with RPV and EFV from cells infected with HIV-1LAI (D) and 
HIV-1BaL (E). EC50 values were calculated using a three parameter nonlinear regression model in GraphPad Prism. 
Drug concentrations used: AMD3100 = 5µM; MVC = 1µM; 3TC = 50µM; TFV = 100µM; EFV = 1µM; RPV = 
1µM; RAL = 500nM; DRV = 500nM; and ATV, 500nM. Error bars represent ± standard deviation. Data are from 2-
4 independent experiments performed in duplicate. 
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genome615. The viral genome in these cells is transcriptionally silent. However, upon stimulation 
with PMA, viral transcription is activated and viral gene expression can be measured by EGFP 
expression, whereas virus production can be assessed by quantification of p24 antigen in the 
culture supernatant (Fig. 24). We found that neither the NNRTIs nor NRTIs reduced the levels of 
EGFP expression relative to the control (Fig. 24). However, consistent with the rCD4 T cell data, 
both EFV and RPV exhibited dose-dependent decreases in p24 production (Fig. 24).  
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Figure 23: T cell activation and cell viability following treatment of rCD4 T cells with different ARVs. (A) 
Cell viability was measured by LIVE/DEAD staining and flow cytometry post-stimulation compared to 
unstimulated controls of cells infected with HIV-1LAI. Surface expression of the T cell activation markers, CD25, 
CD69, and HLA-DR, were measured by flow cytometry seven days post-treatment with ARVs on cells infected 
with HIV-1LAI that were either (B) unstimulated or (C) stimulated with anti-CD3/CD28. * p value < 0.05 
determined by a paired t test. Error bars represent ± standard deviation. Data are from 2-4 independent experiments 
performed in duplicate.  
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Collectively, these data reveal that the NNRTIs EFV and RPV significantly attenuate the 
“kick” of latent HIV-1 from rCD4 T cells by inhibiting release of HIV-1 virus particles. This 
finding is consistent with our prior work which demonstrated that potent NNRTIs impact the late 
stages of HIV-1 replication602, which leads to a decrease in virus production from HIV-1-
transfected 293T or HeLa cells603, 664. Interestingly, in the HeLa and 293T cells micromolar 
concentrations of EFV were required to see a significant reduction in virus production603, 664. In 
contrast, the concentrations of EFV or RPV required to decrease virus production from rCD4 T 
cells was in the nanomolar range (Fig. 22D, 22E), and is significantly lower than the peak 
plasma concentrations following a single oral dose in humans [1.6-9.1µM for EFV665; 0.39-
0.53µM for RPV666]. This suggests that NNRTIs may decrease virus production in HIV-1-
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Figure 24: NNRTI-reduced virus production is not due to decreases in HIV-1 transcription or protein 
translation. In order to determine if the reduced virus production from cells treated with EFV or RPV was due to 
effects on transcription or translation, J89GFP cells were cultured in the absence or presence of different NNRTIs or 
NRTIs and were stimulated with PMA (30nM) for 48hrs. Following stimulation, the cells were analyzed by flow 
cytometry for cell viability, via LIVE/DEAD staining, and GFP expression. Virus production was quantified by p24 
in the culture supernatant. (-) and (+) refer to without and with PMA stimulation in the absence of any ARVs as a 
control. All concentrations shown are in micromolar. For both GFP expression and p24 production, samples were 
normalized to the no ARV (+) PMA control, which was set at 100%. 
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infected individuals using NNRTI-containing regimens enrolled in intervention studies aimed at 
eradicating the latent HIV-1 reservoir.   
To assess whether ARVs impacted the “kill” phenotype due to the cytopathic effect of the 
reactivated virus, we quantified the number of HIV-1-infected cells for both HIV-1LAI (Fig. 25A) 
and HIV-1BaL (Fig. 25B) before and after exposure to the anti-CD/CD28 antibodies by qPCR 
analysis of total HIV-1 DNA. HIV-1 DNA was normalized to the total number of cells assayed 
(assessed by qPCR amplification of the CCR5 gene 608), as described previously235. We observed 
significant decreases in the total number of HIV-1-infected cells treated with each of the ARVs 
following stimulation with anti-CD3/CD28 when compared to the unstimulated controls (Fig. 
25A, 25B). We still observed death of infected cells treated with EFV and RPV, even in the 
absence of virus production (Fig. 25A, 25B). This is consistent with previous findings that 
NNRTIs increase intracellular processing of Gag and Gag-Pol602, 603, 664. This NNRTI-induced 
intracellular processing of Gag/Gag-pol leads to premature protease activation, which is 
cytotoxic and can result in cell death667, 668. 
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6.3 DISCUSSION 
In summary, our data demonstrate that NNRTIs reduce HIV-1 production from latently infected 
rCD4 T cells compared to other classes or ARVs. These findings have significant implications 
for HIV-1 eradication studies. For example, ex vivo studies that use NNRTIs to prevent virus 
spread, or rCD4 T cells from donors on NNRTI containing regimens, should be cautiously 
interpreted. Furthermore, it may be more difficult to observe an increase in plasma viral load 
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Figure 25: Changes in HIV-1 DNA following latency reversal when cells are treated with different ARVs. 
Copies of HIV-1 DNA per cell were quantified in both stimulated and unstimulated cells infected with (A) HIV-1LAI 
(B) or HIV-1BaL. Dose-dependent decrease in HIV-1 infection following treatment with RPV and EFV of cells
infected with (C) HIV-1LAI and (D) HIV-1BaL. Error bars represent ± standard deviation. Data are from 2-4 
independent experiments performed in duplicate.
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following the administration of a LRA to an HIV-1-infected participant on a NNRTI based 
therapy. Finally, our data suggest that there may be a therapeutic application for NNRTIs in 
helping to eliminate cells expressing HIV-1 Gag and Gag-Pol proteins, although additional 
studies are warranted to further explore this possibility. 
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7.0  CONCLUSIONS 
Through the work presented here from AIMs 1 and 2, we have exposed the significance of TN 
cells to the overall HIV-1 latent reservoir. Through the modification of a primary cell model of 
HIV-1 latency, which allowed for the evaluation of TN cells while maintaining the integrity of 
freshly isolated rCD4 T cell subsets, we were able to recapitulate the differences in infection 
frequency between TN and TCM cells seen in HIV-1-infected individuals. This provided a useful 
tool to evaluate both the establishment and reversal of HIV-1 latency. Throughout the 
development of this model, we demonstrated that our culture conditions as well as in vitro HIV-1 
infection did not affect the resting cell phenotype, assessed by no change in T cell activation or 
proliferation. Importantly and significantly, this is the first in vitro primary cell model reported to 
generate direct infection in purified TN cells. 
With this model, we evaluated the similarities and differences of the “kick and kill” 
strategy on TN and TCM cells following latency reversal. As expected, we found more total virus 
production from TCM cells compared to TN cells following latency reversal. However, TN cells 
produced as much, if not more, virus than TCM cells when normalized for differences in HIV-1 
infection (HIV-1 DNA). This result was unexpected and demonstrated that TN cells may be a 
more important contributor to the latent viral reservoir than previously thought.  
Another unexpected finding from this study was that CCL19-mediated direct infection of 
TN and TCM cells did not occur through alleviation of the two known major restriction factors to 
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HIV-1 infection of rCD4 T cells, the actin cytoskeleton and SAMHD1. These data suggest that 
there are additional blocks to HIV-1 infection of rCD4 T cells, which have not yet been 
identified and which are alleviated by CCL19 treatment. Further evaluation of the mechanisms of 
CCL19-mediated enhancement of HIV-1 infection is greatly needed, both to identify novel 
restriction factors in rCD4 T cells, as well as to gain a better biological understanding of direct 
infection of these cells. 
As with any cell model, there is always the question of in vivo relevance. While we could 
not directly evaluate the in vivo contribution of TN cells following latency reversal, we could 
validate our findings from AIM 1 ex vivo from cells obtained from HIV-1-infected individuals 
on long-term ART. Consistent with our findings using our primary cell model, we found that TN 
cells produced more virus than TCM cells in 4 out of 7 donors, even when uncorrected for 
differences in infection frequency. In this study, we were also able to measure the frequency of 
replication-competent virus between TN and TCM cells in a subset of donors and found that the 
level of replication-competent virus between these two cell types was similar when normalized 
for differences in infection. Interestingly, we did not find more replication-competent virus in TN 
cells from donors who had higher levels of virus production compared to TCM cells. Although 
based on a limited sample size, these findings demonstrate that the size of the HIV-1 DNA 
reservoir is not necessarily predictive of the size of the inducible reservoir, and the size of the 
inducible reservoir is not necessarily predictive of the size of the infectious reservoir. 
The field of HIV-1 latency is heavily focused on quantitative measures to try and predict 
subsequent outcomes. While PCR-based measures are extremely sensitive and are necessary to 
quantify the low-level frequency of latently infected cells in HIV-1 infected individuals, these 
assays over-predict the size of the inducible latent reservoir because they do not distinguish 
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between infectious versus non-infectious nucleic acid441. Conversely, measures of the infectious 
viral reservoir have been shown to underestimate the size of the latent reservoir, likely due to 
many contributing factors601. One factor is that not all replication-competent proviruses become 
reactivated following a single low-dose stimulation with PHA601. It has previously been shown 
that a single stimulation is only able to induce a fraction of total replication-competent 
proviruses, while a second stimulation is able to induce an additional fraction of proviruses601. 
However, in this study, not all replication-competent proviruses were inducible, even after 
multiple stimulations. The authors of this study concluded that the size of the inducible latent 
reservoir is at least 60-fold greater than that predicted by the QVOA. A second major factor of 
underestimating the reservoir size is that this assay requires a weekly addition of CD8-depleted, 
PHA-activated, allogeneic feeder cells to propagate infectious virus to detectable levels613. This 
relies on both the susceptibility of the feeder cells to HIV-1 infection, and the functionality of 
these cells to support robust, productive infection. The vast differences in donor susceptibility to 
HIV-1 infection, as well as the differences in virus production following latency reversal in “kick 
and kill” studies suggests that the use of allogeneic feeder cells will affect the outgrowth of 
infectious virus following co-culture. The findings presented in AIM 2 of this thesis are in line 
with these previous works and warrant caution when interpreting inferred correlations based on 
quantitative analyses. 
Moving forward, it is clear that evaluation of all CD4+ T cell subsets that constitute the 
latent viral reservoir is necessary. These different CD4+ T cell subsets have phenotypic and 
physiological differences that likely contribute to the establishment and reversal of HIV-1 
latency in each cell type in vivo. Evaluations of these differences are in their infancy and are not 
well understood. Once proviral latency is established, maintenance of latency is highly regulated 
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and multifaceted. As described previously in section 1.4.4, it is becoming clear that individual 
LRAs are inefficient at reversing latent HIV-1, while combinations of LRAs are proving to be 
more effective. There are likely different mechanisms involved in the maintenance of latent HIV-
1 in the different CD4+ T cell subsets that may need to be targeted differently in order to achieve 
a maximal response. Gaining a better understanding of both the establishment and maintenance 
of HIV-1 latency in different CD4+ T cell subsets will help guide more targeted assessment of 
LRAs and provide critical insight into LRA combinations that may be needed to reduce or 
eliminate the latent reservoir. 
In AIM 3, we evaluated the effect of different ARVs and ARV classes on the “kick and 
kill” approach. Importantly, this strategy is always employed in the presence of ART, either as 
ART in vivo or with as little as a single ARV in vitro. How these ARVs may influence responses 
to LRAs has not previously been evaluated. We found that the NNRTIs EFV and RPV 
significantly inhibited virus production from latently infected cells following treatment with anti-
CD3/CD28. Consistent with previous reports, we found that the restriction imposed by these 
NNRTIs is at the level of virus production and not transcription or translation. This finding 
suggests that in vitro evaluation of LRAs should not be conducted in the presence of NNRTIs, as 
they may mask responses induced by the LRAs if the assay readout is an extracellular virion 
measure. The in vivo implications of these findings are currently unclear.  
While the “kick and kill” approach has been evaluated as a possible mechanism to 
eradicate the latent viral reservoir, studies thus far have largely evaluated the “kick”, with little 
emphasis on the "kill”. Latency reversal strategies using a single agent have thus far proven to be 
ineffective. LRAs that induce T cell activation or proliferation are toxic and LRAs that modestly 
induce viral transcription seem to have little to no effect on reducing the size of the latent 
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reservoir. Additional evaluation of the mechanisms that maintain HIV-1 latency in different T 
cell subsets could provide useful insights into how to specifically target these cells for viral 
reactivation. Further evaluations on the reversal of HIV-1 latency in different T cell subsets 
could help provide information about which drug combinations may need to be used to achieve 
maximal reactivation. 
In practicality, it seems unlikely that the “kick and kill” approach will not work in HIV-1-
infected individuals on ART to significantly reduce or eliminate the latent reservoir. The biggest 
challenge with this approach is that all current LRAs are not specific for HIV-1 but instead target 
cellular factors. This raises major concerns regarding off target effects that could be toxic or 
lethal. Additionally, the only LRAs that have been found to significantly increase virus 
production and/or reduce the size of the latent reservoir ex vivo induce T cell activation, which 
would be an undesirable and toxic outcome to in vivo treatment.  
An alternative approach to achieve a functional cure may be through the therapeutic 
establishment of permanent latency. In 2012, it was shown that an analog of the natural steroid 
alkaloid Cortistatin A, didehydro-Cortistatin A (dCA), inhibited Tat-mediated transcription and 
diminished spontaneous virus production from CD4+ T cells purified from HIV-1-infected 
individuals on ART669. A follow-up study revealed that dCA induced long-term control of HIV-1 
transcription in CD4+ T cells purified from HIV-1-infected individuals on ART, even after dCA 
had been removed, and after stimulation with anti-CD3/CD28 or prostratin670. This led the 
authors to conclude that dCA established a state of permanent latency, possibly through 
epigenetic modification or repression of the HIV-1 promoter670. This could represent a novel 
class of ARVs that could induce a state of permanent latency and establish a functional cure. To 
date, the drug triptolide is the only Tat inhibitor or inhibitor of HIV-1 transcription to reach 
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clinical trials671, 672. Clinical evaluation of dCA would determine if permanent latency could be 
established in vivo and if long-term control of viral replication could be maintained off ART.  
8.0  FUTURE DIRECTIONS 
The data presented in this thesis shed light on novel characteristics of the HIV-1 latent reservoir 
that demonstrated that TN cells are a major contributing cell type to this reservoir in terms of 
viral rebound following latency reversal. While many key findings were identified through this 
work, several additional questions were raised along the way. A few key questions raised will be 
discussed below with suggested experiments on how to address them. 
8.1 HOW DOES CCL19 PROMOTE INFECTION OF rCD4 T CELLS? 
Using our primary cell model of HIV-1 latency, we showed that CCL19 enhances infection of 
both rCD4 TN and TCM cells, albeit to different degrees. A previous report suggested that CCL19 
promoted infection of rCD4 T cells by enhancing actin dynamics and F-actin density456. Our data 
presented in chapter 4.0 demonstrated that while inhibition of F-actin assembly does inhibit HIV-
1 infection (Fig. 9), CCL19 does not alleviate the restriction to HIV-1 infection in rCD4 T cells 
imposed by the actin cytoskeleton (Fig. 10). A publication from the same group came out during 
the writing of this thesis that now suggests that CCL19-mediated enhancement of HIV-1 
infection is driven by phosphatidylinositol-3-kinase (PI3K)-mediated activation of NF-κB673. 
Importantly, in the case of F-actin, changes were only seen at a maximum of 30 minutes post-
CCL19 treatment456, while for NF-κB activation, changes were only measured up to 15 minutes 
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post-CCL19 treatment673. Importantly, in these two studies, cells were infected between 24-72 
hours post-CCL19 treatment456, 673, long after the proposed mechanisms of enhancement were 
measured. NF-κB activation is most frequently associated with increased HIV-1 transcription; 
however, it has been shown in various T cell lines that HIV-1 integration and the establishment 
of HIV-1 latency is dependent on low-levels of NF-κB674, 675. 
Early on in our studies to determine how CCL19 enhances HIV-1 infection of rCD4 T 
cells, we also suspected involvement of PI3K signaling given that many chemokines induce 
signaling through PI3K pathways to modulate cell migration, cell survival, and increase cellular 
functionality676. In addition, CCL19 has been shown to increase PI3K activation in many 
different types of cancer677-682. To test our hypothesis, we treated rCD4 T cells with the PI3K 
inhibitor, PI-103, at various concentrations prior to the addition of CCL19. Following CCL19 
treatment for two days, cells were infected with HIV-1LAI. Seven days post-infection, HIV-1 
DNA was quantified in both the PI-103-treated and the CCL19 only cells. We did not see 
inhibition of HIV-1 infection following PI-103 treatment and did not see a dose response to 
treatment (Fig. 26), and therefore decided not to move forward with this approach. 
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The data published, both by us and other groups, on the mechanism(s) of CCL19-
enhanced HIV-1 infection are an incomplete picture of what CCL19 might be doing to prime 
rCD4 T cells for HIV-1 infection. This is largely due to the approaches taken, which rely on 
published data or hypotheses as to known restriction mechanisms to HIV-1 infection in rCD4 T 
cells or known pathways that can modulate HIV-1 infection. CCL19 may enhance HIV-1 
infection of rCD4 T cells in a manner that has never been explored before or act through an 
unknown restriction factor. 
An alternative approach to identify cellular pathways that are modulated following 
treatment with CCL19 is through the use of the Phospho Explorer Antibody Array developed by 
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Figure 26: Inhibition of the PI3K pathway does not inhibit HIV-1LAI infection of CCL19-treated rCD4 T cells..
rCD4 T cells were either treated with varying concentrations of the PI3K inhibitor, PI-103, or were left untreated for
6 hrs prior to treatment with CCL19 for 48 hours. Following treatment with CCL19, cells were infected with HIV-
1LAI and remained in culture for 7 days. Seven days post-infection, HIV-1 DNA was quantified and normalized to 
cell number. Cells left untreated or stimulated with PMA + IL-2 (10nM, 50U/mL) for 48 hours prior to infected were
used as controls. Preliminary data, N = 1. 
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Full Moon Biosystems. This technology measures the phosphorylation or dephosphorylation of 
over 400 different proteins using 1318 site-specific antibodies that target over 30 signaling 
pathways. Instead of relying on guesswork, we have performed two preliminary experiments 
using the Phospho Explorer Antibody Array technology in which we compared the changes in 
phosphorylation following CCL19 treatment versus no treatment for 6 hours (Fig. 27A) or 24 
hours (Fig. 27B). Although the data are only from a single experiment at each time point, it 
highlights two important findings. One is that there is little to no overlap in the proteins that are 
significantly increased or decreased in phosphorylation following CCL19 treatment at either time 
point between TN and TCM cells. This suggests that either CCL19 enhances HIV-1 infection of 
rCD4 T cells via a pathway not identified in this screen, or that CCL19 enhances HIV-1 infection 
of TN and TCM cells through different mechanisms, which may help explain why there is a 
greater enhancement of HIV-1 infection in TCM cells compared to TN cells. Secondly, these data 
highlight the importance of the timing of the experiments as there was also little to no overlap in 
the significantly phosphorylated or dephosphorylated proteins following CCL19 treatment in TN 
and TCM cells at the two different time points. In addition to the proteins that are identified in 
Figure 24 that were either significantly phosphorylated or dephosphorylated following CCL19 
treatment, there were many additional proteins that had changes in phosphorylation that neared 
significance (data not shown).  
In these initial screens, we also found no significant changes in either cell type in the 
phosphorylation of cortactin, cofilin, filamin A, or LIMK1, which are all cofactors that mediate 
actin polarization and actin dynamics683-689, in addition to actin itself (data not shown). This 
further supports our conclusion that CCL19-mediated enhancement of HIV-1 infection does not 
depend on changes in the actin cytoskeleton. Interestingly, and in partial agreement with the 
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recently published paper673, these screens also found a significant increase in two heterodimeric 
forms of NF-κB at both 6 and 24 hours post-CCL19 treatment for TN cells but not for TCM cells 
(Fig. 27). NF-κB is a family of transcription factors made up of several different heterodimeric 
or homodimeric proteins that can become activated through many different extracellular stimuli 
to regulate a wide range of genes690-692. Therefore, further investigation is needed to understand 
the significance of increased NF-κB activation following CCL19 treatment and how this may 
affect HIV-1 infection of rCD4 T cells. 
Additional experiments should be conducted with cells from multiple donors to gain a 
better understanding of the differences and similarities in CCL19-mediated signaling between TN 
and TCM cells. We would also like to assess phosphorylation/dephosphorylation events at 
different time points because it has previously been published that CCL19-mediated 
enhancement of HIV-1 infection can occur anywhere between 3-72 hours post-CCL19 
treatment456. We preliminarily chose to look 6 and 24 hours post-CCL19 treatment as a starting 
point with the plan to look at both an earlier and later time point. To further evaluate the 
importance of proteins that are significantly phosphorylated/dephosphorylated following CCL19 
treatment, Full Moon Biosystems has 33 additional phosphorylation profile arrays targeting 
specific pathways for a more in-depth analysis of each pathways. They also have 9 protein 
expression profile arrays that could be used in addition to the phospho arrays to identify 
increased or decreased protein expression following CCL19-mediated signaling events. These 
combined approaches would give a more comprehensive and non-biased overview of cellular 
changes that occur following CCL19 treatment. The most difficult challenge will be to ascertain 
which cellular change(s) is responsible for CCL19-mediated enhancement of HIV-1 infection in 
rCD4 T cells. 
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Figure 27: Significant increase or decrease in phosphorylation of specific proteins following CCL19 treatment 
identified by Phospho Explorer Antibody Array imaging. Significant changes (± 2-fold increase or decrease 
compared to no CCL19 control) in the phosphorylation of specific proteins following treatment with CCL19 for 6 
hrs (A) or 24 hrs (B) identified by the phospho explorer antibody array from Full Moon Biosystems, are shown for 
both TN and TCM cells. Gray shading highlights the areas of significance. * = significant change in phosphorylation 
for both TN and TCM cells. N = 1 for both A and B.  
144 
8.2 IS THERE MORE VIRUS BEING PRODUCED PER INFECTED CELL OR 
MORE INFECTED CELLS ABLE TO PRODUCE VIRUS? 
One major question that we have yet to answer in either our primary cell model of HIV-1 latency 
or in HIV-1-infected cells purified from long-term suppressed individuals, is whether TN cells 
are able to produce more virus per infected cell or if more infected TN cells are able to produce 
virus than infected TCM cell. TN cells are often overlooked or considered as an insignificant cell 
type to the HIV-1 latent reservoir based on the consistently lower frequency of HIV-1 DNA 
when compared to the memory cell subsets. However, in the context of latency reversal and virus 
production following latency reversal, TN cells were found to produce as much, if not more, virus 
than TCM cells when corrected for differences in the frequency of HIV-1 infection in the majority 
of individuals evaluated. This raises a critical biological question surrounding where virus comes 
from following viral rebound after treatment cessation or failure, in addition to latency reversal 
strategies. 
One way to address this question would be to perform limiting dilution cultures of both 
TN and TCM cells purified from HIV-1-infected individuals on suppressive ART in replicate 
cultures. Following maximal stimulation of each well with anti-CD3/CD28 antibodies to induce 
virus production from latently infected cells, virus production can be measured in the culture 
supernatant by qRT-PCR. With the limiting dilution culture method, Poisson statistics can be 
used to determine the probability that virion production in a given well came from a single 
provirus. This would allow us to quantitatively determine the amount of virus produced from 
individually infected TN and TCM cells. If individual proviruses from TN cells produce fewer or 
similar levels of virus compared to TCM cells, this would suggest that more infected TN cells are 
able to produce virus compared to TCM cells following stimulation. Alternatively, if individual 
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proviruses from TN cells produce more virus than TCM cells, then we would know that there is 
more virus being produced per infected TN cell compared to infected TCM cell. 
This method has been previously described and was used to determine virion production 
from single inducible proviruses following T cell activation660. In this paper, it was found that 
virion production from individual proviruses could vary as much as 100,000-fold using rCD4 T 
cells purified from HIV-1-infected individuals on ART. These findings further highlight not only 
the dramatic differences between individually infected cells but also between donors. Breaking 
the latent reservoir in rCD4 T cells down into individual subsets could help explain some of 
these differences if certain cell subsets (such as the TN cells) are able to produce more virions per 
inducible provirus in comparison to other cell subsets (such as the TCM cells). Although it was 
beyond the scope of this previous study, it would have been informative to look at virion 
production in each donor individually instead of combined and then also measure the frequency 
of each T cell subset constituting the rCD4 T cells to determine if there were any relationships 
between cell frequency and virion production. 
8.3 IS THE BLOCK IN VIRUS PRODUCTION AT THE LEVEL OF 
TRANSCRIPTION, TRANSLATION, OR BUDDING? 
If it turns out that there is more virus being produced per infected TN cell compared to TCM cell, 
it is important to understand if this is due to differences in transcription, translation, or viral 
budding post-stimulation. Elucidating the mechanistic differences in virus production between 
different cell types may help guide more directed approaches to latency reversal strategies. At 
least one study has found that there was no relationship between levels of unspliced cellular 
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HIV-1 RNA transcription and the level of virion production following treatment with SAHA693, 
which suggests that there are likely post-transcriptional blocks following latency reversal that 
have not yet been described. If there are additional post-transcriptional blocks that prevent virus 
production following latency reversal, identifying new targets may help provide more potent 
LRA combinations to efficiently reactivate latent HIV-1 and reduce/eliminate the latent 
reservoir. 
There are several different approaches that could be taken to quantify latency reversal at 
several different stages in the HIV-1 replication cycle post-stimulation. To measure differences 
in the initial “kick” in transcription following treatment, intracellular levels of full-length HIV-1 
mRNA could be quantified by qRT-PCR. To measure translation of viral proteins, the 
intracellular p24 capsid protein is the most frequently measured by either an ELISA or antibody 
labeling and flow cytometry. Using an ELISA to measure p24 protein levels would give an 
actual quantitative value of p24 (usually in nanograms) in a given number of cells, whereas flow 
cytometry would only be able to provide relative differences in p24, measured by the MFI, 
between TN and TCM cells. Either approach would be able to address differences in protein 
production between TN and TCM cells.  
If there were no observed differences between TN and TCM cells in terms of viral 
transcription or translation following LRA stimulation, it would be important to determine if 
there were defects in either viral assemble or budding from the plasma membrane. To measure 
differences between viral proteins in the cytoplasm and viral proteins at the plasma membrane in 
an assembling virion, equilibrium flotation centrifugation can be used to separate membrane 
bound from unbound viral proteins using cell suspensions694. To determine if viral proteins are 
being retained in the cell and not leading to the production of virions, western blot analysis can 
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be used to measure viral protein levels between cell lysates and virus produced post-stimulation 
with an LRA. This will determine if assembling virions are somehow retained on the plasma 
membrane and are unable to bud from the cell. 
Using these techniques, there are three potential outcomes that would distinguish between 
differences in HIV-1 assembly versus budding: i) there could be equal levels of virion assembly 
and virion production between TN and TCM cells, suggesting no difference in these processes 
between these cell types, ii) there could be higher levels of assembling virions in TN cells but 
lower levels of virion production compared to TCM cells, suggesting a block at the level of virion 
budding in TN cells, and iii) there could be higher levels of assembling virions in TCM cells but 
lower levels of virion production compared to TN cells, suggesting a block at the level of virion 
budding in TCM cells. These data could identify novel restriction factors or post-translation blocks 
to HIV-1 replication following latency reversal that could aid in the development of novel ARV 
targets. 
8.4 NON-RESTING TN OR MEMORY CD4+ T CELL SUBSETS THAT 
CONTRIBUTE TO THE LATENT RESERVOIR AND VIRAL PERSISTENCE 
HIV-1 latency has almost exclusively been identified and studied in rCD4 T cells. This may be 
due to the fact that rCD4 T cells are easy to study on a population level. rCD4 T cells largely 
only contain HIV-1-infected cells that are in a latent state, therefore, when studying these cells as 
a population, HIV-1-producing cells do not have to be distinguished from the non-producing 
cells. Furthermore, rCD4 T cells constitute the majority of CD4+ T cells in the peripheral blood 
and are therefore easy to obtain from HIV-1-infected individuals. However, in HIV-1-infected 
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individuals on long-term ART, in which viral replication is fully suppressed, integrated HIV-1 
DNA has been found in a wide range of other CD4+ cell types, both in the periphery and in 
tissues, suggesting that these cells likely contain latent proviruses (reviewed in 599, 695). 
In addition to the TN and memory CD4+ T cell subsets discussed throughout this thesis, 
additional CD4+ T cell subsets have been implicated as reservoirs for latent HIV-1 in infected 
individuals on long-term ART, such as the T follicular helper cells (TFH), T helper 17 cells 
(TH17), T regulatory cells (TReg), and even activated or partially activated CD4+ T cells599, 695-697. 
These cell types are largely confined to tissues, making them harder to evaluate for HIV-1 
infection. Additionally, it has now been shown, using an in vitro primary cell model, that HIV-1 
latency can be established in both resting and activated CD4+ T cells697. This is consistent with 
the finding that HIV-1 DNA can readily be detected in peripheral activated or total CD4+ T cells 
in HIV-1-infected individuals on ART, in the absence of viral replication. 
Although integrated HIV-1 DNA has been measured in all of these CD4+ T cell subsets 
in HIV-1-infected individuals on ART, there is limited information on their actual contribution to 
the latent viral reservoir or viral persistence. Both peripherally-isolated, HIV-1-infected TFH698 
and TReg699 cells from patients on ART have been shown to persist for several years by 
longitudinal analyses. It was also shown that latently infected TReg cells could be activated to 
produce virus following stimulation with PHA + IL-2699. These data strongly suggest that 
peripheral TFH and TReg cells contribute to the latent viral reservoir in HIV-1-infected individuals 
on ART. However, tissue reservoirs have not yet been sufficiently evaluated. Additional 
techniques and ex vivo analysis is required to fully interrogate HIV-1 persistence in tissue-
derived reservoirs. Sequence analysis of integrated proviruses coupled with measures of viral 
infectivity could help evaluate the contribution of these tissue-derived reservoirs to the total pool 
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of replication-competent, inducible proviruses. A further analysis of HIV-1 latency and 
persistence in individual CD4+ T cell subsets will help give a more complete picture of the 
composition of the latent reservoir in HIV-1-infected individuals on ART and may help identify 
more directed approaches to reduce or eliminate latently infected cells. 
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APPENDIX A 
A.1 SUPPLEMENTAL DATA FROM CHAPTER 4.0
Supplementary Table 1: P values for comparison of PHA-activated CD4+ T cell integration 
site distribution to TN and TCM cells, and to the MRC dataset.   
Sample MRC 
Activated CD4+ 
T cellsa 
CD4+ TN cells 
Within RefSeq 
genesb 
Activated CD4+ T 
cellsa < 2.2 x 10
-308 - - 
CD4+ TN cells 3.45 x 10-106 0.344 - 
CD4+ TCM cells < 2.2 x 10-308 0.003 0.022 
Within 5kb 
(± 2.5kb) of a 
transcriptional start 
siteb 
Activated CD4+ T 
cellsa 1.68 x 10
-09 - - 
CD4+ TN cells 0.85 0.54 - 
CD4+ TCM cells 0.72 0.24 1.00 
Within 5kb 
(± 2.5kb) of a CpG 
islandb 
Activated CD4+ T 
cellsa 1.03 x 10
-21 - - 
CD4+ TN cells 0.64 0.41 - 
CD4+ TCM cells 0.84 0.02 0.76 
Average gene 
density within 1Mb 
(± 0.5Mb) of 
integration sitesc 
Activated CD4+ T 
cellsa < 2.2 x 10
-308 - - 
CD4+ TN cells 1.66 x 10-101 2.3 x 10-04 - 
CD4+ TCM cells < 2.2 x 10-308 0.05 0.02 
Actual counts of sites within RefSeq genes and relative to CpG islands and TSS’s, as well as 
regional gene densities, are shown in Table 3. aPHA-activated CD4+ T cells, bP values calculated 
by Fisher’s exact test, cP values calculated by Wilcoxon rank sum test. 
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A TN cells TCM cells C 
B D 
Supplementary Figure 1: Correlation analyses between level of infection and virus production post-
stimulation from TN and TCM cells latently infected with HIV-1LAI. Correlation analysis of TN cells three (A) and 
ten (B) days post-stimulation with anti-CD3/CD28 microbeads, PMA+PHA, and prostratin. Correlation analysis of 
TCM cells three (C) and ten (D) days post-stimulation with anti-CD3/CD28 microbeads, PMA+PHA, and prostratin. 
P value determined by Spearman correlation analysis. Spearman correlation coefficients (r) are shown. Each dot 
represents a different donor. Dotted lines represent linear regression curve. 
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APPENDIX B 
LIST OF ABBREVIATIONS 
2-LTR: 2-long terminal repeat-containing circles
3TC: Lamivudine
Ab: Antibody
Ag: Antigen
AIDS: Acquired immunodeficiency syndrome
Akt: Protein kinase B
AML: Acute myeloid leukemia
AP-1: Activator protein-1
ART: Antiretroviral therapy
ARV: Antiretroviral
ASCT: Allogeneic stem cell transplantation
ATI: Analytic treatment interruption
ATV: Atazanavir
bp: base pair
CA: Capsid
Cas: CRISPR-associated nuclease
CDK9: Cyclin-dependent kinase 9
cDNA: Complementary DNA
CRISPR: Clustered regularly interspersed palindromic repeats
CSF: cerebral spinal fluid
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CTD: C-terminal domain 
DAPI: 4',6-diamidino-2-phenylindole 
dCA: Didehydro-Cortistatin A 
DNA: Deoxyribonucleic acid 
DNMTi: DNA methyltransferase inhibitor 
dNTP: Deoxynucleoside triphosphate 
dNTPase: Deoxynucleoside triphosphate triphosphohydrolase 
DRV: Darunavir 
DSIF: DRB-sensitivity inducing factor 
DZNep: 3-deazaneplanocin A 
EC: Elite controller 
EFV: Efavirenz 
ELISA: Enzyme-linked immunosorbent assay 
ESCRT: Endosomal sorting complex required for transport 
FACS: Fluorescence-activated cell sorting 
FBS: Fetal bovine serum 
FDA: Food and Drug Administration 
GALT: Gut-associated lymphoid tissue 
GVHD: Graft-versus-host disease 
HDACi: Histone deacetylase inhibitor 
HIV-1: Human immunodeficiency virus type-1 
HLA: Human leukocyte antigen 
HMBA: Hexamethylbisacetamide 
HMTi: Histone methyltransferase inhibitor 
HSCT: Hematopoietic stem cell transplant 
IL-2: Interleukin-2 
IN: Integrase 
InSTI: Integrase strand transfer inhibitor 
IUPM: Infectious units per million cells 
kB: Kilobases 
LOD: Limit of detection 
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LRA: Latency reversing agent 
LTNP: Long-term non-progressor 
LTR: Long-terminal repeat 
MA: Matrix 
MDDCs: Monocyte-derived dendritic cells 
MFI: Mean fluorescence intensity  
MOI: Multiplicity of infection 
MoM: Myeloid only mice 
NC: Nucleocapsid 
NELF: Negative transcription elongation factor 
NFAT: Nuclear factor of activated T cells 
NHP: Non-human primate 
NNRTI: Non-nucleoside reverse transcriptase inhibitor 
NPC: Nuclear pore complex 
NRTI: Nucleoside reverse transcriptase inhibitor 
PBS: Phosphate buffered saline 
PFA: Paraformaldehyde 
PHA: Phytohemagglutinin 
PI: Protease inhibitor 
PI3K: Phosphatidylinositol-3-kinase 
PKC: Protein kinase C 
PMA: Phorbol-12-myristate 13-acetate 
PNAd: Peripheral-node addressin 
PNB: Panobinostat 
Pro: Protease 
P-TEFb: Positive transcription elongation factor b
PTEN: Phosphatase and tensin homolog
qPCR: Quantitative polymerase chain reaction
qRT-PCR: Quantitative reverse transcriptase polymerase chain reaction
QVOA: Quantitative viral outgrowth assay
pDC: Plasmacytoid dendritic cells
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RAL: Raltegravir 
rCD4: Resting CD4+ T cell 
RIC: Reduced-intensity chemotherapy 
RMD: Romidepsin 
RNA: Ribonucleic acid 
RNAi: RNA interference 
RPV: Rilpivirine 
RRE: Rev response element 
RT: Reverse transcriptase 
SAHA: Suberoylanilide hydroxamic acid 
SAMHD1: Sterile alpha motif and histidine/aspartic acid domain-containing protein 1 
SCID: Severe combined immunodeficiency 
SD: Standard deviation 
SEM: Standard error of the mean 
shRNA: Short hairpin RNA 
siRNA: Small interfering RNA 
SIV: Simian immunodeficiency virus 
snRNP: Small nuclear ribonucleoprotein 
TALENS: Transcription activator-like effector nucleases 
TAR: Transactivation response element 
Tat: Trans-activator of transcription 
TBI: Total body irradiation 
TCM: Central memory CD4+ T cells 
TEM: Effector memory CD4+ T cells 
TFH: T follicular helper cells 
TGF-β: Tissue growth factor-beta 
TH17: T helper 17 cells 
ToM: T cell only mice 
TN: Naïve CD4+ T cells 
TNF: Tumor necrosis factor 
TReg: Regulatory T cells 
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TSA: Trichostatin A 
TSCM: Stem cell-like memory CD4+ T cells 
TSSs: Transcription start sites 
TTD: Terminally differentiated CD4+ T cells 
TTM: Transitional memory CD4+ T cells 
VNP: Viremic non-progressor 
ZFN: Zinc-finger nuclease 
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